 
 
Protocol Title : 
 
Phase II Trial of the PD -1 Antibody Nivolumab in Combination with Lenalidomide and  
Low Dose Dexamethasone in Patients with High -Risk Smoldering Multiple Myeloma  
 
 
NCT  #: [STUDY_ID_REMOVED]  
 
IRB Approval Date:   01/23/2018
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
1  
  
Local Protocol #: 16-242 
BMS  Protocol  #: CA209 -607 
 
 
TITLE: Phase  II Trial of the PD -1 Antibody Nivolumab in Combination with  
Lenalidomide and Low Dose Dexamethasone in Patients with High -Risk Smoldering 
Multiple Myeloma  
 
 
Coordinating  Center:  Dana -Farber  Cancer  Institute  
450 Brookline Avenue  
Boston,  MA 02115  
Phone:  617-632-4198 
Fax: 617-582-8608  
 
 
Principal  Investigator  (PI):   Irene M.  Ghobrial,  MD 
Dana -Farber Cancer Institute 
Irene_Ghobrial@dfci.harvard.edu  
 
 
 
Statistician:  Project  Manager:  
Lorenzo Trippa  Alexandra  Savell  
Dana -Farber  Cancer  Institute  Dana -Farber  Cancer  Institute  
ltrippa@partners.org  AlexandraE_Savell@dfci.harvard.edu  
 
Chia-Jen Liu, MD, PhD 
Dana -Farber  Cancer  Institute 
Cliu35@partners.org   
 
 
 
Agent(s):  Nivolumab,  Bristol -Myers  Squibb 
Lenalidomide, Celgene 
Dexamethasone, commercial  
 
 
IND #: 129255  
IND Holder:  Irene  M. Ghobrial,  MD 
Original/ 11.0/ January 23rd 2018  

Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
2  
 CYCLES  1-6 
• 
• 
• Nivolumab  days 1, 15 
Lenalidomide  days 1-21 
Dexamethasone  days 1, 8, 15 Cycle  Length:  28 days  
MAINTENANCE  CYCLES  7-12 
• Nivolumab  days 1,15 
• Lenalidomide  days 1-21 
 
Cycle  Length:  28 days  
Stop 
Therapy   
Event 
Monitoring 
up to 3 
years  **At any time 
• Progression  to Active  Myeloma  
• Unacceptable  Toxicity  
• Refusal  
• Alternative  Therapy  REGISTRATION   
SCHEMA  
 
 
 
 
 
**Disease  Assessment : Day 1 of each cycle  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
3  
  
 
 
Table of  Contents  
LIST  OF ABBREVIATIONS  AND  GLOSSARY  OF TERMS  ................................ ...............................  6 
PROTOCOL  SUMMARY  ................................ ................................ ................................ ........................  10 
1. OBJECTIVES  ................................ ................................ ................................ ................................ ... 13 
1.1 STUDY  DESIGN  ................................ ................................ ................................ ...........................  14 
1.2 NUMBER  OF PATIENTS  ................................ ................................ ................................ ...............  14 
1.3 DURATION  OF STUDY  ................................ ................................ ................................ .................  14 
1.4 PRIMARY  OBJECTIVES  ................................ ................................ ................................ .................  14 
1.5 SECONDARY  OBJECTIVES  ................................ ................................ ................................ ...........  15 
2. BACKGROUND  ................................ ................................ ................................ ...............................  15 
2.1 MULTIPLE  MYELOMA  ................................ ................................ ................................ ................  15 
2.2 MGUS  AND  SMM  CONSISTENTLY  PRECEDES  MULTIPLE  MYELOMA  ................................ ...................  16 
2.3 MOLECULAR  STUDIES  IN MGUS  AND  SMM  ................................ ................................ ..............  16 
2.4 DEFINITION  OF SMM  AND  MM ................................ ................................ ................................ .. 18 
2.5 DEFINITIONS  OF HIGH-RISK SMM  ................................ ................................ .............................  18 
2.6 TREATMENT  OF HIGH  RISK  SMM  ................................ ................................ ...............................  19 
2.7 NIVOLUMAB  ................................ ................................ ................................ ...............................  19 
2.8 PHARMACOKINETICS  AND  DRUG  METABOLISM  ................................ ................................ .........  20 
2.9 TRIAL  RATIONALE  ................................ ................................ ................................ .....................  21 
2.10 CORRELATIVE  STUDIES  BACKGROUND  ................................ ................................ .......................  21 
3. PARTICIPANT  SELECTION  ................................ ................................ ................................ ........  24 
3.1 ELIGIBILITY  CRITERIA  ................................ ................................ ................................ ................  24 
3.2 EXCLUSION  CRITERIA  ................................ ................................ ................................ .................  27 
3.3 INCLUSION  OF WOMEN  AND  MINORITIES  ................................ ................................ ...................  28 
4. REGISTRATION  PROCEDURES  ................................ ................................ ................................ . 28 
4.1 GENERAL  GUIDELINES  FOR  DF/HCC  AND  DF/PCC  INSTITUTIONS  ................................ .............  28 
4.2 REGISTRATION  PROCESS  FOR  DF/HCC  AND  DF/PCC  INSTITUTIONS  ................................ .........  29 
4.3 GENERAL  GUIDELINES  FOR  OTHER  INVESTIGATIVE  SITES ................................ .........................  29 
4.4 REGISTRATION  PROCESS  FOR  OTHER  INVESTIGATIVE  SITES ................................ .....................  29 
5. TREATMENT  PLAN  ................................ ................................ ................................ .......................  30 
5.1 TREATMENT  REGIMEN  ................................ ................................ ................................ ...............  30 
5.2 AGENT  ADMINISTRATION ................................ ................................ ................................ ...........  31 
5.3 GENERAL  CONCOMITANT  MEDICATION  AND  SUPPORTIVE  CARE  GUIDELINES  ..........................  33 
5.4 MANAGEMENT  OF CLINICAL  EVENTS  ................................ ................................ .........................  34 
5.5 CRITERIA  FOR  TAKING  A PARTICIPANT  OFF PROTOCOL  THERAPY  ................................ ............  36 
5.6 DURATION  OF FOLLOW  UP ................................ ................................ ................................ .........  37 
5.7 CRITERIA  FOR  TAKING  A PARTICIPANT  OFF STUDY  ................................ ................................ .. 37 
6. DOSING  DELAYS/DOSE  MODIFICATIONS  ................................ ................................ .............  38 
6.1 RECOMMENDED  CRITERIA  FOR  BEGINNING  OR DELAYING  A SUBSEQUENT  TREATMENT  CYCLE  
38 
6.2 NIVOLUMAB  ................................ ................................ ................................ ...............................  38 
6.3 LENALIDOMIDE  ................................ ................................ ................................ ..........................  41 
6.4 DEXAMETHASONE  ................................ ................................ ................................ ......................  46 
6.5 DOSE  DELA Y GUIDELINES  ................................ ................................ ................................ .........  47 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
4  
 7. ADVERSE  EVENTS:  LIST  AND  REPORTING  REQUIREMENTS  ................................ ........  48 
7.1 DEFINITIONS  ................................ ................................ ................................ ...............................  48 
7.2 EXPECTED  TOXICITIES  ................................ ................................ ................................ ...............  49 
7.3 ADVERSE  EVENT  CHARACTERISTICS  ................................ ................................ .........................  52 
7.4 EXPEDITED  ADVERSE  EVENT  REPORTING  ................................ ................................ ..................  52 
7.5 DF/HCC  EXPEDITED  REPORTING  GUIDELINES  ................................ ................................ ...........  52 
7.6 EXPEDITED  REPORTING  TO THE  FOOD  AND  DRUG  ADMINISTRATION  (FDA)  ............................  55 
7.7 EXPEDITED  REPORTING  TO BRISTOL -MYERS  SQUIBB  (BMS)  ................................ ....................  55 
7.8 EXPEDITED  REPORTING  TO HOSPITAL  RISK MANAGEMENT  ................................ ......................  55 
7.9 ROUTINE  ADVERSE  EVENT  REPORTING  ................................ ................................ .....................  55 
8. PHARMACEUTICAL  INFORMATION  ................................ ................................ .......................  56 
8.1 NIVOLUMAB  ................................ ................................ ................................ ...............................  56 
8.2 LENALIDOMIDE  ................................ ................................ ................................ ..........................  59 
8.3 DEXAMETHASONE  ................................ ................................ ................................ ......................  60 
9. BIOMARKER,  CORRELATIVE,  MRD  ASSESSMENT  AND  SPECIAL  STUDIES  ...............  61 
9.1 MINIMAL  RESIDUAL  DISEASE  ASSESSMENT  (MRD)  ................................ ................................ ... 62 
9.2 BONE  MARROW  ASPIRATE  SAMPLES  ................................ ................................ .........................  64 
9.3 PERIPHERAL  BLOOD  SAMPLES  ................................ ................................ ................................ ... 66 
9.4 BUCCAL  SWAB  SAMPLES  ................................ ................................ ................................ ...........  67 
10. STUDY  CALENDAR  ................................ ................................ ................................ ...................  68 
11. MEASUREMENT  OF EFFECT  ................................ ................................ ................................ . 69 
11.1 DEVELOPMENT  OF SYMPTOMATIC  DISEASE  ................................ ................................ ...............  69 
11.2 ANTITUMOR  EFFECT  ................................ ................................ ................................ ..................  69 
12. DATA  REPORTING  / REGULATORY  REQUIREMENTS  ................................ ...................  76 
12.1 DATA  REPORTING  ................................ ................................ ................................ ......................  76 
12.2 DATA  SAFETY  MONITORING  ................................ ................................ ................................ ...... 77 
13. STATISTICAL  CONSIDERATIONS  ................................ ................................ ........................  77 
13.1 STUDY  DESIGN /ENDPOINTS ................................ ................................ ................................ ........  77 
13.2 SAMPLE  SIZE, ACCRUAL  RATE  AND  STUDY  DURATION  ................................ .............................  78 
13.3 STRATIFICATION  FACTORS  ................................ ................................ ................................ .........  78 
13.4 INTERIM  MONITORING  PLAN ................................ ................................ ................................ ...... 78 
13.5 STOPPING  RULE  FOR  SAFETY  ................................ ................................ ................................ ..... 78 
14. PUBLICATION  PLAN  ................................ ................................ ................................ ................  79 
15. REFERENCES  ................................ ................................ ................................ .............................  80 
APPENDIX  A: PERFORMANCE  STATUS  CRITERIA  ................................ ................................ ...... 85 
APPENDIX  B: SPECIMEN  COLLECTION  SCHEDULE  ................................ ................................ ... 86 
APPENDIX  C: SPECIMEN  REQUISITION  ................................ ................................ .........................  87 
APPENDIX D: MANAGEMENT ALGORITHMS FOR ENDOCRINOPATHY, 
GASTROINTESTINAL, HEPATIC, RENAL, SKIN, NEUROLOGICAL, AND PULMONARY 
ADVERSE EVENTS DUE TO NIVOLUMAB  ................................ ................................ ......................  88 
APPENDIX E: DANA -FARBER/HARVARD CANCER CENTER MULTI -CENTER DATA AND 
SAFETY  MONITORING  PLAN  ................................ ................................ ................................ .............  93 
1. INTRODUCTION  ................................ ................................ ................................ ............................  96 
1.1 PURPOSE  ................................ ................................ ................................ ................................ ..... 96 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
5  
 1.2 MULTI-CENTER  DATA  AND  SAFETY  MONITORING  PLAN  DEFINITIONS  ................................ ..... 96 
2. GENERAL  ROLES  AND  RESPONSIBILITIES  ................................ ................................ ..........  97 
2.1 DF/HCC  SPONSOR  ................................ ................................ ................................ ................................ ...............  97 
2.2 COORDINATING  CENTER  ................................ ................................ ................................ ............  97 
2.3 PARTICIPATING  INSTITUTION  ................................ ................................ ................................ ..... 98 
3. DF/HCC  REQUIREMENTS  FOR  MULTI -CENTER  PROTOCOLS  ................................ ........  98 
3.1 PROTOCOL  DISTRIBUTION  ................................ ................................ ................................ ..........  99 
3.2 PROTOCOL  REVISIONS  AND  CLOSURES  ................................ ................................ ......................  99 
3.3 INFORMED  CONSENT  REQUIREMENTS  ................................ ................................ ........................  99 
3.4 IRB  DOCUMENTATION  ................................ ................................ ................................ .............  100 
3.5 IRB RE-APPROVAL  ................................ ................................ ................................ ................................ ............  100 
3.6 PARTICIPANT  CONFIDENTIALITY  AND  AUTHORIZATION  STATEMENT  ................................ ....... 100 
3.7 DF/HCC  MULTI-CENTER  PROTOCOL  REGISTRATION  POLICY  ................................ ..................  100 
3.8 DF/HCC  PROTOCOL  CASE  NUMBER  ................................ ................................ ........................  101 
3.9 SAFETY  ASSESSMENTS  AND  TOXICITY  MONITORING  ................................ ..............................  103 
3.10 DATA  MANAGEMENT  ................................ ................................ ................................ ...............  103 
4. REQUISITIONING  INVESTIGATIONAL  DRUG  ................................ ................................ ..... 104 
5. MONITORING:  QUALITY  CONTROL  ................................ ................................ .....................  104 
5.1 ONGOING  MONITORING  OF PROTOCOL  COMPLIANCE  ................................ ..............................  104 
5.2 MONITORING  REPOR TS ................................ ................................ ................................ ............  105 
5.3 ACCRUAL  MONITORING  ................................ ................................ ................................ ............  105 
6. AUDITING:  QUALITY  ASSURANCE  ................................ ................................ ........................  105 
6.1 DF/HCC  INTERNAL  AUDITS  ................................ ................................ ................................ ...........................  106 
6.2 AUDIT  NOTIFICATIONS  ................................ ................................ ................................ .............  106 
6.3 AUDIT  REPORTS  ................................ ................................ ................................ ........................  106 
6.4 PARTICIPATING  INSTITUTION  PERFORMANCE  ................................ ................................ ...........  106 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
6  
 LIST  OF ABBREVIATIONS  AND  GLOSSARY  OF TERMS  
Common  abbreviations  used in oncology  protocols  are provided  below.  Program -specific  or 
protocol -specific abbreviations must be added to this list, and unnecessary abbreviations 
removed, as applicable.  Abbreviations that are retained should not be changed.  
 
Abbreviation  Term  
5-HT 3 5-hydroxytryptamine  3 serotonin  receptor  
AE adverse  event  
ALL  acute  lymphoblastic  leukemia  
ALP alkaline  phosphatase  
ALT  alanine  aminotransferase  
AML  acute  myelogenous  leukemia  
ANC  absolute  neutrophil  count  
API active  pharmaceutical  ingredient  
aPTT  activated  partial  thromboplastin  time 
Ara-C Cytarabine  
ASCO  American  Society  of Clinical  Oncology  
AST aspartate  aminotransferase  
AUC  area under  the plasma  concentration  versus  time curve  
AUC 24 hr area under  the plasma  concentration  versus  time curve  from  zero to  24 hours  
AUC inf area under  the plasma  concentration  versus  time curve  from  zero to infinity  
AUC τ area under the  plasma concentration  versus  time curve  from  zero to  next dose 
BCRP  breast  cancer  resistance  protein  
hCG beta-human  chorionic  gonadotropin  
BID bis in die; twice  a day 
BM bone marrow  
BSA  body  surface area 
BUN  blood  urea nitrogen  
BZD  Benzodiazepines  
CBC  complete  blood  count  
CFR Code  of Federal  Regulations  
CL clearance,  IV dosing  
CL P plasma  clearance  
CL Total  total clearance  
Cmax single -dose maximum  (peak)  concentration  
CNS  central  nervous  system  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
7  
  
Abbreviation  Term  
 
CO 2 carbon  dioxide  
CR complete  remission  
CRM  continual  reassessment  method  
CRP C-reactive  protein  
CSF-1R colony -stimulating  factor  1 receptor  
CT computed  tomography  
Ctrough single -dose end of dosing  interval  (trough)  concentration  
CV coefficient  of variation  
CYP  cytochrome  P450 
DDI drug-drug interaction  
DLT  dose-limiting  toxicity  
DME  drug metabolizing  enzymes  
DNA  deoxyribonucleic  acid 
ECG  Electrocardiogram  
ECOG  Eastern  Cooperative  Oncology  Group  
eCRF  electronic  case report  form 
EDC  electronic  data capture  
ELISA  enzyme -linked  immunosorbent  assay  
EOS End of Study (visit)  
EOT  End of Treatment  (visit)  
EU European  Union  
FDA  United  States  Food and  Drug  Administration  
GCP  Good  Clinical  Practice  
G-CSF granulocyte  colony  stimulating  factor  
GGT  gamma  glutamyl  transferase  
GI Gastrointestinal  
GLP Good  Laboratory  Practices  
GM-CSF granulocyte  macrophage -colony  stimulating  factor  
GMP  Good  Manufacturing  Practice  
Hb Hemoglobin  
Hct Hematocrit  
HDPE  high-density  polyethylene  
hERG  human  ether -à-go-go related  gene 
HIV human  immunodeficiency  virus  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
8  
  
Abbreviation  Term  
HNSTD  highest  nonseverely  toxic  dose 
IB Investigator’s  Brochure  
IC50 concentration  producing  50% inhibition  
ICF informed  consent  form 
ICH International  Conference  on Harmonisation  
IEC independent  ethics  committee  
IRB institutional  review  board  
ITT intent -to-treat 
IV intravenous;  intravenously  
IVRS  interactive  voice  response  system  
Ki inhibition  constant  
KPS Karnofsky  Performance  Status  
LDH  lactate  dehydrogenase  
LFT liver function  test(s)  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
Millennium  Millennium  Pharmaceuticals,  Inc., and its affiliates  
MRI magnetic  resonance  imaging  
MRU  medical  resource  utilization  
MTD  maximum  tolerated  dose 
MUGA  multiple  gated  acquisition  (scan)  
NCCN  National  Comprehensive  Cancer  Network  
NCI National  Cancer  Institute  
NCI CTCAE  National  Cancer  Institute  Common  Terminology  Criteria  for Adverse  Events  
NPO  nothing  by mouth  
NYHA  New  York  Heart  Association  
PBMC  peripheral  blood  mononuclear  cell 
PCR polymerase  chain  reaction  
PD progressive  disease  (disease  progression)  
Pgp P-glycoprotein  
PK pharmacokinetic(s)  
PO per os; by mouth (orally)  
PR partial  response  
PRO  patient -reported  outcome  
PSA prostate -specific  antigen  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
9  
  
Abbreviation  Term  
QD quaque  die; each day; once  daily  
QID quater  in die; 4 times  a day 
QOD  quaque  altera  die; every  other  day 
QOL  quality  of life 
QTc rate-corrected  QT interval  (millisec)  of electrocardiograph  
RBC  red blood  cell 
RECIST  Response  Evaluation  Criteria  in Solid  Tumors  
SAE serious  adverse  event  
SC Subcutaneous  
SD stable  disease  
SmPC  Summary  of Product  Characteristics  
t1/2 terminal  disposition  half-life 
TGI tumor  growth  inhibition  
Tmax single -dose time to reach  maximum  (peak)  concentration  
UK United  Kingdom  
ULN  upper  limit  of the normal  range  
US United  States  
Vz volume  of distribution  in the terminal  phase  
WBC  white  blood cell 
WHO  World  Health  Organization  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
10  
  
PROTOCOL  SUMMARY  
 
Study Title: Phase II Trial of the PD -1 Antibody Nivolumab in Combination with 
Lenalidomide  and Low  Dose  Dexamethasone  in Patients  with  High -Risk  Smoldering  
Multiple  Myeloma  
 Phase:  II  
 Number  of Patients:  41  
 Study  Objectives:  
Primary  Objectives  
To determine the proportion of high risk smoldering multiple myeloma patients 
who are progression free at 2 years after receiving Nivolumab and lenalidomide+ 
dexamethasone combination therapy  
 
Secondary  Objectives  
• To assess  the response  rate of the combination  in these  patients  
• To assess  time to progression  and progression  free survival  
• To assess  duration  of response  
• To assess  the safety  of the combination  
• To examine  molecular  evolution  of the tumor  cells 
• To determine  the role of immune  cells in the progression  of smoldering  MM 
• To determine  minimal  residual  disease  (MRD)   
 Overview  of Study  Design:  
This is a single arm  phase  II study  using  the combination  of Nivolumab  and lenalidomide  
+ low dose dexamethasone  in patients  with high risk smoldering  multiple  myeloma.  The 
study  is designed  to examine  novel  therapeutic  immunotherapy  combinations  in patients 
with smoldering MM. The trial will include a safety run in of 10 patients. If three of the 
ten patients experience a serious, unexpe cted adverse event during their first cycle of 
therapy, the study will be suspended temporarily until further safety review.   
 Study  Population:  
SELECT  INCLUSION  CRITERIA  
• Age  18 years.  
• Must  meet  criteria  of high risk smoldering  MM as described  with one of the below 
criteria:  
o Bone  marrow  clonal  plasma cells  ≥10%  and any  one or more  of the following:  
▪ Serum  M protein  ≥3.0g/dL  
▪ IgA SMM  
▪ Immunoparesis with reduction of two uninvolved immunoglobulin 
isotypes  
▪ Serum  involved/uninvolved  free light chain  ratio ≥8 (but less than  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
11  
  
100) 
▪ Progressive  increase  in M protein level  (Evolving type  of SMM)†  
▪ Bone  marrow  clonal  plasma  cells 50-60% 
▪ Abnormal plasma cell immunophenotype (≥95% of bone marrow 
plasma cells are clonal) and reduction of one or more uninvolved 
immunoglobulin isotypes  
* All patients should have four or six color flow cytometry performed on the baseline 
bone marrow sample, as fe asible. Patients evaluated for eligibility by Spanish Criteria 
must have their result confirmed by four color flow cytometry.  If four or six color flow 
cytometry is not available at the site, the baseline bone marrow must be sent to Dana - 
Farber Cancer Ins titute to confirm eligibility prior to enrollment.  
▪ High risk cytogenetics or FISH including t (4;14) or del 17p or 1q 
gain 
▪ Increased  circulating  plasma  cells 
▪ MRI  with diffuse  abnormalities  or 1 focal  lesion  
▪ PET-CT with focal  lesion  with increased  uptake  without  underlying 
osteolytic bone destruction  
† Increase in serum monoclonal protein by ≥10% on two successive evaluations within a  
6 month period  
• No evidence  of CRAB  criteria*  or new criteria  of active  MM which  including  the 
following:  
o Increased calcium levels (corrected serum calcium >0.25 mmol/dL {1mg/dL) 
above the upper limit of normal or >2.75 mmol/dL {11mg/dL});  
o Renal  insufficiency  (attributable  to myeloma); 
o Anemia  (Hb 2g/dL  below  the lower  limit  of normal  or <10g/dL); 
o Bone lesions (lytic lesions or generalized osteoporosis with compression 
fractures) 
o No evidence of the following new criteria for active MM including the 
following:  Bone  marrow  plasma  cells ≥60%,  Serum  involved/uninvolved  FLC 
ratio ≥100*, and MRI with more than one foc al lesion (*except for light chain 
smoldering MM)  
* Participants  with CRAB  criteria  that are attributable  to conditions  other  than the disease 
under study may be eligible  
• ECOG  Performance  Status  (PS) 0, 1, or 2. 
• The following  laboratory  values  obtained  21 days prior  to registration:  
o ANC   1000/ L 
o PLT  50,000/ L 
o Total  bilirubin  ≤ 1.5 mg/dL  (If total is elevated  check  direct  and if normal 
patient is eligible.)  
o AST   3 x institutional  upper  limit  of normal  (ULN) 
o ALT   3 x institutional  upper  limit  of normal  (ULN) 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
12  
  
 SELECT  EXCLUSION  CRITERIA  
• Symptomatic Multiple Myeloma or any evidence of CRAB criteria. Any prior therapy 
for Multiple Myeloma should also be excluded Bisphosphonates are not excluded. 
Patients  who received  prior  therapy  due to being  incorrectly  diagnosed  as having  overt 
multiple myeloma may not be excluded after discussion with the overall PI.  
• Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary 
therapy considered investigational. Prior therapy with bisphosphonate is allowed.  
Prior radiation therapy to a solitary plasmacytoma is allowed.  
• Autoimmune disease: Patients with a history of inflammatory bowel disease, 
including  ulcerative  colitis  and Crohn’s  Disease,  are excluded  from  this study,  as 
are patients with a history of symptomatic disease (eg, rheumatoid arthritis, systemic 
progressive sclerosis [scleroderma], systemic  lupus erythematosus, autoimmune 
pneumonitis, autoimmune vasculitis [eg, Wegener’s Granulomatosis]) and motor 
neuropathy considered of autoimmune origin (e.g. Guillain -Barre Syndrome and 
Myasthenia, Gravis). Patients with Hashimoto’s thyroiditis are eligib le to go on study. 
The Overall  PI must  be consulted  to discuss  any other  autoimmune  disorders  not listed 
here to determine if the patient is eligible for the trial.   
 Duration  of Study:  5 years   
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
13  
  
 
1. OBJECTIVES  
Smoldering Multiple Myeloma (SMM) is a heterogeneous disease entity that includes patients 
who have a disease burden that is higher than that in patients with MGUS but who are not yet 
symptomatic1. The term SMM was first described by Greipp and Kyle et al in 19802 and was 
followed by many other descriptions terming it indolent MM3, or Durie Salmon Stage I4. It was 
not until 2003 that the International Myeloma Working Group (IMWG) described the exact 
definition of this disease. SMM was defined as serum M -protein ≥3 g/L and/or ≥10%  
monoclonal plasma cells in the bone marrow (BM), Table 15,6. While the incidence and 
prevalence of SMM in the population is not well defined, it has been estimated to represent 
approximately 8% to 20% of patients within the MM spect rum1. 
Most  recently,  the IMWG  further  re-defined  the group  of patients  who meet  criteria  for treatment 
and included asymptomatic SMM patients who are likely going to have end -organ damage in the 
near future, previously defined as “ultra -high risk smoldering myeloma”. These include patients 
with bone  marrow  plasmacytosis  ≥60%  7; an abnormal  FLC-ratio ≥100  (involved  kappa)  or 
<0.01 (involved lambda) 8: and/or 2 or more focal bone marrow lesions detected by functional 
imaging including PET -CT and/or MRI 9,10. These patients should therefore not be considered 
SMM anymore but rather re -defined as patients with myeloma -defining events that require 
therapy.  
 
The overall risk of progression of SMM is 10% per year for the first 5 years and 3% per year for 
the next 5 years11. The most common factors used to stratify patients with SMM are the Mayo 
Clinic criteria11,12 and the Spanish PETHEMA criteria13. The Mayo  Clinic criteria are based on 
the tumor burden defined by the serum protein level (by serum protein electrophoresis or light 
chain ratio)  or by the percent bone marrow  plasma cell involvement (see  Table 2 )11,12, leading to 
risks of progression at 5 years of 25% for low risk, 51% for intermediate risk and 76% for high 
risk individuals who have 1, 2 or 3 risk factors respectively11,12. The risk stratification of the 
PETHEMA group is based on identifying the number of clonal plasma cells in the bone marrow 
by flow cytometry (≥95% ratio of abnormal neoplastic plasma cells to normal plasma cells) and 
reduction of uninvolved immunoglobulins, with 5 year -risk of progression being 4%, 46%, and 
72% for patients with 0, 1 or 2 risk factors, respectively13. 
The paradi gm of therapy in Smoldering Multiple Myeloma (SMM) is changing as we develop 
better therapeutic agents that prevent end organ damage and improve survival of patients with 
multiple myeloma (MM)14-16. Indeed, recent studies of a phase III trial of lenalidomi de and 
dexamethasone versus placebo showed improved response, progression free survival and overall 
survival in patients with high risk smoldering MM compared to placebo control17. Therefore, 
there is a need to examine novel therapeutic combinations in pat ients with high risk smoldering 
MM.  
 
Our overarching hypothesis is that early therapeutic interventions in patients with 
smoldering MM will prevent/delay progression to overt MM. We will examine the in vivo 
activity and safety of nivolumab and lenalidomide  in patients with high -risk SMM.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
14  
  
1.1 Study  Design  
 
This is a phase II study using the combination of Nivolumab and lenalidomide + low dose 
dexamethasone in patients with high -risk smoldering multiple myeloma. The trial will include a 
safety run in of 10 patients. If three of the ten patients experience a serio us, unexpected adverse 
event during their first cycle of therapy, the study will be suspended temporarily until further 
safety review . If any one of the study medications is permanently discontinued for any reason 
including toxicity, or FDA mandate, the pa tient may remain on the study at the discretion of the 
principal investigator.  
 
** As of September 2017, the trial has been put on partial clinical hold by the Food and Drug 
Administration: all patients are to discontinue nivolumab indefinitely, and no add itional patients 
will be accrued to the trial. Participants may elect to remain on lenalidomide/dexamethasone or 
lenalidomide therapy alone for disease control after discussion with the overall PI.  
 
 
1.2 Number  of Patients  
 
A total of 41 patients  will be included  on this study.  Enrollment  includes  patients  who receive 
the first day of therapy.  
 
1.3 Duration  of Study  
 
A treatment  cycle  is defined  as 28 consecutive  days.  
 
Patients will receive 6 cycles of induction therapy followed by 6 cycles of maintenance the rapy 
with lower doses of lenalidomide and no dexamethasone for a total of 12 months.  
 
During maintenance, if a patient experiences biochemical progression (≥ 25% increase and an 
absolute increase of ≥ 0.5g/dL from their nadir in their serum or urine m -spike or FLC with no 
CRAB features attributable to MM progression) high -dose dexamethasone may be re -added to 
the combination at a dose of 40mg oral given on days 1, 8, and 15 of a 28 day cycle after 
discussion with the overall PI.  
 
For all treatment cycles a +/ - 7 day window is allowed for Nivolumab. For hold and delay 
guidelines for lenalidomide and dexamethasone, please refer to Table 17. The treatment plan is 
designed to be administered on an outpatient basis, however if necessary , may be given as 
inpatient.  
 
Patients  will be followed  for up to three  years  after discontinuation  of therapy.  
 
1.4 Primary  Objectives  
 
• To determine the proportion of high risk smoldering multiple myeloma patients who are 
progression free at 2 years after rec eiving Nivolumab and lenalidomide + dexamethasone 
combination therapy  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
15  
  
 
1.5 Secondary  Objectives  
 
• To assess  the response  rate of the combination  in these  patients  
• To assess  time to progression  and progression  free survival  
• To assess  duration  of response  
• To assess the  safety  and tolerability  of the combination  
• To examine  molecular  evolution  of the tumor  cells 
• To determine  the role of immune  cells in the progression  of smoldering  MM 
• To determine  minimal  residual  disease  (MRD) by  Adaptiv e’s LymphoSIGHT  sequencing 
platform.  
 
 
2. BACKGROUND  
 
2.1 Multiple Myeloma  
 
Multiple myeloma is a plasma cell neoplasm characterized by multifocal proliferation of clonal, 
long-lived plasma cells associated with an overproduction of monoclonal gammaglobulin 18. In 
2010 the International Myeloma Working Group (IMWG) defined monoclo nal gammopathy of 
undetermined significance  (MGUS) by the presence of serum M -protein < 3g/dL, clonal plasma 
cell population in the bone marrow < 10%, and the absence of end -organ damage such as 
hypercalcemia (serum calcium ≥ 11.5 mg/dL), renal insufficien cy (serum creatinine ≥ 2 mg/dL), 
anemia (hemoglobin value below the lower limit of normal by more than 2 g/dL or hemoglobin 
value < 10 g/dL) and lytic bone lesions (CRAB features) that can be attributed to the plasma cell 
proliferative  disorder 19. Smolder ing multiple  myeloma  was defined  by the presence  of serum  M- 
protein ≥ 3 g/dL or IgA> 2g/ dL or urinary monoclonal protein > 500 mg/ dL and/or clonal bone 
marrow plasma cells ≥ 10% and the absence of CRAB features clinically.  
 
In a large  population  based  study in Olmsted  County,  MN, Kyle  et al. analyzed  serum  samples  of 
more than 75% of residents, 50 years or older, within the county 20. They identified MGUS in 
694 of 21,463 patients tested (3.2%). While the overall prevalence was noted to be 3.2% (95 % 
CI, 3.0 to 3.5), there was a significant age dependent increase in both sexes with the prevalence 
among persons 80 years of age or older  4 times as high as among those 50 -59 years of age. Age - 
adjusted rates were higher in men (4.0 %, 95% C.I., 3.5 to 4.4) than in women (2.7%, 95% C.I., 
2.4 to 3.0). In a subsequent study on a majority of the same patients from Olmsted County, 
Dispenzieri, et al, used the free light chain assay (FREELITE) and showed that 0.8% of people 
older than 50 years had light chain -MGUS. The total MGUS prevalence including the light 
chain -MGUS cases was noted at 4.2% (95% C.I., 3.9 to 4.5%) 21. A limitation of both the se 
studies was that 97.3% of the residents of Olmsted County were white.  
 
For SMM patients a M -protein ≥ 3 g/dL, a FLC ratio outside the range of 0.125 to 8, and ≥ 10% 
plasma cells in the bone marrow are considered as adverse factors in this model 11,12. The 5-year 
rate of progression in patients with 1, 2 and 3 risk factors was 25%, 51% and 76% respectively. 
The time to progression  with these  risk factors  was 10, 5.1 and 1.9 years  respectively.  Recently  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
16  
  
Rajkumar et al have proposed that SMM with >60% plasma cells progress to multiple myeloma 
within  2 years  in 95% cases  and should  be treated  at diagnosis  even  in the  absence  of symptoms.7 
 
 
 
 
 
 
Table  1: Mayo  Clinic  model  for risk factors  and % risk of progression  for smoldering  MM 
 
Model  No. of Risk 
Factors  5-Year  Progression  % Time  to Progression 
(in years)  
Mayo  Clinic  Model  1 25 10 
Risk Factors:  
2 51 5.1 • M-protein  ≥ 3.0g/dL  
• ≥10%  plasma  cells in the BM    
• FLC ratio outside  the range  of 
0.125  to 8 3 76 1.9 
 
2.2 MGUS  and SMM  consistently  precedes  multiple  myeloma  
 
Since  the early  description  of monoclonal  gammopathy  of undermined  significance  it was known 
that some cases of MGUS progressed to symptomatic myeloma but it was not clear whether all 
cases of myeloma are preceded by MGUS. In a study of more than 77,000 individuals, 55 to 74 
years of age, from a cancer screening trial, Landgren et al found 7 1 patients who developed 
multiple myeloma22. They performed serum protein electrophoresis, immunofixation and kappa - 
lambda free light chain assay on prediagnostic samples in these patients. The study showed that 
patients who eventually developed multiple myeloma consistently had MGUS in the years 
preceding development of multiple myeloma. Interestingly, in half the patients, there was a 
steady increase in the M -protein before the development of symptomatic myeloma, while in the 
other half the M -protein sta yed fairly stable. A second study by Weiss et al found a monoclonal 
gammopathy  in 27 of 30 patients  (90%)  in sera 2 or more  years  before  the diagnosis  of myeloma  
23. 
2.3 Molecular  studies  in MGUS  and SMM  
 
A recent study using SNP -based arrays compared MGUS, SMM and MM samples 24. They  
found  copy number abnormalities  in all stages. The incidence  of genomic imbalance did increase 
from a median of 5/case for MGUS to 7.5/case for SMM and 12/case for MM. The stu dy also 
noted certain genomic changes that were exclusive to MM including 11q and 21q gains and 16q 
and 22q deletions. Interestingly, the study found these abnormalities in a small subclone in 
MGUS patients indicating that most if not all of the chromosoma l changes may be already 
present at the MGUS state.  These findings also support a possible role of ‘clonal tides’ in the 
evolution from precursor state to symptomatic myeloma as explained below.  Two major 
pathways  have  been  proposed  as the early  oncogenic  events  in the development  of the myeloma  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
17  
  
cell based on chromosomal abnormalities noted  in MGUS, SMM and MM - the non -hyperdiploid 
and the hyperdiploid pathway. The main cytogenetic changes that have been observed in MGUS 
and SMM are indicated  in the table below.  
 
 
 
 
 
Table  2: Cytogenetic  abnormalities  in MGUS,  SMM  and MM 
 
Cytogenetic  Abnormality  Involved  Oncogene  MGUS%  SMM%  MM%  
IgH Translocations  See below  40-50% 40-50% 50-70% 
t(11;14)(q13;q32)  CCND1  
(Cyclin  D1) 10-25% 10-25% 15% 
t(4;14)(p16;q32)  FGFR3  and MMSET  2-9% 3-13% 10-15% 
t(14;16)(q32;q23)  C-MAF  2-5% 2-5% 2-5% 
Other  IgH Translocations  
• t(6;14)(p21;q32)  
• t(14;20)(q32;q11)  
• etc.  
CCND3  (Cyclin  D3), 
MAFB, etc.   
6-10%  
1-10%  
10% 
13q Deletion  Unknown  25-50% 35-50% 40-50% 
Hyperdiploidy  Unknown  40-50% 40-50% 40-50% 
 
Other  molecular  studies  in MGUS  and SMM  included  microRNA  studies.  MicroRNAs  are single 
stranded RNA molecules that regulate gene expression posttranscriptionally and are being 
implicated in a large number of cancers 25. A study comparing miRNA profiles of normal PC, 
MGUS, SMM and MM found overexpression of mir -21, mir -106~25 and mir18 1a and mir181b 
in MGUS and MM compared to normal PCs 26. The study also found mir -32 and mir17~92 
clusters to be upregulated only in MM and not in any other forms. Mir 17~92 and Mir 106~25  
are known to have a role in B cell development as well as B cell ly mphomas targeting PTEN, 
E2F1, Bcl2 and BIM 25,26. The mir17 cluster has been shown to upregulated by the transcription 
factor c -Myc, which is considered a late event in myeloma progression 27-29. 
 
With  the advances  in deep  sequencing  techniques,  we are now able to study  the whole  genome  of 
myeloma cells and compare that to the normal human genome. Several studies employing these 
techniques are beginning to shift our understanding of the pathogenesis of myeloma. These 
studies have revealed that the previousl y held dogma that cancer progression occurred through a 
linear cumulative acquisition of mutational changes may be too simplistic. A new model of 
clonal heterogeneity is beginning to emerge 30. In fact tumor evolution may indeed proceed like 
Darwinian evol ution with tumor progression involving a branching process with coexistent  
clonal heterogeneity. In this model various subclones exist in a dynamic equilibrium, competing 
for limited  resources  and over time the subclonal  populations  ebb and flow under  environmental  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
18  
  
evolutionary  pressures  with alternating  dominance  of various  subclones  at different  time points31- 
35. Most of these studies were done on patients with symptomatic multiple myeloma and as 
similar studies involving MGUS and SMM emerge, our understanding of the pathogenesis of 
myeloma from these precursor states will continue to evolve. It is possible that the progression 
from  myeloma  precursor  state to symptomatic  disease  also involves  ‘clonal  tides’  with expansion 
of a subclone leading to progression. Several previous studies have identified clonal 
heterogeneity in a subset of MGUS patients24,36,37. 
 
2.4 Definition  of SMM  and MM 
 
The diagnosis  of smoldering  (asymptomatic)  multiple  myeloma  (SMM)38,39 is based  on: 
 
• Serum monoclonal protein (IgG, IgM, IgD or IgA) ≥3 g/dL or urinary monoclonal 
protein  ≥500  mg per 24 h and/or  clonal  bone  marrow  plasma  cells (BPMC)  10–60%.  
• Absence  of myeloma defining  events or amyloidosis  
• No evidence  of the following  CRAB  criteria  or other  Myeloma  defining  events  (MDE):  
o Increased  calcium  levels  (corrected  serum  calcium  >0.25  mmol/dL  above  the 
upper limit of normal or >2.75 mmol/dL) related to MM  
o Renal  insufficiency  (attributable  to MM)  
o Anemia  (Hb 2g/dL  below  the lower  limit  of normal  or <10g/dL)  related  to MM 
o Bone  lesions  (lytic  lesions  or generalized  osteoporosis  with compression 
fractures)  
 
New  MDE  criteria  that indicates  overt  MM  and not SMM38,39 
 
The following criteria  are now  incorporated  with the CRAB criteria  to indicate  that patients meet 
criteria for therapy as symptomatic or overt MM:  
• Bone  marrow  plasma  cells >60%  
• Serum involved/uninvolved FLC ratio ≥100mg/L, provided the absolute level of the 
involved free light chain is at least 100 mg/L and repeated twice (except for mono clonal 
light chain smoldering MM and for those with stable serum light chains for 6 months.)  
• MRI  with two or more  focal  lesion  that is  at least 5  mm or greater in  size 
 
2.5 Definitions  of High -Risk  SMM  
 
Based on the new defined high risk criteria for smoldering myeloma based on 40 as described  in 
table 3 below:  
 
Table  3 Bone  marrow  clonal  plasma  cells ≥10%  and any one or more  of the following:  
Serum  M protein  ≥3.0g/dL  
IgA SMM  
Immunoparesis  with reduction  of two uninvolved  immunoglobulin  isotypes  
Serum  involved/uninvolved  free light chain  ratio ≥8 (but less than 100) 
Progressive  increase  in M protein  level  (Evolving  type of SMM)† 
Bone  marrow  clonal  plasma  cells 50-60% 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
19  
  
Abnormal plasma cell immunophenotype (≥95% of bone marrow plasma cells are clonal) and  
reduction of one or more uninvolved immunoglobulin isotypes  
t (4;14) or  del 17p  or 1q  gain 
Increased  circulating  plasma  cells 
MRI  with diffuse  abnormalities  or 1 focal  lesion  
PET-CT with focal  lesion  with increased  uptake  without  underlying  osteolytic  bone  destruction  
Monoclonal  light chain  excretion  of 500mg/24  hours  or higher*  
† Increase in serum monoclonal protein by ≥10% on two successive evaluations within a 6  
month period  
* Monoclonal  Light  Chain Smoldering  
 
2.6 Treatment  of high  risk SMM  
 
In a randomized open -label phase 3 trial 17, 119 patients with high -risk smoldering myeloma 
were randomized to treatment or observation. Patients in the treatment group received an 
induction  regimen  (lenalidomide  at a dose of 25 mg  per day on  days 1 to 21, plus dexamethasone 
at a dose of 20 mg per day on days 1 to 4 and days 12 to 15, at 4 -week intervals for nine cycles), 
followed by a maintenance regimen (lenalidomide at a dose of 10 mg per day on days 1 to 21 of 
each 28 -day cycle for 2 years). The primary end point was time to progression to sympt omatic 
disease. Secondary end points were response rate, overall survival, and safety. After a median 
follow -up of 40 months, the median time to progression was significantly longer in the treatment 
group than in the observation group (median not reached v s. 21 months; hazard ratio for 
progression, 0.18; 95% confidence interval [CI], 0.09 to 0.32; P<0.001). The 3 -year survival rate 
was also higher in the treatment group (94% vs. 80%; hazard ratio for death, 0.31; 95% CI, 0.10 
to 0.91; P=0.03). A partial res ponse or better was achieved in 79% of patients in the treatment 
group after the induction phase and in 90% during the maintenance phase. Toxic effects were 
mainly grade 2 or lower. Early treatment for patients with high -risk smoldering myeloma delays 
progression to active disease and increases overall survival. ([STUDY_ID_REMOVED]).  
 
2.7 Nivolumab  
 
2.7.1 Preclinical  Experience  
 
Please refer to the current nivolumab Investigator’s Brochure (IB) and Safety Management 
Attachment located in Appendix D  
 
2.7.2 Clinical  Experience  
 
Nivolumab  is a fully  human  monoclonal  antibody  (HuMAb;  immunoglobulin  G4 [IgG4] -S228P) 
that targets the PD -1 cel l surface membrane receptor.  Nivolumab inhibits the interaction of PD - 
1 with its ligands, PD -L1 and PD -L2, resulting in enhanced T -cell proliferation and interferon - 
gamma (IFN -γ) release in vitro.  
 
Nivolumab has demonstrated clinical activity as monother apy in subjects with a variety of 
malignancies  including  lung,  melanoma,  renal  cell carcinoma  and in lymphomas,  responses  have 
been reported for diffuse large B -cell lymphoma, follicular lymphoma, and Hodgkin’s  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
20  
  
lymphoma.  (See IB for details).  
 
Approximately  4,000  subjects  have  received  nivolumab  monotherapy  in single - or multiple -dose 
Phase 1/2/3 studies or studies with nivolumab in combination with other therapeutics 
(ipilimumab, cytotoxic chemotherapy, anti angiogenics, and targeted therapies).  The safety 
profile is generally consistent across completed and ongoing clini cal trials, with no maximum 
tolerated dose (MTD) reached at any monotherapy dose tested up to 10 mg/kg.  There was no 
pattern  in the incidence,  severity,  or causality  of AEs to nivolumab  dose level.  The safety  profile 
of nivolumab combination therapy varies  with the agent combined with nivolumab, but is 
generally  consistent  with the safety  profiles  observed  with either  agent  alone  and, in some cases, 
the frequency of AEs may be greater than that observed with either agent alone.  For nivolumab 
monotherapy and  combination therapy, most high -grade events were manageable with use of 
corticosteroids or hormone replacement therapy.  
 
2.8 Pharmacokinetics  and Drug  Metabolism  
 
2.8.1 Flat Dose  Regimen  
 
The safety and efficacy of 240 mg Q2W flat dose of nivolumab is expected to be similar to 3 
mg/kg Q2W dosing regimen. Using the PPK model, exposure of nivolumab at 240 mg flat dose 
is identical to a dose of 3 mg/kg for subjects weighing 80 kg, which is the  approximate median 
body weight in nivolumab clinical trials. Across the various tumor types in the clinical program, 
nivolumab has been shown to be safe and well tolerated up to a dose level of 10 mg/kg, and the 
relationship  between  nivolumab  exposure  produced  by 3 mg/kg  and efficacy  and safety  has been 
found to be relatively flat. Given the similarity of nivolumab PK across tumor types and the 
similar exposures predicted following administration of 240 mg flat dose compared to 3 mg/kg, 
it is expected  that the safety  and efficacy  profile  of 240 mg nivolumab  will be similar  to that of 3 
mg/kg nivolumab. Hence, a flat dose of 240 mg nivolumab is under investigation.  
 
2.8.2 Shorter Infusion Duration  
 
Establishing that nivolumab can be safely administered using a sho rter infusion time (30 
minutes)  is under  investigation.  Previous  clinical  studies  of nivolumab  monotherapy  have  used a 
60-minute infusion duration wherein, nivolumab has been safely administered up to 10 mg/kg 
over long treatment periods. Infusion reactions including high -grade hypersensitivity reactions 
have been uncommon across nivolumab clinical program. In CA209010, a dose association was 
observed  for infusion  site reactions  and hypersensitivity  reactions (1.7%  at 0.3 mg/kg, 3.7%  at 2 
mg/kg and 18.5% at 10 mg/kg). All the events were Grade 1 -2 and were manageable. An 
infusion duration of 30 minutes for 3 mg/kg nivolum ab (30% of the dose provided at 10 mg/kg) 
is not expected to present any safety concerns compared to the prior experience at 10 mg/kg 
nivolumab dose infused over a 60 -minute duration. Overall, a change in safety profile is not 
anticipated with 30 -minute in fusion of nivolumab.  
 
Additional  information  on the background  and development  of nivolumab  can be found  on the 
Nivolumab Investigator’s Brochure.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
21  
  
2.9 Trial Rationale  
 
Based on the activity of lenalidomide and dexamethasone in patients with SMM and based on  
the data that progression of tumors is based on evasion and suppression of the host immune 
system, we believe that the combination of a PD -1 inhibitor with lenalidomi de will induce high 
responses and delay development of symptomatic MM in patients with high risk Smoldering 
MM.  
 
Patients who develop symptomatic disease will receive induction therapy with standard 
therapeutic options for multiple myeloma including combin ations such as those of proteasome 
inhibitors, immunomodulators and steroids or cyclophosphamide, proteasome inhibitors and 
dexamethasone.  
 
2.9.1 Dexamethasone  effect  on immune  response  
 
The use of dexamethasone  in this study  may blunt  the immune  response  to Nivolumab.  However, 
all prior studies of lenalidomide and dexamethasone in smoldering myeloma have used the 
combination of both agents. Therefore, to assess the true significance of adding Nivolumab to 
this combination, we will not omit dexamet hasone from the regimen. In addition, recent studies 
in MM have shown that pulse dexamethasone used in our regimens of myeloma does not 
significantly blunt the immune response41. Moreover, recent studies in relapsed myeloma have 
shown preliminary strong ac tivity of immune -mediated antibodies in combination with 
lenalidomide and dexamethasone. Moreover, we will monitor for immune cell numbers and 
checkpoint regulation on immune cells at the start of therapy and during therapy to define the 
effect  of these  agents on immune  regulation.  If patients  cannot  tolerate  dexamethasone,  then dose 
reductions will be permitted as described in dose reduction/modification sections.  
 
2.9.2 Stem  Cell Mobilization and Collection  
 
Patients who are eligible for stem cell collection an d who intend to go on to transplant will have 
the option to collect stem cells during the course of therapy on this trial at the time of best 
response (PR,VGPR, or CR or at investigator’s discretion) or after 6 cycles of induction therapy, 
however, collect ion may be done at any time during the study after discussion with the Overall 
PI. Institutional guidelines should be followed in regards to stem cell mobilization and  
collection. Patients should be mobilized as soon as possible after stopping study treatm ent. 
Patients may delay resuming treatment for up to 3 weeks after collection is complete.  
 
Plerixafor should be utilized as a mobilization agent primarily; however cyclophosphamide or 
other agents may be used at the investigator’s discretion. Based on dat a using combination 
therapies for induction, there have been no major concerns regarding stem cell collections after 
treatment with these agents.  
 
2.10 Correlative  Studies  Background  
 
2.10.1  DNA  and RNA  sequencing  of tumor  cells 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
22  
  
The "clonal evolution" model of cancer emerged amid ongoing advances in technology, 
especially in recent years during which next generation sequencing has provided ever higher 
resolution pictures of the genetic changes in cancer cells and heterogeneity in tumors where 
tumor progression proceeds in a branching rather than in a linear manner, leading to substantial 
clonal diversity and coexistence of wide genetic heterogeneity42,43. The genomic complexity in 
MM was recently corroborated by massive parallel -sequencing studies displaying the lack of a 
universal driving mutation30. Recent studies have shown intraclonal heterogeneity that occurs at 
different stages of progression in MM31,32. Most recently, exome sequencing confirmed that the 
heterogeneity observed  in the transformation from MGUS/SMM to MM is likely to be an 
essential  feature  of clonal  evolution  and disease  progression44,45. Point  mutations  such as N-RAS, 
K-RAS, MYC up -regulation46, and gain or loss of chromosome 1q or 1p seem to correlate with 
disease progression from MGUS and SMM29. A progressive increase in the incidence of copy 
number abnormalities from MGUS to SMM and to MM has been recently observed47. 
 
We plan to perform exome sequencing and RNA sequencing studies on tumor cells obtained at 
the time of screening as well as from subsequent bone marrow biopsy samples to examine clonal 
heterogeneity, resistant clones at best response and at time of end of study or tumor progression. 
The hypothesis is that clonal evolution and the progression/respo nse of different clones in 
response to immunotherapy would be critical to better understand clonal evolution in MM and 
help in the development of future therapeutic options for patients with MM.  
 
The tumor research samples will be collected at the time of scheduled bone marrow biopsies. 
From these samples, high quality DNA (for tumor cells) and RNA for both exome sequencing 
and RNA sequencing will be obtained. In brief, BM aspirates will be obtained after informed 
consent. The tumor cells will be collected using CD138+ bead selection (over 90% purity based 
on prior publications)30,31. For samples that have a small fraction of plasma cells, we will use 
flow sorting for CD138/CD38/CD56 and CD19 -ve to obtain a pure malignant plasma cell 
population based on prio r published markers of malignant plasma cells48. Germline DNA will 
also obtained from a buccal swab from all patients.  
 
2.10.2  Exome  sequencing  of tumor  cells 
 
Whole -exome capture libraries will be constructed from 100ng of tumor and normal DNA 
followed by shearing, end repair, phosphorylation and ligation to barcoded sequencing adapters. 
The DNA will be size -selected to exonic hybrid capture using SureSelect v2 Exome bait 
(Agilent, CA). Samples will be multiplexed and sequenced on Illumina HiSeq flowcells with the 
goal of an average depth of coverage of 100x. The resulting data will be analyzed with the 
current Illumina pipeline, which generates data files (BAM f iles). The details of the current 
analysis pipeline are published elsewhere30,49. Briefly, somatic single nucleotide variants are 
determined using the MuTect algorithm50. Indels and translocations are determined by the 
algorithms IndelLocator and dRanger, respectively. The MutSig algorithm identifies genes in 
which the observed mutations are inconsistent with what would be expected at random51. To 
accurately assess the significance of mutations, MutSig takes into account several covariates, 
which influence the background mutation model. These include the expression level of genes  
(for which published gene expression data of MM samples can be used), and other gene 
characteristics  observed  empirically  to co-vary with mutation  rate: local  relative  replication  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
23  
  
time52, and open  vs. closed  chromatin  status53. Focal  as well as arm-level  copy  number  variations 
will be determined based on whole exome sequencing and subsequent application of  the GISTIC 
algorithm54. 
 
2.10.3  RNA  sequencing  of tumor  cells.  
 
For RNA Sequencing, poly -A selection and cDNA synthesis will be performed, followed by 
library preparation, sequencing (76bp or 101bp paired reads), and sample identification with 
quality control. Details of experimental design are described in55,56 -58. We  will perform library 
construction using a non -strand specific Illumina TruSeq Protocol and sequence coverage to 
100M total reads. Analysis will be performed as described in the preliminary data and in  
previous studies56-58. 
 
2.10.4  Immune  cell characterization  in peripheral  blood  and bone marrow  
 
Peripheral blood and bone marrow derived mononuclear cells will undergo immunologic 
assessments to assess the impact of therapy on general measures of cellular immunity. We will 
determine the number of immune cells (T -regs, CD4 effector T cells, CD8 T -regs, CD8 effector 
T cells, NK, NKT, B cells, MSCs, M1 and M2 macrophages, Dendritic cells and MDSCs at 
screening and during therapy. These  cells will be quantified using CyTOF. Each cell type will be 
defined by unique combi nations of antibodies based on previous publications59,60. Regulatory T 
cells will be defined as CD4/CD25/FOXP3+ cells.  Levels of naïve, effector and central memory 
cells will be quantified as CD45RA, CD45RO/CD62L -/CD27 - and CD45RO/CD62L+/CD27+ 
cells, resp ectively.  NK cells will be quantified by expression of CD56+ subsets. MDSCs will be 
quantified by CD33+/lineage -/DR- and CD11b/lineage -/DR- cells. We will also examine the 
percent expression of checkpoint regulators and how they are modulated with therapy.  These 
checkpoint regulators include PD -1, Lag -3, Tim -3 and CTLA -4. 
 
2.10.5  RNA  sequencing of  immune  cells during  therapy  
 
We will dissect molecular alterations that occur in these cells during progression in MM and the 
role of therapy on these cells. We will obt ain the T -regs, NK cells and MDSCs from the 
peripheral blood and bone marrow at the same time points described above. Similar samples will 
be obtained from the comparative untreated cohort. The cells will be isolated by flow sorting 
using single cell seque ncing and submitted for RNA sequencing as described above. Single cell 
sequencing of immune cells has recently shown significant advances in understanding immune 
regulation of the tumor microenvironment. Therefore, we believe that these studies will help 
define the immune microenvironment in smoldering MM before and after therapy with a PD -1 
inhibitor.  
 
2.10.6  Cell free DNA  to monitor  genomic  evolution  
 
Human  cancers are caused by the accumulation of genetic alterations in cells. Of special 
importance is the sequence at which the genetic events arise, as early events likely result in 
common oncogenic dependency that represents favorable therapeutic targets. No n-invasive  
liquid  biopsies,  by means  of circulating  tumor  cells (CTC)  and circulating  free DNA  (cfDNA),  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
24  
  
facilitate the continuous monitoring of genomic evolution. CTCs have been identified in solid 
tumors as well as in multiple myeloma (MM). Likewise, massive parallel sequencing of cfDNA 
has been shown to track genomic evolution of several types of cancer du ring the course of the 
disease. This could potentially complement current invasive biopsy approaches and constitute a 
new paradigm for monitoring clonal evolution in human cancers and provide the possibility for 
an early detection of known MM driver mutati ons that could predict risk of progression. CfDNA 
sequencing can be challenging because of the small fragment size of DNA in the peripheral  
blood (around 166bp), the low yield of DNA and the usual low allelic fraction of tumor -derived 
DNA  among the  cfDNA. Therefore, we developed two different  approaches  to sequence cfDNA. 
After high -speed centrifugation of frozen samples, to eliminate residual cells from plasma, 
cfDNA is extracted using the Qiagen circulating nucleic acid kit. As little as 5ng of cfDNA is 
then subjected to library preparation using the Kapa HyperPlus kit, which enables us to prepare 
libraries from small DNA fragments and minimal DNA yield. CfDNA libraries are qualified for 
further sequencing using  ultra-low-pass whole genome sequencing (ULP -WGS). The  ULP -WGS 
is a low cost approach developed by the Blood Biopsy Group to nominate samples containing 
sufficient fraction of tumor -derived DNA for whole exome sequencing (WES). Large numbers  
of cfDNA libraries are multiplexed and sequenced to an aver age of 0.1X genome -wide 
sequencing coverage. Samples with lower than 5% purity, not suitable for WES, are analyzed by 
a targeted deep sequencing approach for cfDNA to increase the sensitivity of detection of low 
allelic fraction mutations. Our custom ampli con set includes 109 genes exons to detect single 
nucleotide variants (SNVs). WES and targeted libraries are then sequenced on a HiSeq 4000. 
Mutations are called using MuTect in single -sample mode. All known germline variants are 
filtered out (1000 Genome Project Consortium release 2.2.2) and somatic SNVs are  
characterized for their presence in the Catalogue of Somatic Mutations in Cancer (COSMIC) 
database. All somatic SNVs are reviewed manually with Integrative Genomic Viewer (IGV) to 
validate their accura cy. We assess the reproducibility of our assay by running samples in 
duplicates, which show a high correlation between the 2 replicates in the same test run.  
 
3. PARTICIPANT  SELECTION  
 
3.1 Eligibility  Criteria  
 
3.1.1 Age  18 years.  
 
3.1.2 Must  meet  criteria  of high risk smoldering  MM based  on the criteria  
described below:  
 
Definition  of high -risk SMM:  
 
• Bone marrow clonal plasma cells ≥10% and ≤60% and any one  
or more of the following:  
o Serum  M protein  ≥3.0g/dL  (IgA,  IgG, IgM,  or IgD) 
o IgA SMM  
o Immunoparesis  with reduction  of two uninvolved 
immunoglobulin isotypes  
o Serum  involved/uninvolved  free light chain  ratio ≥8 (but 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
25  
  
less than 100) 
▪ Free Light  Chain  Smoldering  Myeloma  patients  as 
defined in section 2.4 are not excluded  
o Progressive  increase  in M protein level  (Evolving  type of 
SMM)  
▪ Increase in serum monoclonal protein by ≥10% on 
two successive  evaluations  within  a 6 month  period  
o Bone  marrow  clonal  plasma  cells 50-60% 
o Abnormal  plasma  cell immunophenotype  (≥95%  of bone 
marrow plasma cells are clonal) and reduction of one or 
more uninvolved immunoglobulin isotypes  
o t (4;14) or  del 17p  or 1q  gain 
o Increased  circulating  plasma  cells 
o MRI  with diffuse  abnormalities  or 1 focal  lesion  
o PET-CT with one focal  lesion  with increased  uptake 
without underlying osteolytic bone destruction  
o Urine  monoclonal  light chain  excretion  ≥500  mg/24  hours  
3.1.3 ECOG  Performance  Status  (PS) 0, 1, or 2 (Appendix  A) 
 
3.1.4 The following laboratory values obtained  21 days prior to registration  
and confi rmed prior to the first dose of study drug:  
• ANC   1000/ L 
• PLT  50,000/ L. Platelet  transfusions  to help patients  meet  eligibility 
criteria are not allowed within 3 days before study enrollment.  
• Total  bilirubin  ≤ 1.5 mg/dL  (If total is elevated  check  direct  and if 
normal patient is eligible.)  
• AST   3 x institutional  upper  limit  of normal  (ULN)  
• ALT   3 x institutional  upper  limit  of normal  (ULN)  
• WBC  ≥2000/μL  
 
3.1.5 Ability to understand and willingness to sign a written informed consent 
before performance of any study -related procedure not part of normal 
medical care, with the understanding  that consent  may be withdrawn  by the 
subject at any time without prejudice to  future medical care.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
26  
  
3.1.6 Female patients who are postmenopausal for at least 1 year before the 
screening visit or are surgically sterile. Females of childbearing potential* 
must have a negative serum or urine pregnancy test with a sensitivity o f at 
least 25 mIU/mL within 10 – 14 days and again within 24 hours prior to 
prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 
days as required by Revlimid REMS®) and must either commit to 
continued abstinence from heterosexual int ercourse or begin TWO 
acceptable methods of birth control, one highly effective method and one 
additional effective method AT THE SAME TIME, at least 28 days before 
she starts taking lenalidomide. Females of reproductive potential must  
agree to follow inst ructions for method(s) of contraception for the duration 
of treatment with any study drug(s) plus 5 half -lives of study plus 30 days 
(duration of ovulatory cycle) for a total of 120 days after their last dose of 
lenalidomide (Revlimid). Women must not brea stfeed.  
 
Female patients who are of childbearing potential must use contraception 
for 5 half -lives plus 30 days after their last dose of nivolumab for a total of 
5 months . 
 
* A female  of childbearing  potential  is a sexually  mature  female  who:  
 
• Has not undergone a hysterectomy (the surgical removal of the 
uterus)  or bilateral  oophorectomy  (the surgical  removal  of both 
ovaries) or  
• Has not been  naturally  postmenopausal  (amenorrhea  following  
cancer therapy does not rule out childbearing potential) for at 
least 24 consecutive months (i.e., has had menses at any time 
during the preceding 24 consecutive months)  
 
3.1.7 All study participants must be registered into the mandatory Revlimid 
REMS®  program,  and be willing  and able to  comply  with the requirements 
of the REMS® program.  
 
3.1.8 Females of reproductive potential must adhere to the scheduled pregnancy 
testing as required in the Revlimid REMS® program.  
 
3.1.9 Men must agree to use a latex condom during sexual contact with a female 
of childbearing potential even if they have had a successful vasectomy 
during the entire study treatment period and through 154 days after the last 
dose of lenalidomide (Revlimid) or agree to practice true abstinence when 
this is in l ine with the preferred and usual lifestyle of the subject.  (Periodic 
abstinence [eg, calendar, ovulation, symptothermal, post -ovulation 
methods] and withdrawal are not acceptable methods of contraception.)  
 
Men who are sexually  active  with women  who are of childbearing  potential 
must adhere to contraception for a period of 5 half -lives plus 90 days for a  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
27  
  
total of 7 months after  their last dose of nivolumab.  
 
3.2 Exclusion  Criteria  
 
3.2.1 No evidence  of CRAB  criteria*  or new criteria  of active  MM which  
including the following:  
• Increased  calcium  levels  (corrected  serum  calcium  >0.25  mmol/dL  
{>1mg/dL}  above  the upper  limit  of normal  or >2.75 mmol/dL  
{11mg/dL}  ) related  to MM 
• Renal  insufficiency  (attributable  to MM)  
• Anemia  (Hb 2g/dL  below  the lower  limit  of normal  or <10g/dL) 
related to MM  
• Bone  lesions  (lytic  lesions  or generalized  osteoporosis  with 
compression fractures)  
• Bone  marrow  plasma  cells >60%  
• Serum involved/uninvolved FLC ratio ≥100, provided the absolute 
level  of the involved  free light chain  is at least 100 mg/L  and repeated 
twice (light chain smoldering myeloma as described in section 2.4 is 
not an exclusion criteria).  
• MRI  with two or more  focal  lesions  that are at least 5 mm or greater  in 
size 
*Participants  with CRAB  criteria  that are attributable  to conditions  other 
than the disease under study may be eligible  
 
3.2.2 Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary 
therapy  considered  investigational.  Prior  therapy  with bisphosphonate  is allowed. 
Prior therapy for smoldering myelo ma MM may not be an exclusion criterion,  
discussion with Principal Investigator must occur before enrolling patients with 
prior treatments. Prior radiation therapy to a solitary plasmacytoma is allowed. 
Patients who received prior therapy due to being inco rrectly diagnosed as having 
overt  multiple  myeloma  may not be excluded  after discussion  with the overall  PI. 
 
3.2.3 Serious medical or psychiatric illness likely to interfere with participation in this 
clinical study.  
 
3.2.4 Diagnosed or treated for another malignancy  within 2 years of enrollment, with 
the exception of complete resection of basal cell carcinoma or squamous cell 
carcinoma of the skin, an in situ malignancy, or low -risk prostate cancer after 
curative therapy.  
 
3.2.5 Uncontrolled intercurrent illness including,  but not limited to, ongoing or active 
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac 
arrhythmia, or psychiatric illness/social situations that would limit compliance 
with study requirements.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
28  
  
3.2.6 Autoim mune disease: Patients with a history of inflammatory bowel disease, 
including  ulcerative  colitis  and Crohn’s  Disease,  are excluded  from  this study,  as 
are patients with a history of symptomatic disease (eg, rheumatoid arthritis, 
systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, 
autoimmune pneumonitis, autoimmune vasculitis [eg, Wegener’s 
Granulomatosis]) and motor neuropathy considered of autoimmune origin (e.g. 
Guillain -Barre Syndrome and Myasthenia, Gravis). Patients with Hashimoto’s 
thyroiditis are eligible to go on study.  
 
3.2.7 Pregnant or nursing women will be excluded from the study because 
lenalidomide is an agent with the p otential for teratogenic or abortifacient  
effects.  
 
3.2.8 History of severe allergic reactions attributed to compounds of similar chemical 
or biologic composition to Nivolumab or lenalidomide.  
 
3.2.9 Known seropositive for or active viral infection with human immunode ficiency 
virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).  Patients who 
are seropositive because of hepatitis B virus vaccine are eligible.  
 
3.2.10  Major  surgery  within  4 weeks  of enrollment.  
 
3.2.11  Myeloma -related  central  nervous  system  involvement.  
 
3.2.12  Known Amyloid  involvement.  
 
3.2.13  Participation in other clinical trials, including those with other investigational 
agents not included in this trial, within 30 days of the start of this trial and 
throughout the duration of this trial.  
 
3.2.14  Prior  CVA  with persistent  neurological  deficit.  
 
3.2.13  Inability  to tolerate thromboprophylaxis.  
 
3.3 Inclusion  of Women  and Minorities  
 
3.3.1 Both  men and women  of all races  and ethnic  groups  are eligible  for this trial. 
 
 
4. REGISTRATION  PROCEDURES  
 
4.1 General  Guidelines  for DF/HCC  and DF/PCC  Institutions  
 
Institutions  will register  eligible  participants  in the Clinical  Trials  Management  System  (CTMS) 
OnCore. Registrations must occur  prior to the  initiation of  protocol therapy. Any participant not 
registered to the protocol before protocol ther apy begins will be considered ineligible and 
registration will be denied.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
29  
  
 
An investigator  will confirm  eligibility  criteria  and a member  of the study  team  will complete  the 
protocol -specific eligibility checklist.  
 
Following registration, participants may begin protocol therapy. Issues that would cause 
treatment  delays  should  be discussed  with the Overall  Principal  Investigator  (PI). If a participant 
does not receive protocol therapy following registration, the participant’s registration on the 
study  must  be canceled.  Registration  cancellations  must  be made  in OnCore  as soon  as possible.  
 
 
4.2 Registration  Process  for DF/HCC  and DF/PCC  Institut ions 
 
DF/HCC  Standard  Operating  Procedure  for Human  Subject  Research  Titled  Subject  Protocol 
Registration (SOP #: REGIST -101) must be followed.  
 
4.3 General  Guidelines  for Other  Investigative  Sites  
 
The Research Project Manager will enter eligible participants on study at DFCI. All sites should 
call or email the Research Project Manager, to ensure enrollment availability prior to consenting 
any patients.  
 
Following registration, participants should be gin protocol therapy as soon as feasible. Issues that 
would cause treatment delays should be discussed with the Overall PI.  If a participant does not 
receive  protocol  therapy  following  registration,  the participant’s  registration  on the study  must  be 
cance led. The Research Project Manager should be notified of cancellations as soon as possible.  
 
4.4 Registration  Process  for Other  Investigative  Sites  
 
To register a participant, the following documents should be completed by the research nurse or 
data manager and e -mailed to the Research Project Manager:  
• Copy  of labs and clinical  information  that satisfy  inclusion  criteria  
• Signed  participant  consent form  
• HIPAA  authorization  form  
• Registration  Form  
 
The research nurse or data manager at the participating site will then call or e -mail the Research 
Project Manager, to verify eligibility. To complete the registration process, the Research Project 
Manager will follow DF/HCC  Standard Operating  Procedure  for Human Subject  Research Titled 
Subject Protocol Registration (SOP #: REGIST -101) and register the participant on the protocol. 
The Research Project Manager will fax or e -mail the participant study n umber, and if applicable 
the dose treatment level, to the participating site.  The coordinator will also call the research 
nurse or data manager at the participating site and verbally confirm registration  
 
Treatment may not begin without confirmation from t he Coordinating Center that the 
participant has been registered.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
30  
  
NOTE : Registration with the coordinating center can only be conducted during the 
business hours of 8:00 AM and 5:00 PM Eastern Time Monday through Friday. Same day 
treatment  registrations  will only be accepted  with prior  notice  and discussion  with the study  team 
at DFCI.  
 
 
5. TREATMENT  PLAN  
 
5.1 Treatment  Regimen  
 
Treatment will consist of 6 cycles of induction therapy followed by maintenance therapy for a 
total of 12 months. A treatment cycle is defined as 28 consecutive days.  
 
For treatment  cycles  1 through  12, a +/- 7 day window  for nivolumab  dosing  is allowed  
For further guidance on lenalidomide and dexamethasone holds and delays, please see Table 17. 
No investigational or commercial agents or therapies other than those described below may be 
administered with the intent to treat the participant's malignancy.  
 
** As of September 2017, the trial has been put on partial clinical hold by the Food and Drug 
Administration: all patients are to discontinue nivolumab indefinitely, and no additional patients 
will be accrued to the trial. Participants may elect to remain on  lenalidomide/dexamethasone or 
lenalidomide therapy alone for disease control after discussion with the overall PI.  
 
Induction  Cycles  
 
Table  7: Nivolumab  and Lenalidomide  and Dexamethasone  Combination  (Cycles  1-6) 
Agent  Pre-medications/ 
Precautions  Dose  Route  Schedule  Cycle 
Length  
Nivolumab  None  240 mg Intravenous  Days  1,15  
 
 
28 days Lenalidomide  None  25 mg Oral Days  1-21 of 
each cycle  
 
Dexamethasone  Take with food; 
Recommended  to be 
taken in  the morning   
40 mg  
Oral  
Days  1, 8, 15 
 
Maintenance  Cycles**  
 
Table  8: Nivolumab  and Lenalidomide  Combination  (Cycles  7-12) 
Agent  Pre-medications/ 
Precautions  Dose  Route  Schedule  Cycle 
Length  
Nivolumab  None  240 mg Intravenous  Days  1, 15  
28 days 
Lenalidomide  None  15 mg* Oral Days  1-21 of 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
31  
  
    each cycle   
 
* If patient was dose reduced during the induction phase for lenalidomide below 15mg, then 
maintenance phase starts at that dose reduction and not at the higher 15 mg dose.  
 
** During  maintenance, if a patient  experiences  biochemical  progression  (≥ 25% incre ase and  an 
absolute increase of ≥ 0.5g/dL from their nadir in their serum or urine m -spike or FLC with no 
CRAB features attributable to MM progression) high -dose dexamethasone may be re -added to 
the combination at a dose of 40mg oral given on days 1, 8, an d 15 of a 28 day cycle after 
discussion with the overall PI.  
 
The participant will be requested to maintain a medication diary. The medication diary 
should be returned to clinic staff at the end of each cycle.  
 
5.2 Agent  Administration  
 
The drugs  may be  administered in  any order.  
 
5.2.1 Nivolumab  
 
5.2.1.1  Administration  
 
 
Nivolumab  will be administered  at a dose of 240 mg as an intravenous  infusion  over 
60 minutes (+/ - 10 minutes) every 2 weeks (Days 1 and 15 of each 28 day cycle).  
 
See section  8.1.7  for guidelines  on drug preparation  and section  8.1.8  for further  guideline s for 
drug administration.  
 
Administer  the infusion  over 60 minutes  (+/- 10 minutes)  through  an intravenous  line containing 
a sterile, non -pyrogenic, low protein binding in -line filter (pore size of 0.2 micrometer to 1.2 
micrometer).  
 
Do not co-administer  other  drugs  through  the same  intravenous  line. 
Flush the intravenous line at end of infusion.  
5.2.1.2  Dose Delay or Interruption 
Please  refer  to section  6.2 of the protocol.  
5.2.2 Lenalidomide  
 
Lenalidomide  will be obtained  from  commercial  supply  in this study.  This may lead to added 
costs for the participant or the participant’s insurance company.  
 
Lenalidomide  will be given  as a single  daily  oral dose of 25 mg per day on days 1-21 followed  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
32  
  
by a 7-day rest period  for induction  (cycles  1-6) and 15 mg per day on days 1-21 for maintenance 
(cycles 7 -12) (if a patient was dose reduced during the induction phase for lenalidomide below 
15mg, then maintenance phase starts at that dose reduction and not at the higher 15 mg dose). 
Please refer to Table 17 for specific hold and delay in structions for lenalidomide. Dose 
modification guidelines are described in Section 6.3.  
 
Lenalidomide capsules should be swallowed whole, and should not be broken, chewed or  
opened. Administration of lenalidomide should be at approximately the same time ea ch day. 
Drug may be taken with or without food. If a dose is missed and less than 12 hours has elapsed 
since the missed dose, the patient may take the dose for that day. If more than 12 hours has 
elapsed since missing a dose at the normal time, the patient  should not take the dose,  but take  the 
next dose at the normal time on the following day. If a dose is missed, it should be taken as soon 
as possible on the same day. If a dose is vomited, the dose should not be made up and the 
participant should continue  with the regular schedule of the drug at the next dose. A drug diary 
must be provided to participants to record oral administration of doses.  
 
Participants who take more than the prescribed dose of lenalidomide should be instructed to seek 
emergency medic al care  if needed and contact study staff  immediately.  Participants experiencing 
adverse events may need study treatment modifications (see Section 6.3).  
 
Lenalidomide related resources must be provided to all patients prior to receiving lenalidomide 
therapy as part of the Revlimid REMS program. For more information regarding program 
registration and drug ordering, refer to section 8.2.  
 
5.2.2.1  Dose Delay or Interr uption 
Please  refer  to section  6.3 of the protocol.  
5.2.3 Dexamethasone  
 
Dexamethasone will be obtained from commercial supply in this study. This may lead to added 
costs for the participant or the participant’s insurance company.  
 
Dexamethasone will be given as  a single oral dose of 40mg on days 1, 8, and 15 of each 28 day 
cycle during the induction phase of this study (Cycles 1 -6 only).  
 
Dexamethasone should be taken at approximately the same time each day. It is recommended  
that dexamethasone be taken in the m orning to reduce insomnia. Each dose should be taken with 
food. If a dose of dexamethasone is vomited, the participant should continue with the regular 
schedule of  the drug at the next dose. If  a dose is missed and  less than 12  hours has elapsed since 
the missed dose, the patient may take the dose for that day. If more than 12 hours has elapsed 
since missing a dose at the normal time, the patient should not take the dose, but take the next 
dose at the normal time on the following day. If a dose is missed, i t should be taken as soon as 
possible on the same day. If a dose is vomited, the dose should not be made up and the 
participant should continue with the regular schedule of the drug at the next dose.. A drug diary 
must be provided to participants to record  oral administration of doses. Dose modification 
guidelines are described in Section 6.3.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
33  
  
 
5.2.3.1  Dose Delay or Interruption 
Please  refer  to section  6.4 of the protocol.  
 
5.3 General  Concomitant  Medication  and Supportive  Care  Guidelines  
 
5.3.1 Medications  and supportive  care 
• Patients who experience worsening neuropathy from baseline should be observed 
for recovery, have dose reductions/delays as indicated in the protocol, and any 
supportive  therapy  or intervention  may be initiated  as appropriate  at the discretion 
of the investigator.  
 
• Supportive  measures  consistent  with optimal  patient  care may be given 
throughout the study.  
 
• Stem cell collection may be performed at the time of best response (PR, VGPR or 
CR or at the investigator’s discretion) or after 6 cycles of therapy for those who 
are transplant eligible, and/or who plan to pursue transplant in the future. The 
standard mob ilization procedures of the treating institution should be followed. 
Plerixafor should be the preferred mobilization agent, though cyclophosphamide 
or other agent may be used at the investigator’s discretion. A delay of no more 
than 3 weeks is allowed betw een the end of collection and re -initiation of therapy 
especially if chemotherapy such as high dose cyclophosphamide was used for 
stem cell mobilization. Mobilization should occur as soon as possible after study 
treatment is stopped.  
• Use of white cell grow th factors (Filgrastim or acceptable equivalent) is allowed 
for management of treatment -induced neutropenia at physician discretion. 
Filgrastim  or equivalent  should  be given  according  to local  institutional  guidelines 
or per the package insert. Pegfilgrast im is not to be used in place of filgrastim.  
 
• Patients  may be transfused  with red cells and platelets  as clinically  indicated  and 
according to institutional guidelines.  
 
• Patients  may receive  bisphosphonates  per recommendations  of myeloma  therapy, 
or may follow  local  standard  of care.  A note should  be placed  about  patients  who 
are not receiving bisphosphonates, such as osteonecrosis of the jaw.  
 
• If nausea  and/or  vomiting  is/are  noted  at any point  in time,  premedication  with 
prochlorperazine or other antiemetics may be used before future doses. 
Antiemetics, including 5 -HT3 serotonin receptor antagonists, may be used as 
needed at the discretion of the investigator.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
34  
  
• If nausea  persists  in spite  of the use of standard  antiemetics,  additional  symptom 
management should be initiated per institutional standard.  
 
• Loperamide  or other  antidiarrheal  may be used for symptomatic  diarrhea  at 
discretion of the investigator. The dose and regimen will be according to 
institutional guidelines. IVF may be given to prevent volume depletion.  
 
• Thromboprophylaxis is recommended for all participants. Thromboprophylactic 
initiation and regimen choice is at the discretion of the treating physician or sites 
may follow  the current  package  insert  for Revlimid.  It is recommended  that if the 
platelet count falls below 30,000/mm3, thromboprophylaxis be held to minimize 
the risk of bleeding and then resumed wh en platelet counts are equal to or above 
30,000/mm3. 
• Nonsteroidal  anti-inflammatory  drugs  (NSAIDs)  should  be avoided  with impaired 
renal function given reported NSAID -induced renal failure in patients  with 
decreased renal function.  
 
• Patients may be at an increased risk of infection including reactivation of herpes 
zoster and herpes simplex viruses. Antiviral therapy such as acyclovir, 
valacyclovir, or other antivirals may be initiated as clinically ind icated at the 
discretion of the treating investigator. Antivirals for other indications are also 
allowed.  
 
• The following  procedures  are prohibited  during  the study:  
 
o Any antineoplastic treatment with activity against MM, other than study  
drugs  
 
o Radiation  therapy  (note  that, in general,  the requirement  for local  radiation 
therapy indicates disease progression)  
 
5.4 Management  of Clinical  Events  
 
5.4.1 Rash  
• Symptomatic measures such as antihistamines or corticosteroids (oral or 
topical) have been successfully used to manage rash and have been used 
prophylactically in subsequent cycles.  The use of  a topical, IV, or oral steroid 
(eg, prednisone ≤ 10 mg per day or equivalent) is permitted.  
 
• Management of a Grade 3 rash may require intravenous antihistamines or 
corticosteroids.  Administration of lenalidomide (and/or other causative agent  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
35  
  
if given in combination) should be modified per protocol and r e-initiated at a 
reduced level from where rash was noted.  
 
• In line with clinical practice, a dermatology consult that includes a biopsy of 
Grade 3 or higher rash or any SAE involving rash is recommended. 
Prophylactic measures should also be considered if a  patient has previously 
developed a rash (eg, using a thick, alcohol -free emollient cream on dry areas 
of the body or oral or topical antihistamines).  
 
• A rare risk is Stevens -Johnson Syndrome, a severe and potentially life - 
threatening rash with skin peeli ng and mouth sores, should be managed 
symptomatically according to standard medical practice.  Punch biopsies for 
histopathological analysis are encouraged at the discretion of the investigator.  
 
5.4.2 Thrombocytopenia  
 
• Blood counts will be monitored regularly as outlined in the protocol with 
additional testing obtained according to standard clinical practice. 
Thrombocytopenia may be severe but has been manageable with platelet 
transfusions according to standard clinical practice. Lenalidomide 
administration should be modified as noted as per dose modification 
recommendations  in the protocol  when  thrombocytopenia  occurs  (see Section 
6.3). Therapy may be reinitiated at a reduced level upon recovery of platelet 
counts.  
• A rare risk is thrombotic  thrombocytopenic  purpura  (TTP),  a rare blood  disorder 
where blood clots form in small blood vessels throughout the body  
characterized by thrombocytopenia, petechiae, fever, or possibly more serious 
signs and symptoms. TTP should be man aged symptomatically according to 
standard medical practice.  
 
5.4.3 Neutropenia  
 
• Blood counts will be monitored regularly as outlined in the protocol with 
additional testing obtained according to standard clinical practice.  Neutropenia 
may be severe but has been manageable.  Growth factor support is not required 
but may be considered ac cording to standard clinical practice.  Lenalidomide 
administration  should  be modified  as per dose modification  recommendations  in 
the protocol when neutropenia occurs (see Section 6.3).  
 
5.4.4 Pregnancy  
 
• Female patients participating in this  study should  avoid becoming pregnant, and 
male patients should avoid impregnating a female partner.  Non-sterilized 
female  patients  of reproductive  age group  and male  patients  should  use effective 
methods of contracepti on through defined periods during and after study 
treatment as specified below.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
36  
  
o Female  patients  must  meet  1 of the following:  
▪ Postmenopausal  for at least 1 year before  the screening  visit 
▪ Surgically  sterile  
▪ If they are of childbearing potent ial, agree to practice 2 
effective  methods  of contraception  from  the time of signing  of 
the informed  consent  form  through  120 days after the last dose 
of lenalidomide ( Revlimid) of study drug  
• Women who are of childbearing potential, agree to 
practice  contraception  for a period  of 5 months  after 
their last dose of nivolumab  
▪ Agree  to practice  true abstinence,  when  this is in line with the 
preferred and usual lifestyle of the subject.  
• Periodic abs tinence (eg, calendar, ovulation, 
symptothermal,  postovulation  methods)  and withdrawal 
are not acceptable methods of contraception.  
• Male  patients,  even  if surgically  sterilized  (ie, status  postvasectomy)  must 
agree to 1 of the following:  
o Practice  effective  barrier  contraception  during  the entire  study 
treatment period and through 154 days after the last dose of 
lenalidomide ( Revlimid)  
▪ Men receiving  nivolumab  who are sexually  active  with women 
of childbear ing potential must adhere to contraception for a 
period of 7 months after the last dose of nivolumab  
o Agree  to practice  true abstinence,  when  this is in line with the 
preferred and usual lifestyle of the subject.  
▪ Periodic abstinence (eg, calendar, ovulation , symptothermal, 
postovulation  methods  for the female  partner)  and withdrawal 
are not acceptable methods of contraception.  
 
5.5 Criteria  for Taking  a Participant  Off Protocol  Therapy  
 
Patients  will be informed  that they have  the right  to withdraw  from  the study  at any time for any 
reason, without prejudice to their medical care.  
In the absence of treatment delays due to adverse event(s), treatment may continue for 12 cycles 
or until one of the following criteria applies:  
 
• Progression  to overt  Multiple  Myelo ma 
 
• Intercurrent  illness  that prevents  further administration  of treatment  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
37  
  
 
• Unacceptable  adverse event(s)  
 
• Participant  demonstrates  an inability  or unwillingness  to comply  with the oral 
medication regimen and/or documentation requirements  
 
• Participant  decides  to withdraw  from  the protocol  therapy  
 
• General  or specific  changes  in the participant's  condition  render  the participant 
unacceptable for further treatment in the judgment of th e treating investigator  
 
 
Participants will be removed from the protocol therapy when any of these criteria apply.  The 
reason for removal from protocol therapy, and the date the participant was removed, must be 
documented in the case report form (CRF). Alternative care options will be discussed with the 
participant.  
 
A Treatment Ended/Off Study Form will be filled out when a participant is removed from 
protocol therapy. This form will be provided by the lead site. External sites should submit the 
form to the Research Project Manager.  
 
In the event  of unusual  or life-threatening  complications,  treating  investigators  must  immediately 
notify the Overall PI, Irene Ghobrial at telephone number 617 -632-4198.  
 
5.6 Duration  of Follow  Up 
 
Participants  will be followed  for 3 years  after removal  from  protocol  therapy  or until progression 
to active symptomatic MM or need for new therapy , whichever occurs first.  Participants 
removed from protocol therapy for unacceptable adverse event(s) will be followed until 
resolution or stabilization of the adverse event.  
 
5.7 Criteria  for Taking a  Participant  Off Study  
 
Participants  will be removed  from  study  when  any of the following criteria  apply:  
 
• Lost to follow -up 
• Withdrawal  of consent  for data submission  
• Death  
• Progression  to active  myeloma  and subsequent  treatment  
 
The reason for taking a participant off study, and the date the participant was removed, must be 
documented in the case report form (CRF).  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
38  
  
A Treatment Ended/Off Study Form will be filled out when a participant is removed from 
protocol therap y. This form will be provided by the lead site. External sites should submit the 
form to the Research Project Manager.  
 
 
6. DOSING  DELAYS/DOSE  MODIFICATIONS  
 
6.1 Recommended  Criteria  for Beginning  or Delaying  a Subsequent  Treatment  Cycle  
 
Patients must meet eligibility criteria on Cycle 1 Day 1 to begin treatment. There are no pre - 
treatment criteria to begin a new cycle of nivolumab.  
 
For a new cycle of treatment with lenalidomide to begin, the patient must meet the following 
criteria:  
 
• ANC  must  be ≥ 1,000/ L. 
• Platelet  count  must  be ≥ 50,000/ L. 
• All other  clinically  significant,  study  drug related  non hematologic  toxicity  must  have 
resolved to ≤ Grade 1 or to baseline condition  
 
If the participant fails to meet the above -cited criteria for initiation of a new cycle of treatment  
on day 1 of the cycle, dosing of all medications should be delayed for 1 week. At the end of that 
time, the participant should be re -evaluated to determine whether the above criteria have been 
met. If the participant continues to fail to meet the above -cited criteria, delay therapy and 
continue to re -evaluate. The maximum delay for toxicity related to stud y treatment before 
treatment is permanently discontinued will be 3 weeks. If a delay of > 3 weeks is clinically  
necessary, and the patient is showing benefit from treatment, the patient may continue on  
study after discussion and approval by the Principal I nvestigator.  
 
If any one of the study medications is permanently discontinued for any reason including 
toxicity, or FDA mandate, the patient may remain on the study at the discretion of the principal 
investigator.  
 
6.2 Nivolumab  
 
No dose reductions for Nivolum ab are allowed. If Nivolumab is held on Day 1 of a new cycle, 
treatment  with Lenalidomide/Dexamethasone  will also be delayed.  If Nivolumab  is held during 
any cycle on day 15, the treating investigator should decide if lenalidomide and/or 
dexamethasone  will be skipped  using  recommended  guidance  for retreatment  below.  Nivolumab 
may be delayed for up to 21 days or 3 weeks. A delay of up to 14 days will be allowed for 
participants for non -AE related events (i.e.; vacation, family emergency, etc) after discussio n 
with the overall PI. If an alternate treatment plan for a suspected nivolumab related toxicity is 
proposed and is not listed in Table 11, you must first discuss and obtain approval from the 
Overall PI.  
 
Dose  delays  and modifications  will be made  as indicated  in the following  table(s).  The 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
39  
  
descriptions and grading scales found in the revised NCI Common Terminology Criteria for 
Adverse  Events  (CTCAE)  version  4.03 will be utilized  for dose delays  and dose modifications.  A 
copy of the CTCAE version 4.03 can be downloaded from the CTEP website  
 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
* If any on e of the study medications is permanently discontinued for any reason including 
toxicity, or FDA mandate, the patient may remain on the study at the discretion of the principal 
investigator.  
 
 
Table  11 Suggested  Guidelines  for Nivolumab  Suspected  Toxicity  
 
CTCAE  4.0 Category  CTCAE  Grade  Nivolumab  Action  
 
Pneumonitis  
(See Section 6.2.1 for 
management  guidelines)  Grade  1 Continue  to treat- Do NOT  OMIT  
Grade  2 Hold  dose until resolved  to ≤ Grade  1 
≥ Grade  3 Permanently  discontinue  nivolumab  
 
Colitis  
(See Section 6.2.2 for 
management  guidelines)  Grade  1 Continue  to treat- Do NOT  OMIT  
Grade  2 
or 
Grade  3  
Hold  dose until resolved  to ≤ Grade  1 
Grade  4 Permanently  discontinue  nivolumab  
Increase 
in 
AST  and/or  ALT  
(See Section 6.2.3 for 
management  guidelines)  Grade  1 Continue  to treat- Do NOT  OMIT  
Grade  2 Hold  dose until resolved  to ≤ Grade  1 
≥ Grade  3 Permanently  discontinue  nivolumab  
Increase 
in 
Blood  Bilirubin  
(See Section 6.2.3 for 
management  guidelines)  Grade  1 Continue  to treat- Do NOT  OMIT  
Grade  2 Hold  dose until resolved  to ≤ Grade  1 
≥ Grade  3 Permanently  discontinue  nivolumab  
 
Increase  
in 
Creatinine  
(See Section 6.2.4 for 
management  guidelines)  Grade  1 Continue  to treat- Do NOT  OMIT  
Grade  2 
or 
Grade  3  
Hold  dose until resolved  to ≤ Grade  1 
Grade  4 Permanently  discontinue  nivolumab  
All other related 
toxicities not listed 
previously  in this table  
(See Section 6.2.6 for 
management  guidelines)  Grade  1 Continue  to treat- Do NOT  OMIT  
Grade  2 Continue  to treat- Do NOT  OMIT  
Grade  3 Hold  dose until resolved  to ≤ Grade  1 
Recurrent  Grade  3 
or Permanently  discontinue  nivolumab  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
40  
  
 Grade  4  
 
If the patient  discontinues  nivolumab,  he or she does not need  to come  off protocol  therapy  
 
6.2.1 Immune -Mediated  Pneumonitis  
 
Monitor  patients  for signs  and symptoms  of pneumonitis.  Administer  corticosteroids  at a dose of 
1 to 2 mg/kg/day prednisone equivalents for Grade 2 or greater pneumonitis, followed by 
corticosteroid  taper.  Permanently  discontinue nivolumab  for severe  (Grade  3) or life-threatening 
(Grade 4) pneumonitis and withhold nivolumab until resolution for moderate (Grade 2) 
pneumonitis.  
 
6.2.2 Immune -mediated  colitis  
 
Monitor  patients  for immune -mediated  colitis.  Administer  corticosteroids  at a dose of 1 to 
2 mg/kg/day  prednisone  equivalents  followed  by corticosteroid  taper  for severe  (Grade  3) or life- 
threatening (Grade 4) colitis. Administer corticosteroids at a dose of 0.5 to 1 mg/kg/day 
prednisone equivalents followed by corticosteroid taper for moderate (Grade 2) colitis of mo re 
than 5 days duration;  if worsening  or no improvement  occurs  despite  initiation  of corticosteroids, 
increase dose to 1 to 2 mg/kg/day prednisone equivalents. Withhold NIVOLUMAB for Grade 2 
or 3 immune -mediated colitis. Permanently discontinue NIVOLUMAB for Grade 4 colitis or for 
recurrent colitis upon restarting NIVOLUMAB  
 
6.2.3 Immune -Mediated  Hepatitis  
 
Monitor patients for abnormal liver tests prior to and periodically during treatment. Administer 
corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents for Grade 2 or greater 
transaminase elevations, with or without  concomitant elevation in total bilirubin. Withhold 
nivolumab  for moderate  (Grade  2) and permanently  discontinue  nivolumab  for severe  (Grade  3) 
or life -threatening (Grade 4) immune -mediated hepatitis.  
 
6.2.4 Immune -Mediated  Nephritis  and Renal  Dysfunction  
 
Monit or patients for elevated serum creatinine prior to and periodically during treatment. 
Administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by 
corticosteroid taper for life -threatening (Grade 4) serum creatinine elevation  and permanently 
discontinue nivolumab. For severe (Grade 3) or moderate (Grade 2) serum  creatinine elevation, 
withhold nivolumab and administer corticosteroids at a dose of 0.5 to 1 mg/kg/day prednisone 
equivalents followed by corticosteroid taper; if wor sening or no improvement occurs, increase 
dose of corticosteroids  to 1 to 2 mg/kg/day  prednisone  equivalents  and permanently  discontinue 
nivolumab.  
 
6.2.5 Immune -Mediated  Hypothyroidism  and Hyperthyroidism  
 
Monitor  thyroid  function  prior  to and periodically  during  treatment.  Administer  hormone 
replacement therapy for hypothyroidism. Initiate medical management for control of  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
41  
  
hyperthyroidism.  There  are no recommended  dose adjustments  of nivolumab  for hypothyroidism 
or hyperthyroidis m. 
 
6.2.6 Other  Immune -Mediated  Adverse  Reactions  
 
Other clinically significant immune -mediated adverse reactions can occur. Immune -mediated 
adverse reactions may occur after discontinuation of nivolumab therapy. For any suspected 
immune -mediated  adverse  reactio ns, exclude  other  causes.  Based  on the severity  of the adverse 
reaction, withhold nivolumab, administer high -dose corticosteroids, and if appropriate, initiate 
hormone -replacement therapy. Upon improvement to Grade 1 or less, initiate  
corticosteroid  taper  and continue  to taper  over at least 1 month.  Consider  restarting  nivolumab 
after completion of corticosteroid taper based on the severity of the event  
 
6.2.7 Immune  Mediated  Cardiac  Toxicity  
 
 
Cardiac  * Management/Next  Dose  for Nivolumab  
≤ Grade  1 Hold dose pending evaluation and observation.**  Evaluate for signs 
and symptoms of CHF, ischemia, arrhythmia or myositis.  Obtain 
history  EKG,  CK (for concomitant  myositis),  CK-MB. Repeat  troponin, 
CK and EKG 2 -3 days.  If troponin and labs normalize may res ume 
therapy.  If labs worsen or symptoms develop then treat as below.  
Hold  pending  evaluation  
Grade  ≥2 with  suspected  
myocarditis  Hold dose.**  Admit to hospital.  Cardiology consult.  Rule out MI 
and other causes of cardiac disease.  Cardiac Monitoring.  Cardiac 
Echo.  Consider cardiac MRI and cardiac biopsy.  Initiate high dose 
methylprednisolone.  If no improvement  within  24 hours,  add either 
infliximab, ATG or tacrolimus. Consult algorith m for more details.  
Resume  therapy  if there  is a return  to baseline  and myocarditis  is 
excluded  or considered  unlikely.  
Grade  ≥2 with  confirmed  
myocarditis  Off protocol  therapy.  Admit  to CCU  (consider  transfer  to nearest 
Cardiac Transplant Unit).  Treat as above.  Consider high dose 
methylprednisolone  
Add ATG  or tacrolimus  if no improvement.  Off treatment.  
  
*Including  CHF,  LV systolic  dysfunction,  Myocarditis,  CPK,  and troponin  
**Patients  with  evidence  of myositis  without  myocarditis  may  be treated  according  as “other  event”  
Note:  The optimal  treatment  regimen  for immune  mediated  myocarditis  has not been  established.  
Since  this toxicity  has caused  patient  deaths,  an aggressive  approach  is recommended.  
 
6.3 Lenalidomide  
 
Hematologic  Toxicities:  For adverse  hematologic  events  that are considered  possibly,  probably 
or definitely related to Lenalidomide, the following criteria for retreatment and dose 
modification should be followed unless discuss ed and approved first by the overall principal  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
42  
  
investigator.  The treating  investigator  should  determine  the clinical  significance  of laboratory 
values  and attribution  to study  medications  before  a treatment  decision  is made. All  instances 
where lenalidomide is held, the dose will be considered missed, and will not be made up.  
 
Non Hematologic Toxicity: For adverse non hematologic events that are considered to be 
possibly, probably or definitely related to Lenalidomide, the followi ng criteria for retreatment 
and dose modification should be followed unless discussed and approved first by the overall 
principal investigator. The treating investigator should determine the clinical significance of 
laboratory  values  or radiographic  findin gs and attribution  to study  medications  before  a treatment 
decision is made. All instances where lenalidomide is held, the dose will be considered missed, 
and will not be made up.  
 
Dose delays  and modifications should  be made as indicated  in the following table(s) unless first 
discussed with the Overall PI. The descriptions and grading scales found in the revised NCI 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for 
dose delays  and dose modifications.  A copy  of the CTCA E version  4.0 can be downloaded  from 
the CTEP website  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
Table  12 Lenalidomide  Hematologic  Toxicities  
 
CTCAE  4.0 
Category  CTCAE  
Grade  Lenalidomide  Dose  Modification  
 Grade  1  
 or Continue  to treat- Do NOT  OMIT  and DO NOT  REDUCE  therapy  
 Grade  2  
Absolute    
 Hold  dose 
Neutrophil  Count 
(ANC)1  
Grade  3 Administer  Filgrastim  
Resume  at same  dose when  ANC  is ≥ 1000  if neutropenia  is the only 
hematologic toxicity  
  If other  hematologic  toxicity  ≥Grade  2 is present,  reduce  dose one level  
  when  ANC≥1000  
   
Hold  dose 
 Grade  4 Administer  Filgrastim  
  Resume  therapy  at one dose level  lower  when  ANC  is ≥ 1000  
Neutropenia  with 
Fever    
 
ANC  <1000  and 
temperature  ≥38.5o 
C or 101ºF  Grade  3 
or 
Grade  4 Hold  dose 
Administer  Filgrastim  
Reduce  dose one level  when  ANC≥1000  
 
Thrombocytopenia  Grade  1 
or 
Grade  2  
Continue  to treat- Do NOT  OMIT  and DO NOT  REDUCE  therapy  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
43  
  
 
 
Aspirin prophylaxis 
should be held if 
platelets  are ≤50,000   
 
 
 
 
Grade  3 
or 
Grade  4 Provide  platelet  transfusion  support 
Redraw platelets  
 
If redrawn  platelet  value  ≥ 50,000  -> Do NOT  OMIT  and DO NOT 
REDUCE therapy  
 
If redrawn platelet value <50,000 continue to transfuse at the discretion of 
the investigator  and hold therapy  until platele ts are ≥ 50,000  on Day 1 or ≥ 
30,000 intracycle  
 
Resume  therapy  at one dose level  lower  when  the patient’s  platelets  are ≥ 
50,000 on Day 1 or ≥ 30,000 intracycle  
 
 
Anemia  Grade  1 
Grade  2 
Grade  3 Continue  to treat- Do NOT  OMIT  and DO NOT  REDUCE  therapy 
Transfuse at the discretion of treating investigator  
 
Grade  4 Hold  treatment 
Transfuse  
Resume  treatment  when  hemoglobin  ≥ 8.0 g/dL 
DO NOT REDUCE therapy  
1 ANC can be calculated two ways: From the percentage of neutrophils: White Blood Count (WBC) x total 
neutrophils  (polys%  + bands%)  x 10. From  the absolute  number  of cells:  (Absolute  polys  + Absolute  bands)  x 10. 
 
Table  13 Lenalidomide  Non Hematologic  Toxicities  
 
CTCAE  4.0 
Category  CTCAE  
Grade  Lenalidomide  Dose  Modification  
 
 
Infection  or Viral 
Illness  with  ANC1 
≥1000  
 
Including herpes 
zoster  reactivation   
 
 
 
N/A Day 1 of Cycle: Delay cycle until infection/viral 
illness  has resolved.  Resume  treatment  at the same 
dose level. Do not dose reduce.  
 
Intracycle: Hold lenalidomide for a maximum of 21 
days to allow  for recovery.  Resume  treatment  at same 
dose level.  
 
If patient has delay  of greater  than 21 days,  the patient 
must come off -study  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
44  
  
 
 
 
 
Infection  or Viral 
Illness  with  ANC1 
< 1000   
 
 
 
 
 
N/A Day 1 of Cycle:  Delay  cycle  until infection/viral 
illness has resolved. Administer filgrastim or 
equivalent as indicated.  
 
Reduce  one dose level  when  infection/virus  has 
resolved, and ANC ≥1000  
 
Intracycle: Hold lenalidomide for a maximum of 21 
days.  Reduce  one dose level  when  infection/vi rus has 
resolved and ANC ≥ 500  
 
If patient  has a delay  of less than or equal  to 21 days, 
dose reduce  to next dose level.  If patient  has delay  of 
greater  than 21 days,  the patient  must  come  off-study  
 
 
 
 
 
 
 
 
Allergic  reaction  or 
hypersensitivity to 
Lenalidomide  
 
Including  Rash 
related to 
Lenalidomide  Grade  1 Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
Grade  2 Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
 
Grade  3 
or 
Grade  4 Hold lenalidomide 
Follow  at least weekly.  
 
If toxicity  resolves  to ≤ grade  2, restart  at next lower 
dose level  
 
 
Renal/Metabolic  
 
 
For all grades, 
provide  hydration  and 
other supportive care 
as needed at the 
discretion of the 
treating investigator   
Grade  1  
Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
 
 
Grade  2 Hold  Lenalidomide  until < grade  2 and resume 
treatment  at the same dose level  
 
If toxicity  recurs,  dose reduce  one dose level  at the 
treating investigator’s discretion  
 
Grade  3 
or 
Grade  4 Hold  Lenalidomide  until < grade  2 and resume 
treatment  with one dose level reduction  
 
If the toxicity  remains  ≥ grade  3, omit dose and restart 
at subsequent scheduled visit with one dose level  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
45  
  
  reduction  
 
If treatment -related  toxicity  occurs  on day one of the 
cycle, the cycle will be delayed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diarrhea, 
Constipation, 
Nausea,  or Vomiting   
Grade  1 Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
 
 
Grade  2 Treat  at the discretion  of the investigator 
Provide aggressive supportive care  
DO NOT  REDUCE  therapy  
 
Grade  3 Hold  Lenalidomide  until toxicity  resolves  to < grade  2 
 
If the patient  has received  maximum  supportive  care, 
resume therapy with one dose level reduction  
 
 
Grade  4 Hold  Lenalidomide  until toxicity  resolves  to < grade  2 
Resume therapy with one dose level reduction  
 
 
All other related 
toxicities  not listed 
previously in this 
table   
Grade  1  
Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
 
 
Grade  2 Continue to treat - Do NOT OMIT and DO NOT 
REDUCE  therapy  unless  considered  to be a clinically 
significant finding  
 
Provide  supportive  care as needed  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
46  
  
  
Grade  3 Hold  Lenalidomide  until toxicity  resolves  to < grade  2 
 
Resume  therapy  with one dose level  reduction  at the 
discretion of the treating investigator  
 
 
 
 
 
Grade  4  
Hold  Lenalidomide  until toxicity  resolves  to < grade  2 
Resume therapy with one dose level reduction  
If treatment -related  toxicity  occurs  on day one of the 
cycle, the cycle will be delayed.  
 
If patient  has a delay  of less than or equal  to 21 days, 
dose reduce  to next dose level.  If patient  has delay  of 
greater  than 21 days,  the patient  must  come  off-study  
 
If the patient  discontinues  lenalidomide,  he or she does is not required  to come  off protocol 
therapy.  
 
Table  14 Lenalidomide  Dose  Reduction  
 
Dose  Level  Lenalidomide  Dose  
0 25 mg 
-1 20 mg 
-2 15 mg 
-3 10 mg 
-4 5 mg 
 
If lenalidomide  is reduced  for any toxicity,  the dose may not be re-escalated.  
6.4 Dexamethasone 
Dexamethasone  Dose  Modifications  
For adverse events that are considered to be possibly, probably or definitely related to 
dexamethasone,  the following  criteria  for retreatment  and dose modification  should  be followed 
unless discussed and approved first by the Overall Principal Investigator. The treating 
investigator should determine the clinical significance and attribution of the toxicity to 
dexamethasone.  If toxicity is unlikely or not related to dexamethasone, do not om it or reduce 
therapy. Patients may continue on study if dexamethasone has been permanently discontinued  
 
Table  15 Dexamethasone  Dose  Modifications  
 
CTCAE  4.0 
Category  CTCAE  Grade  Dexamethasone  Dose  Modification  
Hyperglycemia  Grade  1 Continue  to treat- Do NOT  OMIT  and DO NOT  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
47  
  
 
Treat  with oral 
medication or 
insulin at 
discretion of 
treating 
investigator   REDUCE  therapy  
 
Grade  2 Hold  dexamethasone  until < Grade  2 and resume  at 
same dose level at the discretion of the treating 
investigator  
 
Grade  3 Hold  dexamethasone  until < Grade  2 
 
Resume  therapy  with one dose level  reduction  at the 
discretion of the treating investigator  
 
Grade  4 Hold  dexamethasone  until < Grade  2 
 
Resume  therapy  with one dose level  reduction  
Symptomatic 
pancreatitis  Any Grade  Discontinue  dexamethasone  permanently  
 
 
 
 
OTHER   
Grade  1 or 2  
Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
Grade  3 Hold  dexamethasone  until ≤ Grade  2 
Resume  therapy  with one dose level  reduction  
Grade  4 Hold  dexamethasone  ≤ Grade  2 
Resume  therapy  with one dose level  reduction  
 
If the patient discontinues dexamethasone prior to maintenance, he or she is not required to  
come off protocol therapy . 
 
Table  16 Dexamethasone  Dose  Reduction  
 
Dose  Level  Dexamethasone  Dose  
0 40 mg 
-1 20 mg 
-2 10 mg 
 
 If dexamethasone  is reduced  for any toxicity,  the dose may not be re-escalated.  
 
 
6.5 Dose  Delay  Guidelines  
 
Required study schedule assessments should always correlate with the nivolumab dosing 
schedule. If lenalidomide and/or dexamethasone are held during a cycle, then study assessments 
should continue per the schedule of assessments in Section 10. If nivolumab is held at any 
timepoint,  study  calendar  assessments  for that day should  be repeated  prior  to re-initiation  of 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
48  
  
nivolumab.  
 
Table  17 Dose  Delay  Instructions  
 
 To be resumed 
within  window?  Lenalidomide  Dexamethasone  Nivolumab  
Nivolumab  
delayed  on Day 
1 of Cycle   
N/A To be delayed  
until Nivolumab  is 
resumed  To be delayed  
until Nivolumab 
is resumed  Resume  
dosing= new 
Day 1 of Cycle  
 
Nivolumab 
held on Day 15 
of Cycle   
 
Yes  
Dosing  to continue 
as scheduled   
Dosing to 
continue  as 
scheduled  Resume dose 
any day within 
window; dose 
time point not 
skipped  
Nivolumab 
held on Day 
15of Cycle   
No Dosing  to continue 
as scheduled  Dosing to 
continue  as 
scheduled  Resume  dosing 
at next dosing 
time point  
 
 
7. ADVERSE  EVENTS:  LIST  AND  REPORTING  REQUIREMENTS  
 
7.1 Definitions  
 
7.1.1 Adverse  Event  Definition  
Adverse  event  (AE)  means  any untoward  medical  occurrence  in a patient  or subject  administered 
a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or d isease temporally associated with the 
use of a medicinal (investigational) product whether or not it is related to the medicinal product. 
This includes  any newly  occurring  event,  or a previous  condition  that has increased  in severity  or 
frequency since the administration of study drug. CTCAE version 4.03 will be used for this 
study.  
An abnormal laboratory value will not be assessed as an AE unless that value leads to 
discontinuation  or delay  in treatment,  dose modification,  therapeutic  intervention,  or is 
considered by the investigator to be a clinically significant change from baseline.  
 
7.1.2 Serious  Adverse  Event  Definition  
 
Serious  AE (SAE)  means  any untoward  medical  occurrence  that at any dose:  
• Results  in death . 
• Is life-threatening  (refers  to an AE in which  the patient  was at risk of death  at the time of 
the event.  It does not refer to an event which hypothetically  might have caused death  if it 
were more severe).  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
49  
  
• Requires inpatient hospitalization or prolongation of an existing hospitalization  (see 
clarification in the paragraph below on planned hospitalizations).  
• Results in persistent or significant disability or incapacity . (Disability is defined as a 
substantial disruption of a pe rson’s ability to conduct normal life functions).  
 
• Is a congenital  anomaly/birth  defect . 
 
• Is a medically important event . This refers to an AE that may not result in death, be 
immediately life threatening, or require hospitalization, but may be considered serious 
when, based on appropriate medical judgment, may jeopardize the patient, require 
medical or surgical intervention to prevent one of the outcomes listed above, or involves 
suspected  transmission via a medicinal product  of an infectious agent.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blo od dyscrasias or convulsions that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse; any 
organism, virus, or infectious particle (eg, prion protein transmitting Transmissible 
Spongiform Encephalopathy), pathoge nic or nonpathogenic, is considered an infectious 
agent.  
 
Clarification  should  be made between a  serious  AE (SAE) and an AE  that is considered severe  in 
intensity (Grade 3 or 4), because the terms serious and severe are NOT synonymous.  The 
general term severe is often used to describe the intensity (severity) of a specific event; the event 
itself, however, may be of relatively minor medical significance (such as a Grade 3 headache). 
This is NOT the same as the serious , which is based on patient/event outcom e or action, criteria 
described above, and is usually associated with events that pose a threat to a patient’s life or 
ability to function.  A severe AE (Grade 3 or 4) does not necessarily need to be considered 
serious.  For example, a white blood cell count  of 1000/mm3 to less than 2000 is considered 
Grade  3 (severe)  but may not be  considered  serious.  Seriousness  (not intensity)  serves  as a guide 
for defining regulatory reporting obligations.  
 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
following list of reported and/or potential AEs (Section 7.2) and the characteristics of an 
observed AE (Section 7.3) will determine whether the event requires exped ited reporting in 
addition to routine reporting.  
 
 
7.2 Expected  Toxicities  
 
▪ Adverse  Events  List(s)  
 
7.2.1.1  Adverse  Event  List of Nivolumab  
 
Events that  are listed  as very common (experienced in ≥10%  of patients)  according to  the current 
IB ( Version 15 dated June 24 2016) include the following: diarrhea, nausea, fatigue, rash, and 
pruritis .  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
50  
  
Events that are listed as common (experienced in ≥1% to <10% of patients )include: 
hypothyroidism,  hyperthyroidism,  hyperg lycemia, colitis,  stomatitis,  mouth  ulceration,  vomiting, 
abdominal pain, constipation, dry mouth, pyrexia edema ( general and peripheral), hepatitis, 
infusion related reactions, upper respiratory infections, increased lipase, increased amylase, 
increased  aspartate  aminotrasferase,  increase  alanine  aminotransferase,  increased  blood  bilirubin, 
hyponatremia, decreased appetite, musculoskeletal pain, arthralgias, peripheral neuropathy, 
headache, dizziness, nephritis, pneumonitis, dyspnea, cough, vitiligo, dry skin, erythema, 
alopecia, and hypertension  
 
Events that are listed as uncommon  ≥0.001% of patients to < 1% include the following: 
urticaria, vasculitis, rosacea, psoriasis, erythema multiforme, lung infiltration, tubulointerstitial 
nephritis, renal failure , acute kidney injury, encephalitis, autoimmune neuropathy, facial nerve 
paresis, myasthenic syndrome, demyelization, Guillain -Barre Syndrome, polymyalgia 
rheumatica, histiocytic necrotizing lympadenitis, bronchitis, hypersensitivity, anaphylactic 
reaction , duodenal ulcer,  pancreatitis,  uveitis,  diabetes  mellitus,  diabetic  ketoacidosis,  thyroiditis, 
autoimmune hypophysitis, hypopituitarism, adrenal insufficiency, tachycardia, arrhythmias,  
 
Toxic epidermal necrolysis (including Stevens Johnson Syndrome) is i ncluded as a rare risk 
(experienced by ≥0.00001% to <0.001% of patients).  
 
7.2.1.2  Other  Immune  Mediated  Adverse  Events  
 
For suspected immune -related adverse reactions, adequate evaluation should be performed to 
confirm etiology or exclude other causes. Based on the severity of the adverse reaction, 
nivolumab should be withheld or discontinued, and corticosteroids administer ed accordingly. 
Upon improvement, nivolumab may be resumed after corticosteroid taper. If there is recurrence 
of any Grade  3 or 4 immune -related  adverse  reactions  or life-threatening  immune -related  adverse 
reactions, nivolumab must be permanently discontin ued. Rare cases of myotoxicity (myositis, 
myocarditis,  and rhabdomyolysis),  some  with fatal outcome, have  been  reported  with nivolumab. 
If a patient develops signs and symptoms of myotoxicity, close monitoring should be 
implemented, and the patient referred to a specialist for assessment and treatment without delay. 
Based on the severity of myotoxicity, nivolumab should be withh eld or discontinued, and 
appropriate treatment instituted. For Grade 3 myocarditis, nivolumab should be permanently 
discontinued.  
 
The following events have been identified during post approval use of nivolumab. Because 
reports are voluntary from a populat ion of unknown size, an estimate of frequency cannot be 
made.  
 
• Solid organ and tissue transplant rejection has been reported in patients who have previously 
undergone transplantation and who were subsequently treated with programmed cell death 
1/programmed  cell death ligand 1 (PD -1/PD -L1) inhibitors, including nivolumab. Treatment 
with nivolumab may increase the risk of rejection in solid organ or tissue transplant 
recipients.  
 
• Rapid -onset and severe GVHD, some with fatal outcome, has been reported in patie nts who 
had undergone  prior  allogeneic  HSCT  and subsequently  received  PD-1/PD -L1 inhibitors.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
51  
  
Subjects  should  be screened  to determine  whether  they have  undergone  a prior  allogeneic 
HSCT prior to participating in nivolumab clinical trials.  
 
• Complications of allogeneic HSCT after treatment with PD -1/PD -L1 inhibitors including 
nivolumab, administered before allogeneic HSCT, may be associated with an increased risk 
of transplant -related complications, including GVHD. Fatal cases have been reporte d in 
clinical studies. Patients should be monitored closely for early evidence of transplant -related 
complications  
 
7.2.1.3  Adverse  Event  List for Lenalidomide  
 
Events that have occurred in >10% of individuals treated with lenalidomide include neutropenia, 
anemia, thrombocytopenia, fatigue, rash, diarrhea, constipation, nausea, loss of appetite, itching, 
dry skin, muscle cramps, lack or loss of strength, dizziness , insomnia, swelling of the  
extremities, headache, back and joint pain, fever, cough, upper respiratory infection, and  
dyspnea.  
 
Events that have occurred in >1% of individuals treated with lenalidomide include risk of DVT, 
PE, and blood clots that could l ead to stroke, heart attack, or organ failure, febrile neutropenia, 
atrial fibrillation, pneumonia or lung infections, sepsis, dehydration and renal failure.  
 
Events that have occurred in <1% of individuals treated with lenalidomide include rare  
treatment -emergent adverse events of angioedema, serious skin reactions including Stevens - 
Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) or an allergic skin reaction 
similar to that seen with thalidomide, tumor lysis syndrome (TLS), tumor flare reactio n (TFR), 
and rhabdomyolysis. In  addition,  lenalidomide  has been  shown  to increase the level  of digoxin  in 
the blood in some patients. Patients will be instructed to inform their doctor if taking digoxin.  
 
There may be an increased risk of second cancers in  patients who are on lenalidomide 
maintenance therapy after a bone marrow transplant.  
 
7.2.1.4  Adverse  events  list of Dexamethasone  
 
Events that have occurred in 10 -15% of individuals treated with dexamethasone include 
increased appetite, weight gain, sleep distur bance, hypertension, fluid retention, ankle swelling, 
bruising, infection, mood changes, slow wound healing, depression, and hyperglycemia, which 
may lead to fatigue, weight loss, excessive thirst and frequent urination. Events that have 
occurred in 1 -9% o f individuals treated with dexamethasone include loss of appetite, muscle 
twitching, increased thirst, frequent urination, increased perspiration, diarrhea, nausea,  headache, 
bone thinning, spinal fracture or fracture of bones, tachycardia, fungal infectio ns. Events that 
have occurred in <1% of individuals treated with dexamethasone include blurred vision, 
personality changes, stomach ulcers with bleeding that may cause hematemesis, blood in the 
stool and abdominal pain. Other, less frequent, events may inc lude bowel perforation, irritation 
and bleeding of the esophagus, heart failure, allergic reaction that may lead to facial redness, 
shortness of breath, abdominal cramps and hypotension, convulsions, brain swelling, dizziness, 
cataracts, glaucoma and incre ased blood pressure in the eye, development of diabetes, pancreatic 
inflammation,  abdominal  swelling,  hypokalemia,  DVT  or PE, malaise,  swelling  and/or  redness  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
52  
  
of skin, allergic skin  reactions, itching, hirsutism, muscle weakness or loss of muscle mass, 
rupture of tendons, menstrual cycle disturbances, facial puffiness, leading to the appearance of a 
“moon face” hormonal disturbances, and hiccups.  
 
7.3 Adverse  Event  Characteristics  
 
• CTCAE term (AE description) and grade:  The descriptions and grading scales found 
in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version  
4.0 will be utilized for AE reporting.  All appropriate treatment areas shoul d have access 
to a copy of the CTCAE version 4.0.  A copy of the CTCAE version 4.0 can be 
downloaded from the CTEP web site:  
 
http://ctep.cancer.gov/protocolDevelo pment/electronic_applications/ctc.htm.  
 
• Attribution  of the AE: 
- Definite  – The AE is clearly  related  to the study  treatment.  
- Probable  – The AE is likely  related  to the study  treatment.  
- Possible  – The AE may be related  to the study  treatment.  
- Unlikely  – The AE is doubtfully  related  to the study  treatment.  
- Unrelated  – The AE is clearly  NOT  related  to the study  treatment.  
 
7.4 Expedited  Adverse  Event  Reporting  
 
▪ Investigators  must report  to the Overall  PI any serious  adverse  event  (SAE)  that 
occurs after the initial dose of study treatment, during treatment, or within 30 
days of the last dose of treatment on the local institutional SAE form.  
 
For multi -institution studies where a DF/HCC investigator  is serving as the Overall Principal 
Investigator, each participating institution must abide by the reporting requirements set by the 
DF/HCC. This applies to any medical event equivalent to an unexpected grade 2 or 3 with a 
possible, probable or definite a ttribution to nivolumab (the study medication), all grade 4 
toxicities, and grade 5 (death) regardless of study phase or attribution.  
 
7.5 DF/HCC  Expedited  Reporting  Guidelines  
 
Investigative sites within DF/HCC  and DF/PCC will report SAEs directly  to the DFCI  Office for 
Human Research Studies (OHRS) per the DFCI IRB reporting policy.  
 
Other investigative sites will report SAEs to their respective IRB according to the local IRB’s 
policies and procedures in reporting adverse events. A copy of the submitted insti tutional SAE 
form should be forwarded to the Overall PI within the timeframes detailed in the table below.  
 
Table  18- DF/HCC  Reportable  AEs 
 
 
Attribution  Gr. 2 & 3 
AE 
Expected  Gr. 2 & 3 
AE 
Unexpected  Gr. 4 
AE 
Expected  Gr. 4 
AE 
Unexpected  Gr. 5 AE 
Expected  or 
Unexpected  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
53  
  
Unrelated 
Unlikely  Not required  Not required  5 calendar 
days# 5 calendar 
days 24 hours*  
Possible 
Probable 
Definite   
Not required  5 calendar 
days 5 calendar 
days# 5 calendar 
days  
24 hours*  
# If listed  in protocol  as expected  and not requiring  expedited  reporting,  event  does not need  to 
be reported.  
* For participants enrolled and actively participating in the study or for AEs occurring within  
30 days of the last intervention, the AE should be reported within 1 business day of learning of 
the event.  
 
The Overall PI will submit SAE reports from outside institutions to the DFCI OHRS according  
to DFCI IRB policies and procedures in reporting adver se events.  
 
If, following initiation of the investigational product, it is subsequently discovered that a study 
subject is pregnant or may have been pregnant at the time of investigational product exposure, 
including during at least 6 half lives  after prod uct administration, the investigational product will 
be permanently discontinued in an appropriate manner (e.g., dose tapering if necessary for 
subject safety).  
 
Protocol -required procedures for study discontinuation and follow -up must be performed on the 
subject unless contraindicated by pregnancy (e.g., x -ray studies). Other appropriate pregnancy 
follow -up procedures should be considered if indicated. The investi gator must immediately  
notify the BMS, Celgene (or designee) Medical Monitor of this event and complete and forward 
an SAE Form to BMS and Celgene (or designee) within 24 hours and in accordance with SAE 
reporting procedures described in this section.  
 
Pregnancy  
Any pregnancy that occurs in a female partner of a male study participant should be reported to 
the Overall PI. Information on this pregnancy will be collected on the BMS Pregnancy 
Surveillance Form. Follow -up information regarding the course of the  pregnancy, including 
perinatal  and neonatal  outcome  and, where  applicable,  offspring  information  must  be reported  on 
the Pregnancy Surveillance Form. Please contact the Research Project Manager if you do not 
have this form in your regulatory files.  
 
Pregn ancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on lenalidomide, or within  28 
days of the subject’s last dose of lenalidomide, are considered immed iately reportable events. 
Lenalidomide is to be discontinued immediately. The pregnancy, suspected pregnancy, or 
positive pregnancy test must be reported to Celgene Drug Safety immediately by facsimile or 
email using the Pregnancy Initial Report Form. The female subject should be referred to an 
obstetrician -gynecologist, preferably one experienced in reproductive toxicity for further 
evaluation and counseling.  
 
The Investigator  will follow  the female  subject  until completion  of the pregnancy,  and must  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
54  
  
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow -up Report Form.  If the outcome of the 
pregnancy was abnormal (e.g., spontaneous or therapeutic abortion), the Investiga tor should 
report the abnormal outcome as an AE. If the abnormal outcome meets any of the serious  
criteria,  it must  be reported  as an SAE  to Celgene  Drug  Safety  immediately  by facsimile,  or other 
appropriate method, within 24 hours of the Investigator’s kn owledge of the event using the SAE 
Report Form.  
 
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs. In addition, any infant death after 28 days that the Investigator suspects is 
related to the i n utero exposure to the IP should also be reported to Celgene Drug Safety 
immediately by facsimile, or other appropriate method, within 24 hours of the Investigator’s 
knowledge of the event using the SAE Report Form.  
 
Male  Subjects  
If a female partner of a  male subject taking investigational product becomes pregnant, the male 
subject taking lenalidomide should notify the Investigator, and the pregnant female partner 
should be advised to call their healthcare provider immediately.  
 
Celgene  Drug  Safety  Contact  Information:  
Celgene  Corporation  
Global  Drug  Safety  and Risk Management 
Connell Corporate Park  
300 Connell Dr.  Suite 6000 
Berkeley  Heights,  NJ 07922 
Fax: (908) 673 -9115  
E-mail:  drugsafety@celgene.com  
 
Overdose  
 
An overdose is defined as the accidental or intentional administration of any dose of a product 
that is considered both excessive and medically important. All occurrences of o verdose must be 
reported as SAEs.  
 
There is no specific experience in the management of lenalidomide overdose in patients with 
MM, MDS, or MCL. In dose -ranging studies in healthy subjects, some were exposed to up to  
200 mg (administered  100 mg BID)  and in single -dose studies,  some  subjects  were  exposed  to up 
to 400 mg. Pruritus, urticaria, rash, and elevated liver transaminases were the primary reported 
AEs. No clinically significant changes in ECGs, blood pressure, or pulse rate were observed.  
While  no hematologic  events  were  associated  with an overdose,  such events  may be expected 
since in clinical trials; the dose -limiting toxicity was essentially hematologic. In the event of 
overdose, supportive care is advised.  
 
There is no available information concern ing overdose with nivolumab. Depending on the 
symptoms  and/or  signs  leading  to the suspicion  of overdose,  supportive  medical management 
should be provided. There is no specific antidote.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
55  
  
 
 
 
 
 
 
 
 
7.5.1 Protocol -Specific  Expedited  Adverse  Event  Reporting  Exclusions  
 
7.5.1.1  There  are no  protocol specific exclusions.  
 
7.6 Expedited  Reporting  to the Food  and Drug  Administration  (FDA)  
 
The Overall PI, as study sponsor, will be responsible for all communications with the FDA. The 
Overall PI will report to the FD A, regardless of the site of occurrence, any serious adverse event 
that meets the FDA’s criteria for expedited reporting following the reporting requirements and 
timelines set by the FDA.  
 
7.7 Expedited  Reporting  to Bristol -Myers  Squibb  (BMS)  
 
The Overall  PI, as study  sponsor,  will be responsible  for all communications  with the BMS  via 
the MedWatch 3500A form:  
 
http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/ucm2007307.htm  
 
With the exception of any serious adverse event that meets the FDA’s criteria for expe dited 
reporting,  one should  follow  the reporting  requirements  and timelines  set by the FDA.  All SAEs 
and SUSARs should simultaneously be faxed or e -mailed to BMS by each participating site at:  
 
Global  Pharmacovigilance  & Epidemiology 
Bristol -Myers Squibb C ompany  
Fax Number:  609-818-3804  
Email:  Worldwide.safety@bms.com  
 
The written  report  must  be completed  and supplied  to BMS  by facsimile  or e-mail within  24 
hours.  
 
7.8 Expedited  Reporting  to Hospital  Risk  Management  
 
Participating  investigators  will report  to their local  Risk Management  office  any participant 
safety reports or sentinel events that require reporting according to institutional policy.  
 
7.9 Routine  Adverse  Event  Reporting  
 
All Adverse Events must be reported in routine study data submissions to the Overall PI on the 
toxicity  case report  forms. AEs reported  through  expedited  processes  (e.g.,  reported  to the 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
56  
  
IRB,  FDA,  etc.) must  also be reported  in routine  study  data  submissions.  
 
 
8. PHARMACEUTICAL  INFORMATION  
 
A list of the adverse events and potential risks associated with the Nivolumab and lenalidomide 
administered in this study can be found in Section 7.  
 
8.1 Nivolumab  
 
8.1.1 Description  
 
Nivolumab  is a fully  human  monoclonal  antibody  (HuMAb;  immunoglobulin  G4 [IgG4] -S228P) 
that targets  the PD-1 cell surface  membrane  receptor.  Nivolumab  inhibits  the interaction  of PD-1 
with its ligands, PD -L1 and PD -L2, resulting in enhanced T -cell proliferation and interferon - 
gamma (IFN -γ) release in vitro.  
 
8.1.2 Form  
 
Nivolumab Injection,  100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to 
opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug 
product is a sterile, nonpyrogenic, single -use, isotonic aqueous solution formulated at 10 mg /mL 
in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), 
and polysorbate  80, pH 6.0 and includes  a 0.7 mL overfill  to account  for vial, needle,  and syringe 
(VNS) holdup. It is supplied in 10 -cc Type I flint glass vials, stoppered with butyl rubber 
stoppers and sealed with aluminum seals.  The only difference between the two drug product 
presentations is the vial fill volume.  
 
8.1.3 Storage and Stability  
 
The product  does not contain  a preservative.  Vials  of nivolumab  injection  must  be stored  at 2- 
8C (36 -46F) and protected from light, freezing, and shaking.  
 
After  preparation,  store  the nivolumab  infusion  either:  
• At room  temperature  for no more  than 4 hours  from  the time of preparation.  This includes 
room temperature storage of the infusion in the IV container and time for administration 
of the infusion or  
• Under  refrigeration  at 2°C to 8°C (36°F -46°F)  for no more  than 24 hours from  the time of 
infusion preparation.  
• Do not freeze.  
 
If a temperature excursion is noted at your site, the site must complete a temperature excursion 
form  provided  by the lead site. The lead site will then submit  to Bristol - Myers  Squibb  to assess 
if the drug is appropriate for use, or should be destroyed.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
57  
  
8.1.4 Compatibility  
 
Do not co-administer  other  drugs  through  the same  intravenous  line. 
Flush the intravenous line at end of infusion.  
No incompatibilities  between  nivolumab  and polyvinyl  chloride  (PVC),  non PVC/non  DEHP 
(di(2 -ethylhexyl)phthalate) IV components, or glass bottles have been observed.  
 
8.1.5 Handling  
 
Qualified  personnel,  familiar  with procedures  that minimize  undue  exposure  to themselves  and 
the environment, should undertake the preparation, handling, and safe disposal of the 
chemotherapeutic agent in a self -contained and protective environment.  
 
8.1.6 Availability  
 
Nivolumab  for injection  will be supplied  free of charge  by BMS.  The study  team  will provide  all 
external sites with a study specific order form  
 
8.1.7 Preparation  
 
Visually inspect drug product solution for particulate matter and discoloration prior to 
administration.  Nivol umab  is a clear  to opalescent,  colorless  to pale-yellow  solution.  Discard 
the vial if the solution is cloudy, is discolored, or contains extraneous particulate matter other 
than a few translucent -to-white, proteinaceous particles.  Do not shake the vial.  
 
• Withdraw  the required  volume  of nivolumab  and transfer  into an intravenous  container.  
• Dilute nivolumab with either 0.9% Sodium Chloride Injection, USP or 5% Dextrose 
Injection,  USP,  to prepare  an infusion  with a final concentration  ranging  from  1 mg/mL 
to 10 mg/mL.  
o Mix diluted  solution by  gentle  inversion. Do  not shake.  
o Discard  partially  used vials  or empty  vials  of nivolumab.  
 
8.1.8 Administration  
 
Administer  the infusion  over 60 minutes  (+/- 10 minutes)  through  an intravenous  line containing 
a sterile, non -pyrogenic, low protein binding in -line filter (pore size of 0.2 micrometer to 1.2 
micrometer).  
 
Nivolumab  will be administered  at a flat dose of 240 mg as an intravenous  infusion  over 
60 minutes (+/ - 10 minutes) every 2 weeks (Day s 1 and 15 of each 28 day cycle).  The 
administration  of nivolumab  infusion  must  be completed  within  24 hours  of preparation.  
 
8.1.9 Ordering  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
58  
  
Each participating institution will order nivolumab directly from the supplier Bristol Myers 
Squibb  Pharmaceuticals  (BMS).  A participating  site may order  the agent(s)  only after the initial 
IRB approval  for the site has been  forwarded  by the Coordinating  Center.  A study  specific  order 
form will be supplied by the lead site.  
 
8.1.10  Accountability  
 
The investigator,  or a responsible  party  designated  by the investigator,  should  maintain  a careful 
record of the inventory and disposition of the agent using the NCI Drug Accountability Record 
Form (DARF) or another comparable drug accountability form.  (See the NCI Investigator’s 
Handbook for Procedures for Drug Accountability and Storage.)  
 
8.1.11  Destruction  and Return.  
 
For this study, study drugs (those supplied by BMS or sourced by the investigator) such as 
partially used study drug containers, vials and syringes may be destroyed on site.  
 
Any unused study drugs can only be destroyed after being in spected and reconciled by the 
responsible DFCI Study Monitor or designee unless study drug containers must be immediately 
destroyed as required for safety, or to meet local regulations (eg, cytotoxics or biologics).  
 
On-site destruction  is allowed  provided  the following  minimal  standards  are met: 
• On-site disposal  practices  must  not expose  humans  to risks  from  the drug.  
• On-site disposal practices and procedures are in agreement with applicable laws and 
regulations,  including  any special  requirements  for controlled  or hazardous  substances.  
• Written  procedures  for on-site disposal  are available  and followed.  The procedures  must 
be filed with the site’s SOPs and a copy provided to BMS upon request.  
• Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification (ID) of the person disposing the 
contain ers. The method  of disposal,  (eg, incinerator,  licensed  sanitary  landfill,  or licensed 
waste disposal vendor) must be documented.  
• Accountability  and disposal  records  are complete,  up-to-date,  and available  for the 
Monitor to review throughout the clinical trial period.  
 
If conditions  for destruction  cannot  be met the responsible  Study  Monitor  will make 
arrangements for return of study drug.  
It is the investigator’s  responsibility  to arrange  for disposal  of all empty  containers,  provided  that 
procedures  for proper  disposal  have  been  established  according  to applicable  federal,  state,  local, 
and institutional  guidelines  and procedures,  and provided  that appropriate  records  of disposal  are 
kept.  
If study drug will not be destroyed upon completion or termination of the study, all unused 
and/or  partially  used study  drug that was supplied  by BMS  must  be returned  to BMS.  The return 
of study drug will be arranged by the responsible Study Monitor.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
59  
  
8.2 Lenalidomide  
 
8.2.1 Description  
 
Lenalidomide (REVLIMID®), a thalidomide analogue, is an immunomodulatory agent with 
antiangiogenic properties. The chemical name is 3 -(4-amino -1-oxo 1,3 -dihydro -2H- isoindol -2- 
yl) piperidine -2,6-dione and it has the following chemical structure:  
 
3-(4-amino -1-oxo  1,3-dihydro -2H-isoindol -2-yl)  piperidine -2,6-dione.  
 
The empirical formula for lenalidomide is C13H13N3O3, and the gram molecular weight is 
259.3.  
 
8.2.2 Form  
 
Lenalidomide is off -white to pale -yellow solid powder. It is soluble in organic solvent/water 
mixtures, and buffered aqueous solvents. Lenalidomide is more  soluble in organic solvents and 
low pH solutions.  Solubility  was significantly  lower  in less acidic  buffers,  ranging  from  about  
0.4 to 0.5 mg/ml. Lenalidomide has an asymmetric carbon atom and can exist as the optically 
active forms S( -) and R(+), and is produced as a racemic mixture with a net optical rotation of 
zero.  
 
Lenalidomide is available for this study as 5 and 25 mg capsu les for oral administration. Each 
capsule contains lenalidomide as the active ingredient and the following inactive ingredients: 
lactose anhydrous, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.  
 
8.2.3 Storage and Stability  
 
At the st udy site, all investigational study drugs will be stored in a locked, safe area to prevent 
unauthorized access. Lenalidomide should be stored at room temperature away from direct 
sunlight and protected from excessive heat and cold.  
 
8.2.4 Handling  
 
Females of ch ildbearing potential should not handle or administer lenalidomide unless they are 
wearing gloves.  
 
Qualified personnel, familiar with procedures that minimize undue exposure to themselves and 
the environment, should undertake the preparation, handling, and safe disposal of the 
chemotherapeutic agent in a self -contained and protective environment.  
 
8.2.5 Avail ability  
 
Lenalidomide  supply  will be obtained  through  commercial  supply.  
 
8.2.6 Preparation  
 
Lenalidomide  is an oral drug,  and does not require  specific  preparation  details.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
60  
  
8.2.7 Administration  
 
Lenalidomide will be given daily on days 1 -21 of each 28 day cycle. At all times when 
dispensing lenalidomide protocol therapy, study site personnel will review the instructions, 
printed on the packaging, with participants.  
 
8.2.8 Ordering  
 
Commercial supply of lenalidomide (Revlimid®) will be ordered through the participant’s 
insurance and will be filled through a retail pharmacy, and shipped on a per cycle basis to the 
patient’s home or to the treating institution’s outpatient pharmacy, whichever the study team  
prefers.  Lenalidomide will be provided in accordance with the Celgene Corporation’s Revlimid 
REMS® program.  Per standard Revlimid REMS® program requirements (as listed in section 
3.1.7),  all physicians who prescribe lenalidomide for research subjects enro lled into this trial, 
and all research subjects enrolled into this trial, must  be registered in, and must comply with, all 
requirements of the Revlimid REMS® program.  
 
8.2.9 Accountability  
 
As drug is from  commercial  supply,  sites should  keep  records  per their institutional  policies.  
 
8.2.10  Destruction  and Return  
 
Unused or returned supplies of lenalidomide should be destroyed and documented according to 
institutional policies.  
 
8.3 Dexamethasone  
 
8.3.1 Description  
 
Dexamethasone is a synthetic adrenocortical steroid. Cor ticosteroids are naturally occurring 
chemicals produced by the adrenal glands located above the kidneys. Corticosteroids affect the 
function of many cells within the body and suppress the immune system. Corticosteroids also 
block inflammation and are used in a wide variety of inflammatory diseases affecting many 
organs.  
 
The molecular weight for dexamethasone is 392.47. It is designated chemically as 9 - fluoro - 
11β,17,21 -trihydroxy -16α-methylpregna -1,4-diene -3,20-dione. Dexamethasone is stable in air 
and al most insoluble in water.  
 
8.3.2 Form  
 
Dexamethasone  is a white  to practically  white,  odorless,  crystalline  powder.  It is available  in 2 or 
4 mg tablets (commercially) for oral administration. Each tablet contains dexamethasone as the 
active ingredient, and the following inactive ingredients: calcium phosphate, lactose, magnesium 
stearate,  and starch. The  tablet  shell  may contain the  follow ing: D&C  Yellow  10, FD&C Yellow  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
61  
  
6, and/or  FD&C  Blue  1. 
 
8.3.3 Storage and Stability  
 
At the study site, all investigational study drugs will be stored in a locked, safe area to prevent 
unauthorized access. Dexamethasone should be stored at control led room temperature, 68 -77◦F 
(20-25◦C) and not frozen, and according to label requirements.  
 
8.3.4 Handling  
 
Dexamethasone should be handled by trained pharmacy staff. The use of gloves and other 
appropriate protective clothing is recommended as necessary.  
 
8.3.5 Availability  
 
Dexamethasone  supply  will be obtained  through  commercial  supply.  
 
8.3.6 Preparation  
 
Dexamethasone  is an oral drug,  and does not require  specific  preparation  details.  
 
8.3.7 Administration  
 
During induction therapy, participants will receive dexamethasone as a single oral daily dose of 
40mg on Days 1, 8 and 15 of cycles 1 -6. 
 
 
8.3.8 Ordering  
 
Dexamethasone  will be ordered  from  retail  pharmacy  through  commercial  drug supply.  
 
8.3.9 Accountability  
 
As drug is from  commercial  supply,  sites should  keep  records  per their institutional  policies.  
 
8.3.10  Destruction  and Return  
 
Unused or returned supplies of dexamethasone should be destroyed and documented according  
to institutional policies.  
 
9. BIOMARKER,  CORRELATIVE,  MRD  ASSESSMENT  AND  SPECIAL  STUDIES  
 
The mandatory correlative studies will consider several potential predictive biomarkers. As 
discussed in the appropriate sections of the protocol, mutations such as N -RAS, K -RAS, MYC 
up-regulation, and gain or loss of chromosome 1q or 1p are hypothesized t o correlate with 
disease progression. The sample size of this phase -2 study, 41 patients, will allow exploratory 
analyses  on TTP correlation  with biomarkers.  The number  of biomarkers  and the associated  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
62  
  
multiplicities will only  allow us to pr ovide empirical point estimates and confidence intervals  
for TTP -biomarker concordance indexes.  
 
Please  refer  to Appendix  B for a full sample  collection  table.  This trial will provide  samples  from 
consenting SMM patients treated with Nivolumab, lenalidomide and dexamethasone to 
comprehensively characterize the MM genome and immune cells function and define molecular 
events driving development and progression of MM.  
 
We will attempt to obtain sa mples on all patients at several time points during the study, 
including before therapy, at the end of cycle 6, at the time of response determination (CR),at 
disease relapse, and at the time of completion of the study. It is anticipated that approximately 
90% of samples collected will be adequate for sequencing studies proposed.  
 
The tumor  cells will be collected  as described  below. From  these  samples,  high quality  DNA  (for 
tumor cells) and RNA (for tumor cells and immune cells) for both exome sequencing an d RNA 
sequencing will be obtained. Germline DNA will be also obtained from a buccal swab from all 
patients at any time point of the study.  Samples collected for the purpose of research at Dana 
Farber Cancer Institute will be banked and retained for researc h use indefinitely.  
 
Peripheral blood and bone marrow derived mononuclear cells will undergo immunologic 
assessments to assess the impact of therapy on general measures of cellular immunity, MM 
reactive T cells, and antigen specific immunity.  The percentag e of circulating and bone marrow 
derived regulatory immune cells will be determined.  
 
9.1 Minimal  residual  disease  assessment  (MRD)  
 
MRD will be assessed using Adaptive’s LymphoSIGHT platform as part of normal clinical care. 
Bone marrow samples will be collected per the collection time described in the table of sample 
collection. The collection kits and shipping supplies will be provide d to the sites by Adaptive  
Inc. These samples will be packaged whole, and shipped to Adaptive, Inc. the same day priority 
overnight. Using Adaptive’s LymphoSIGHT platform, rearranged immunoreceptor loci from 
genomic DNA will be extracted, amplified, and se quenced using V and J segment primers for 
each immunoreceptor gene.  Tumor -specific clonotypes will be identified for each patient based 
on their high prevalence in peripheral blood.  Sequences will be analyzed using standardized 
algorithms  for clonotype  determination.  Adaptive  MRD  levels  will be quantified  using  spiked -in 
reference sequences.  
Adaptive Inc. will hold samples for up to 6 months after they have been analyzed, and then will 
subsequently be destroyed.  
 
The processing of these samples will be bill ed to the patient’s insurance, and therefore, all 
information requested on the online test ordering portal  must be filled out completely, and not 
de-identified.  
 
For Adaptive Inc. samples, use the packing supplies provided in each individual kit and follow  
the directions below to establish your account and order the required testing:  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
63  
  
1. Create an online ordering profile for your physician and any staff  who may order this test 
for your patients using the Physician Registration Form provided to yo u by the lead site.  
a. Enter all information under the “Ordering Physician” as the site 
responsible PI for the trial at your site  
b. “Online Access” should be checked off to enable online portal ordering of 
tests 
c. The “Designated Point of Contact” should be one n on-physician member 
of the team  as the contact for any and all study/order related questions  
d. The “Designated Point of Contact” should be the person ( along with the 
physician) who will have access to the patient’s results and be able to  
send them to the lead site  
e. Be sure to include  your own practice  as the Primary  Institution  
f. Additional  points of contact should list any other members of the study 
team who may place orders for the patients on the trial  
g. Submit the form to clinicalservices@adaptivebiotech.com  to establish  
your s ite 
 
 
2. Order kits for your site by placing an order to clinicalservices@adaptivebiotech.com  ; 
ensure that you identify yourself as being part of trial  16-242; Overall PI Irene Ghobrial, 
MD and p rovide the proper shipping address for the kits  
 
 
3. To order  a ClonoSEQ  ID test(also  known  as the B-Cell Clonality  Test required  at 
baseline/screening) or a Follow up Test (MRD  or Tracking Test)  for a patient:  
a. After  logging  into your account,  click  “New  Order”  
b. Choose  Ordering  Physician  associated  with 16-242 
c. Under  Trial/Study  Code,  enter  16-242 
d. Click Pick a Patient, and then Create New Patient ( for follow up/MRD 
samples, select established patient - Their information will populate the 
form)  
e. Enter  patient  complete  demographics (new  patients  only)  
f. Under  Diagnosis (es)/Clinical Indication ICD Codes, Multiple Myeloma 
C90.00 not having achieved a remission should be selected.  
g. Under clonoSEQ  Assay, choose B Cell Clonality  Test (Diagnostic  ID test) 
if it is the baseline  sample.  For follow  up samples,  select  Tracking  Test 
( Minimal Residual Disease “MRD” test)  
h. Under Billing Information, select Insurance, and enter the patient’s 
complete insurance information (new patients only)  
i. Under patient status, select “outpatient” and enter your full institution 
name  
j. Enter any secondary insurance information for the patient if applicable 
(new patients only)  
k. Enter  the patient’s  complete  billing  address  (new  patients  only)  
l. Under Specimen Infor mation, select “ Shipping Specimen to Adaptive”, 
Specimen Type: fresh bone marrow and the collection date  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
64  
  
m. The unique specimen ID should be chosen by the site and able to be 
connected  to the patient later on ( you may use either letters or nu mbers or 
a combination of the two)  
n. Under special instructions, please enter Fed Ex tracking number of the 
package  
o. Print out a copy of the Test Requisition Form ( TRF) and have either the 
Point of Contact, Additional Contacts or the Physician listed on the 
Physician Registration Form sign the designated signature space,  and 
include it in the shipment  
p. Retain retain a co py of the Fed Ex Waybill in the patient’s research folder 
attached to the copy of the TRF and file in the patient’s research chart  
q.  Please  email  Patrick  Henrick  (Phenrick@dfci.harvard.edu ) and Alexandra 
Savell ( asavell@dfci.harvard.edu ) to notify of an out going shipment.  
 
 
Diagnostic  Portal  Log In: https://diagnostics.adaptivebiotech.com/account/login  
 
 
To order  kits for your  site: Please  order  via clinicalservices@adaptivebiotech.com  and 
reference the study number, 16 -242 , and  include the address where the kits should be shipped  
 
Results:  The results of these tests will be sent to the lea d site in the form of a PDF/scanned 
document emailed to the study team listed abovein real time. The patient’s PHI should be 
redacted  appropriately  with only the patient’s  date of birth,  and study  specific  identifier  (initials 
and assigned study number) visible.  
 
* External  sites may choose  to use an alternate  method/source  to bill for this test, if 
they so choose.  This must  first be discussed  and approved  by the lead site prior  to ordering  any 
test. 
 
9.2 Bone  Marrow  Aspirate  Samples  
 
Collection of bone marrow aspirate specimens for exploratory analysis are requested at the times 
of all standard  of care bone marrow  collections. Specimens  will be shipped  (via traceable  carrier) 
to and subsequently processed, analyzed, and stored at Dana -Farber Cancer Institute.  
 
9.2.1 Specimens  Requested  
 
2 Purple  Top Tubes  (K2EDTA),  10mL  each(3  tubes  at baseline).  Specimens  must  be 
collected on Mondays to Thursdays for same -day shipment. For complete sample 
collection table, please refer to Appendix B  
 
9.2.2 Processing  Information  
 
Package  tubes  at room  temperature  and wrap  in a liberal  amount  of paper  towel  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
65  
  
around the tubes to ensure adequate insulation of the specimen(s) and absorption in 
the event of a breakage. Place wrapped specimen in a biohazard labeled Ziploc bag 
with a fridge pack and zip close. Wrap bubble wrap around the bag and place in a 
cardboard  box. If space remains in the box, stuff with extra paper towel to reduce 
shifting of samples. Complete the shipping requisition form using the address listed 
below. Prepare the package for shipping, applying packing tape as needed. Ship the 
package using FedEx First Priority Overnight delivery the same day the sample was 
collected. Please only ship Monday -Thursday.  Please see Appendix B and C for 
Collection Schedule and Requisition Form  
 
 
9.2.3 Shipping  Information  for Bone  Marrow  Aspirate  Specimens  sent to DFCI  
 
Label all specimens with the following: Subject Initials, Subject study number (will 
include protocol number), Visit at which sample was drawn (screening, response, 
Cycle X, etc.  or progression), Date sample drawn (mm/dd/yyyy), Time sample 
drawn (24 hour c lock).  
 
Shipping  Instructions  
 
Shipments  must  be sent on the day of collection  and cannot  be batched.  
 
1. Samples should be placed in a sealed biohazard bag and placed in a box with a fridge 
pack.  
 
2. An inventory sheet including a complete list of samples shipped (patient number, 
timepoint, study #) must accompany each shipment. Please sign and date the requisit ion 
form.  
 
3. An electronic copy (Word or Excel) of the sample requisition form must also be sent via 
email. The listing must also include a contact name, address and phone number of the 
person who is responsible for the shipment.  
 
4. Please email Patrick Henric k (Patrick_Henrick@dfci.harvard.edu ) and Alexandra Savell 
(AlexandraE_Savell@dfci.harvard.edu ) to notify of an incoming shipment.  
 
5. Please ship Monday to Thursday  as shipments cannot be received on weekends and/or 
on holidays.  
 
6. Once  drawn,  samples may  be shipped  via overnight  air to: 
 
Irene Ghobrial, MD, Dana -Farber Cancer Institute, 77 Avenue Louis Pasteur HIM 
Building room 240, MA551, Boston, MA 02215  Phone: (617) 582 -9857 Fax: (617) 
632-8535. Please retain a copy for site record maintenan ce. Please see Appendix B 
and C for Collection Schedule and Requisition Form  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
66  
  
9.3 Peripheral  Blood Samples  
 
Collection of peripheral blood specimens (including serum and plasma) for 
exploratory analysis are requested for all patients on this trial. Purple top tube 
collections will be requested at the same timepoints as bone marrow samples for 
correlative studies  (see Section 10 and Appendix B for specific time points and 
instructions). These specimens should be taken at the time of routine blood  
collection required for this study. Specimens will be processed on site according to 
instructions below and shipped (vi a traceable carrier) to Dana -Farber Cancer 
Institute. Once the shipment is received, samples will be subsequently processed, 
analyzed, and stored at Dana -Farber indefinitely. Please see Appendix B and C for 
Collection Schedule and Requisition Form  
 
Specime ns Required: 2 x 10mL purple top tubes (K2EDTA) and 1 x 10 mL Streck 
tube should be collected Mondays to Thursdays for same -day shipment.  
 
• Label  all specimens  with the following:  
 
o Subject Initials, Subject study number (will include protocol number), Visit at 
which sample was drawn (screening, response, Cycle X, progression etc.), Date 
sample drawn (mm/dd/yyyy), Time sample drawn (24 hour clock)  
 
9.3.1 Processing  Information:  
 
Package tub es at room temperature and wrap in a liberal amount of paper towel around the tubes 
to ensure adequate insulation of the specimen(s) and absorption in the event of a breakage. Place 
wrapped specimen in a biohazard labeled Ziploc bag with a fridge pack  and zip close. Wrap 
bubble wrap around the bag and place in a cardboard box. If space remains in the box, stuff with 
extra  paper  towel  to reduce  shifting  of samples.  Complete  the shipping requisition  form  using  the 
address listed below. Prepare the package for  shipping, applying packing tape as needed. Ship  
the package  using  FedEx or  UPS First  Priority  Overnight the  same  day the  sample  was collected. 
Only ship Monday -Thursday.  
 
With  each shipment,  please  include  the following:  
 
1. Samples should be placed in a sealed biohazard bag and placed in a box with a fridge 
pack.  
 
2. An inventory sheet including a complete list of samples shipped (patient number, 
timepoint, study #) must accompany each shipment. Please sign and date the form, an d 
retain a copy for site record maintenance. See Appendix C for Sample Requisition 
Form  
 
3. An electronic copy (Word or Excel) of the sample list must also be sent via email and 
include  the tracking  number of  the package. The  listing  must also  include  a conta ct name, 
address and phone number of the person who is responsible for the shipment.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
67  
  
 
4. Please  email  the lead site Project  Manager  to notify  of an incoming  shipment.  
 
5. Please ship Monday to Thursday as shipments cannot be received on weekends and/or on 
holidays.  
 
6. Once  drawn,  samples may  be shipped  via overnight  air to: 
 
Irene Ghobrial, MD, Dana -Farber Cancer Institute, 77 Avenue Louis Pasteur HIM 
Building room 240, MA551 , Boston, MA 02215 Phone: (617) 582 -9857 Fax: (617) 632 - 
8535. Please retain a copy for site record maintenance.  
 
9.4 Buccal  Swab  Samples  
 
9.4.1 Collection,  Processing,  and Shipping  
 
1. Ideally  have  the patient  rinse  mouth  out with water  immediately  prior  to sample 
collection  at least one hour after eating, drinking, or brushing teeth  
2. Pull open the package from  one end 
3. Remove  the swab  from  the tube,  taking  care not to touch  the white  swab  head  with 
your fingers  
4. Insert the swab into your mouth and rub firmly against the inside of your cheek or 
underneath  lower  and upper  lip. For standard  DNA  collection,  rub for 1 minute  and 
in all cases, for a minimum of 20 sections. Please use reasonable, firm, solid 
pressure  
5. Slide the plastic  cap over the swab  handle  with the flat side of the cap facing 
upwards and the swab facing downwards  
6. Insert  the swab  into the clear  plastic  tube and push  the cap into place - Next,  hold the 
cap while pulling the swab handle outwards to release the swab material into the 
tube 
7. Close  the cap by pushing  the stopper  fully  into the cap ensuring  the stopper  is flush 
with the cap - The tube is now completely sealed  
8. Mail  same  day, ambient  to the lead site for processing.  The caps can be placed  in an 
envelope or other container with the trial number, patient study number (if 
registered), date of birth, site name, co llection date and time  
9. Two swabs  should  be used for each patient  to ensure  adequate  sample  for analysis  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
68  
 10. STUDY  CALENDAR  
Screening evaluations are to be conducted within 28 days of registration. Imaging assessments that are completed within 6 
weeks of registration need not be repeated at screening. If a patient had a bone marrow core biopsy done within 6 weeks of 
registration, a bone marrow aspirate sample need only be collected for baseline and research purposes. Baseline 
assessments are to be conducted on C1D1 of initial therapy and should be considered separate from screening evaluations. 
If screening assessments are performed within 7 days of C1D1, disease assessments (SPEP, UPEP, Immunofixation, Free 
light chain assay, quantitative immunoglo bulins) do not need to be repeated. Lab values that are used to prove eligibility  
for patients with progressive (evolving) smoldering myeloma do not need to be within the 21 day window, but screening 
values will need to be established in window. All assess ments must be performed prior to administration of any study 
medication. See below for detailed scheduled of assessments. Study medications will be administered according to the 
schedule and guidelines outlined in Section 5.  
 
Pre-registration  Cycles  1-12 (28 days)  3   
Follow -Up 
 
 
 
Tests  and procedures   
 28 
days 
prior to 
registrat 
ion  
 21 
days 
prior to 
registrat 
ion  
 
Day 1 of 
cycles  1- 
61  
 
Day 1 of 
cycles 7 -12  
Cycle  7 
Day 1 
and to 
confirm 
CR8  
 
End of 
Treatment18  
 
Every 3 
Months11 
History  and exam,  height,  weight. 
Performance Status  X  
X X  
X X 
Response  Assessment17   X X  X X 
Toxicity  Notation    X X  X  
Hematology  group  (WBC  w/ diff, 
PLT, Hgb, ANC)   
X X X  
X X 
Chemistry4  X X X  X X 
Direct  & total bilirubin2  X X X  X  
Free light chain  assay   X X X  X X 
Serum and Urine Immunofixation 
(SPEP and UPEP) with quantitative 
immunoglobulins9   
X  
X  
X   
X  
X 
2M, CRP,  LDH16  X X X  X  
TSH,  Free T4, Free T3  X X X  X  
Metastatic  Bone  Survey  and Spine 
MRI OR PET/CT only10 X     X  
EKG15  X    X  
Serum  pregnancy  test12  X      
Unilateral  bone  marrow  aspirate  and 
biopsy5 X    
X X  
Research  bone  marrow  aspirate6 X5    X6 X6  
Research  Blood7 X7  X7 X7 X7 X7  
Buccal  Swab13 X       
1- Cycle  1, Day 1 laboratory  values  need  to meet  eligibility  criteria  
2- Direct  bilirubin  to be obtained  if total bilirubin  is abnormal.  
3- Scheduling  allows  for +/- 7 days all cycles.  
4- Chemistry includes sodium, potassium, chloride, bicarbonate, bun, creatinine, calcium, glucose, albumin, ALT (SGPT), total pr otein, AST (SGOT), total bilirubin,  
magnesium, and phosphorus.  
5- A bone marrow biopsy is required within 6 weeks of registration. A b one marrow aspirate for clinical and research purposes is  required pre -treatment and may be  
performed up to 28 days prior to registration. Both core and aspirate are required any time during the course of the study to  confirm CR, and is also required at C7 D1 
6- Research  bone  marrow  aspirate  and biopsy  at the same  time as clinically  indicated  bone  marrow  biopsy  and to confirm  response.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
69  
 7- Peripheral  blood  samples  for correlative  studies  may be done  at any time pre-treatment,  though  baseline  and C1D1  samples  should  be considered  separate  time 
points.  
8- If C7D1  or confirmation  of response  BM aspirate  and core biopsy  was performed  within  3 weeks  of either  timepoint,  the procedure  need  not be repeated.  At 
minimum, an aspirate sample is required  
9- Disease assessment/response assessment is required each Day 1 starting with C2 -If the participant’s disease response is not followed primarily via a UPEP (24 hour  
urine collection) and Urine immunofixation, these tests may be done only at screening, end of  treatment, and every 3 months during treatment.  
10-A CD of scans at  screening and end of treatment  is required  to be  sent to the  lead site for  central  review. Screening scans should  be sent with the  eligibility  packet to  
the lead site - This requirement in cludes a full body skeletal survey in addition to spinal MRI  OR the patient may have only a low dose PET CT  
11- Follow -up should  occur  every  3 months  (+/- 14 days)  for up to 3 years  after end of treatment.  
12- Women  of child -bearing  potential  must  abide  by revlimid  REMS  procedures  and may require  additional  pregnancy  testing  as described  in section 3.1.7.  
13- Buccal  swab  may be collected  at any time throughout  the study  but should  be collected  pre treatment  on C1D1  
14- Thyroid  labs are required  at screening,  C3D1,  C6D1  and every  3 cycles  thereafter,  at end of treatment,  and at any time that it is clinically  indicated  
15- Alert  Overall PI immediately  if there is concern for cardiac toxicity (At minimum, the following should be performed: cardiology consu lt, EKG, echocardiogram,  
and labs  CPK and troponin; refer to section 6.2.7 for more details  
16- B2M,  CRP,  and LDH  are required  at screening,  C3D1,  C6D1  and every  3 cycles  thereafter,  at end of treatment,  and at any time that it is clinically  indicated  
17- A disease  response  assessment  will be required  at every  Day 1 starting  with Cycle  2, end of treatment,  and every  follow  up visit ( q3 months)  until completion,  
withdrawal, disease progression, subsequent therapy or death  
18- All end of treatment  assessments  will be performed  within  14 days from  the date that the decision  to end treatment  was made  by the study  team 
 
 
11. MEASUREMENT  OF EFFECT  
 
11.1 Development  of symptomatic  disease  
 
In this study,  the final endpoint  is development  of symptomatic  MM that requires  therapy.  
This is defined  as one of the following  criteria  (≥1 CRAB  Criterion  and Myeloma  Defining  Events  ≥1 MDE):  
 
• Increased calcium levels (corrected serum calcium >0.25 mmol/dL above the upper limit of normal 
or >2.75 mmol/dL) due to myeloma  
• Renal  insufficiency  (attributable  to myeloma);  
• Anemia  (Hb 2g/dL  below  the lower  limit  of normal  or <10g/dL)  due to myeloma  
• Bone  lesions  (lytic  lesions  or generalized  osteoporosis  with compression  fractures)  
• Myeloma  Defining  Events  (MDE)  as follows:  
o Clonal  bone  marrow  plasma  cell percentage  ≥ 60%7 
o An abnormal  FLC-ratio ≥100  (involved  kappa)  or <0.01  (involved  lambda)8 
o 2 or more  focal  lesions  on MRI  or PET-CT studies9,10 
For measurement  of response:  
 
The disease  response  will be assessed  using  criteria  based  on the International  Myeloma  Working  Group 
Uniform Response Criteria in Section 11.2.2.1 or FreeLite™ Dis ease Response Criteria in Section 11.2.2.2.  
 
Disease  response  by the Modified  EBMT  Response  Criteria  in Section  11.3.2.3  will also be collected  on 
participants as a secondary measure.  
 
The same method of assessment and technique should be used for disease measurement at baseline and 
during  follow -up. Disease  response  should  be confirmed  by two consecutive  assessments.  
 
11.2 Antitumor  Effect  
 
11.2.1  Methods  for Evaluation  of Disease  
 
All baseline  evaluations  should  be performed  on Cycle  1, Day 1 of initial  therapy.  Response  will be assessed  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
70  
 every  cycle  for the first 6 cycles  and then every  3 months  in the maintenance  phase. Response  will be assessed 
by M -protein quantification,  protein electrophoresis  and immunofixation  from serum and a 24 -hour urine 
collection.  A serum  sample  for FreeLiteTM testing  will be obtained.  In addition,  bone  marrow aspiration  and 
biopsy, as well as skeletal survey will be performed  to determine overall response or confirm  response.  
 
The same  method  of assessment  and technique  should  be used  for disease  measurement  at 
baseline and during follow -up. 
 
11.2.2  Response  Criteria  
 
A confirma tion measurement  for disease  response  assessments  is required  in this protocol.  
 
11.2.2.1  International  Myeloma  Working  Group  Response  Criteria  
 
Response criteria for all categories and subcategories of response except CR are applicable only  to 
patients who have ‘measurable’  disease, as defined in Section 11.1.1 All response categories require two 
consecutive assessments made at any time before the institution of any new therapy; all categories also 
require no known evidence of progressive or  new bone lesions if radiographic studies were performed. 
Radiographic studies are not required to satisfy these response requirements.  
 
 
Response  Criteria  for Response  
 
 
 
 
Stringent  CR 
(sCR)  CR as defined  below  plus normal  free light chain  ratio and absence  of 
clonal cells in bone marrow* by immunohistochemistry  or 
immunofluorescence.** 
*Confirmation  with repeat  bone  marrow  biopsy  is not needed.  
 
**Presence/absence  of clonal  cells is based  upon  the k/λ ratio.  An abnormal 
k/l ratio by immunohistochemis try and/or immunofluorescence requires a 
minimum of 100 plasma cells for analysis. An abnormal ratio reflecting 
presence of an abnormal clone is k/λ of > 4:1 or < 1:2.  
 
Complete 
Response  (CR)  Negative immunofixation on the serum and urine and disappearance of 
any soft tissue plasmacytomas and <5% plasma cells in bone marrow.  
 
*Confirmation  with repeat  bone  marrow  biopsy  is not needed.  
Very  Good  Partial 
Response  (VGPR)  Serum and urine M -protein  detectable by immunofixation  but not on 
electrophoresis  or 90% or greater  reduction  in serum  M-protein  plus urine 
M-protein level <100mg per 24 hours.  
 
 
 
 
 
Partial  Response 
(PR)  > 50% reduction  of serum  M-protein  and reduction  in 24-h urinary  M-protein  by > 
90% or to < 200mg per 24 hours.  If the serum  and urine M -protein  are 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
71  
  unmeasurable,  a > 50% decrease in the difference between involved and 
uninvolved  free light chain levels is required in place of the M -protein criteria 
(definition  of measurable  disease  in Section  10.2.3). If serum and  urine  M-protein 
are unmeasurable,  and serum free light assay is also unmeasurable,  > 50% 
reduction  in plasma  cells is required  in place  of M -protein,  provided  baseline  bone 
marrow  plasma  cell percentage  was > 30%. In addition  to the above  listed  criteria, 
if present  at baseline,  a > 50% reduction  in the size of soft tissue  plasmacytomas  is 
also required.  
Stable  Disease 
(SD)  Not meeting  criteria  for CR,  VGPR, PR or progressive  disease.  This 
is not recommended  as an indicator  of response;  stability  of disease  is 
best described by providing the time to progression estimates.  
 
 
 
 
Progressive 
Disease  (PD)  > 25% increase of serum M -protein (which must also be an absolute increase of > 
0.5 g/dL)  and/or  urine  M-protein  (which  must  also be an absolute  increase  of > 200 
mg/24hr).  If serum and urine M -protein are unmeasurable,  there must be an 
absolute  increase  of > 10 mg/dL  between  involved  and uninvolved  FLC levels.  PD 
is also measured  by an absolute increase in bone marrow plasma cells > 10%.  In 
addition  to the above  listed  criteria,  progression  may also be measured  by a definite 
development  of new bone  lesions  or soft tissue  plasmacytomas  or definite  increase 
in the size  of existing  bone lesions  or soft tissue  plasmacytomas  or development  of 
hypercalcemia  (corrected  serum  calcium  > 11.5 mg/dL  or 2.65 mmol/L)  that can be 
attributed solely to the plasma cell proliferative disorder.  
 
11.2.2.2  FreeLite™  Disease  Response  Criteria  
 
Response  Criteria  for Response  
 
 
 
 
 
Complete  Response  (CR)  For those patients being followed by serum free light 
chain (and NO measurable serum or urine M -spike), 
which were immunofixation negative at enrollment, 
normalization of serum free light chain ratio.  
 
Normalization is defined as the serum free light 
chain  ratio being within the normal range.  If the 
serum  free light chain ratio is not within the normal 
range, but the individual kappa and lambda light 
chain values are within normal range, this may be 
considered  CR. 
 
 
 
 
 
 
 
 
Partial  Response  (PR)   
If only measurable parameter is serum 
immunoglobulins  free light chain  (FLC),  EITHER  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
72  
 Criteria  for Responsea Response   of the following  changes  qualify  as partial  response:  
 
• ≥50% decrease in the difference between 
involved and uninvolved FLC levels from the 
lowest response level, which must also be an 
absolute increase of at least 10 mg/dL  
OR 
• ≥50% decrease  in the level of involved  FLC 
AND  a ≥50% decrease in the ratio of 
involv ed/uninvolved FLC from the lowest 
response level.  
 
 
 
 
 
 
Progressive  Disease  (PD)   
If only measurable parameter is serum 
immunoglobulins  free light (FLC),  EITHER  of 
the following qualify as progression:  
 
• ≥50% increase in the difference between 
involved and uninvolved FLC levels from the 
lowest response level, which must also be an 
absolute increase of at least 10 mg/dL  
OR 
• ≥50% increase in the level of involved FLC 
AND  a ≥50% increase in the ratio of 
involved/uninvolved FLC from the lowest 
response level.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11.2.2.3  Modified  EBMT  Response  Criteria  
 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
73  
  
 
 
 
 
Complete  Response 
(CR)  Requires  all of the following:  
 
Disappearance of the original monoclonal protein  from  the blood and  urine on at 
least two determinations  for a minimum  of six weeks  by immunofixation  studies.  
 
<5%  plasma  cells in the bone  marrow  on at least two determinations  for a 
minimum of six weeks. b 
 
No increase  in the size or number  of lytic bone  lesions  (development  of a 
compression fracture does not exclude response).c 
Disappearance  of soft tissue  plasmacytomas  for at least six weeks.  
 
Near  Complete  Response 
(nCR)  Requires  the following:  
Same  as CR, but immunofixation  studies  continue  to show  presence  of the 
monoclonal protein  
Very  Good  Partial 
Response  
(VGPR)  Requires  the following:  
> 90% reduction  in serum  M-protein  plus urine  M-protein  level  <100mg  per 24 
hours on at least two determinations for a minimum of six weeks.  
 
 
 
 
 
 
 
Partial  response  (PR)   
PR includes participants in whom some, but not all, criteria for CR are fulfilled 
providing  the remaining  criteria  satisfy  the requirements  for PR. Required  all of 
the following:  
 
≥50%  reduction  in the level  of serum  monoclonal  protein  for at least two 
determinations six weeks apart.  
 
If present,  reduction  in 24-hour urinary  light chain  excretion  by either  ≥90%  or to < 
200 mg for at least two determinations six weeks apart.  
 
≥50%  reduction  in the size of soft tissue  plasmacytomas  (by clinical  or 
radiographic examination) for at least six weeks.  
 
No increase  in size or number  of lytic bone  lesions  (development  of compression 
fracture does not exclude response).c 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
74  
   
 
 
 
 
 
 
Minimal  response  (MR)  MR included participants in whom some, but not all, criteria for PR were 
fulfilled,  providing  the remaining  criteria  satisfied  the requirements  for MR. 
Required all of the following:  
 
≥25%  to 49% reduction  in the level  of serum  monoclonal  protein  for at least two 
determinations six weeks apart.  
 
If present,  a ≥50 to 89% reduction  in 24-hour light chain  excretion,  which  still 
exceeds 200 mg/24 h, for at least two determinations six weeks apart.  
 
≥25-49% reduction  in the size of plasmacytomas  (by clinical  or radiographic 
examination) for at least six weeks.  
 
No increase  in size or number  of lytic bone  lesions  (development  of compression 
fracture does not exclude response).c 
No change  (NC)  Not meeting  the criteria  for MR or PD. 
 
 
 
 
 
 
 
 
Progressive  disease 
(PD)  
(for participants  not in 
CR)  
Requires  one or more  of the following:  
 
>25%  increased in the level  of serum  monoclonal  paraprotein,  which  must  also be 
an absolute increase of at least 5 g/L and confirmed on a repeat investigation.  
>25% increased in 24 -hour urinary light chain excretion, which must also be an 
absolute  increase  of at least 200 mg/24  h and confirmed  on a repeat  investigation.  
>25%  increased in plasma  cells in a bone  marrow  aspirate  or on trephine  biopsy, 
which must also be an absolut e increase of at least 10%.  
 
Definite  increase  in the size of existing  lytic bone  lesions  or soft tissue 
plasmacytomas.  
 
Development  of new bone  lesions  or soft tissue  plasmacytomas  (not including 
compression fracture).  
 
Development  of hypercalcemia  (corrected  serum  calcium  >11.5  mg/dL  or 2.8 
mmol/L not attributable to any other cause).   
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
75  
  
 
a Based  on the criteria  reported  by Blade  et al., 1998.  
b Per Blade et al., 1998, if absence of the monoclonal protein is sustained for 6 weeks it is not necessary to repeat the bone marrow except i n participants with  
nonsecretory myeloma where the marrow examination must be repeated after an interval of at least 6 weeks to con firm CR.  
c Per Blade et al., 1998, skeletal X -Rays are not required for  the definition of response,  but if performed there must be no evidence  of progression of bone  disease  
(no increase in size or number of lytic bone lesions).  
d It is suggested that the refe rence point for calculating any increase should be the lowest value of the preceding confirmed response (MR, PR or CR) or the  
baseline value if there is no previous confirmed response.  
e Other  clinical  data may be requested  by the IRC,  as necessary,  to assess  the cause  of the hypercalcemia.  
 
11.2.3  Criteria  for Molecular  CR and Minimal  Residual  Disease  (MRD)  measurement  
 
We will measure MRD in patients who achieve CR to determine the number of patients who are MRD negative 
vs MRD positive.  
 
11.2.3.1  MRD  by LymphoSIGHT  (Adaptive  Inc.) 
 
MRD will be carried out according to the LymphoSIGHTTM method (Adaptive Inc, Seattle, WA) 61. Prio r 
studies have compared this technique to the traditional MRD immunofluorescence technique, as previously 
reported 62 and showed that MRD by LymphoSight is a sensitive method that can be used in future clinical 
practice.  
 
For MM diagnostic samples, genomi c DNA will be amplified using locus -specific primer sets for the 
immunoglobulin heavy -chain locus (IGH ) complete (IGH -VDJH), IGH incomplete (IGH -DJH), and 
immunoglobulin κ locus (IGK ). The amplified product will be subjected to sequencing, and the sequence s and 
frequencies of the different clonotypes in the sample will be obtained. Myeloma gene rearrangements will be 
identified. Patients in whom a high -frequency myeloma clone (>5%) is not identified will be excluded from the 
MRD analysis. MRD will be assess ed in patients with a high -frequency myeloma clone using the IGH -VDJH 
and IGK or IGH -VDJH, IGH -DJH, and IGK assays. Once the absolute amount of total cancer -derived 
molecules present in a sample will be determined, a final MRD measurement will be calculate d, providing the 
number of cancer -derived molecules per 1 million cell equivalents. In cases in which 2 or more tumor clones 
existed, the clone with the highest MRD value will be reported. Molecular CR will be defined according to the 
International Myeloma  Working Group (IMWG) consensus recommendations63.  
Required  at least one of the following:  
 
Reappearance of serum or urinary paraprotein on immunofixation or routine 
electrophoresis  confirmed  by at least one follow -up and excluding  oligoclonal 
immune reconstitution.  
 
≥5%  plasma  cells in the bone  marrow  aspirate  or biopsy.  
 
Development of new lyti c bone lesions or soft tissue plasmacytomas or definite 
increase  in the size of residual  bone  lesions  (not including  compression  fracture).  
 
Development  of hypercalcemia  (corrected  serum  calcium  >11.5  mg/dL  or 2.8 
mmol/L not attributable to any other cause)e.  
 
 
 
 
 
 
Relapse  from  CR 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
76  
  
11.2.4  Duration  of Response  and Endpoint  Definitions  
 
11.2.4.1  Duration  of overall  response  
The duration of  overall response  is measured as the time from initiation of first 
response to first documentation  of disease  progression or death.  Patients  who have not 
progressed or died are censored at the date last known progression -free. 
 
11.2.4.2  Duration  of overall  complete  response  
The duration of overall  CR is progression or death. Patients  who have not progressed or 
died are censored at the date last known progression -free. 
 
11.2.4.3  Time to  progression  
Time to progression is defined as the time of randomization until progression.  Patients 
who have  died without  evidence  of progression  are censored  in the TTP analysis  at the time 
of death  and patients  who are alive  without  progression  are censored  at the last disease 
assessment.  
 
11.2.5  Progression -Free Survival  
 
The secondary  endpoint  in this study,  PFS is defined  as the time from  randomization  to the 
disease  progression  or death  from  any cause.  Patients  who have  not progressed  or died are 
censored at the date last known progression -free. 
 
11.2.6  Response  Review  
 
Central  review  of disease  response  assessments  is not planned.  
 
12. DATA  REPORTING  / REGULATORY  REQUIREMENTS  
 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 (Adverse Events: 
List and Reporting Requirements).  
 
12.1 Data Reporting  
 
12.1.1  Method  
 
The DFCI  Office  of Data  Quality  will collect,  manage,  and perform  quality  checks  on the data for this study.  
 
12.1.2  Responsibility  for Data  Submission  
 
Investigative sites within DF/HCC or DF/PCC are responsible for submitting data and/or data forms to the Data 
Safety Mo nitoring Committee According to the schedule set by the Office of Data Quality.  
 
Data should be entered within 14 business days of the corresponding visit and within 14 business days of 
the end of a cycle for any forms to be completed per cycle.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
77  
 12.2 Data Safety  Monitoring  
 
The DF/HCC Data and Safety Monitoring Committee (DSMC) will review and monitor toxicity and accrual 
data from this study. The committee is composed of clinical specialists with experience in oncology and who 
have no direct relationship with the study. Info rmation that raises any questions about participant safety will be 
addressed with the Overall PI and study team.  
 
The DSMC will review each protocol up to four times a year or more often if required to review toxicity and 
accrual data. Information to be pr ovided to the committee may include: up -to-date participant accrual; current 
dose level information; DLT information; all grade 2 or higher unexpected adverse events that have been 
reported; summary of all deaths occurring with 30 days of intervention for Phase I or II protocols; for gene 
therapy protocols, summary of all deaths while being treated and during active follow -up; any response 
information; audit results, and a summary provided by the study team. Other information (e.g. scans, laboratory 
values)  will be provided upon request.  
 
13. STATISTICAL  CONSIDERATIONS  
 
13.1 Study  Design/Endpoints  
 
The proportion of patients who achieve progression free at 2 years will be compared to the rate published for  
the high risk SMM. By the Mayo Clinic model for risk factors,  the median time to progression for patients with 
high risk SMM was only 1.9 years. Therefore, we assume that, a 2 -years progression -free rate of 50% will not 
be considered promising and a true progression free rate of 70% or higher will be considered prom ising. A 
single -stage design will be employed with 39 eligible patients entered. If 24 or more of the 39 eligible patients 
are progression free at 2 years (observed rate of 62%), we will conclude that this treatment warrants further 
study. The probability of concluding that the treatment is effective if the true rate is 50% is 0.10 and is >0.9 if 
the true rate is 70%. Assuming a dropout rate of 5%, we will accrue 41 patients to the trial in order to have 39 
eligible  patients.  The Type  I and II error  probabilities  have  been  derived  using  exact  binomial 
probabilities.  
 
13.1.1  Analysis  of Primary  Endpoint  
 
The primary endpoint will be the 2 -year progression -free rate and will be analyzed using binomial probability 
and corresponding 90% confidence interval. All patients who have received one dose of study treatment will be 
included for the TTP analysis, including those who die or are lost to follow -up within 2 years.  
 
13.1.2  Analysis  of Secondary  Endpoints  
 
The objective response rate (partial response or better according to the modified IMWG criteria) and the 
proportion of patients with a MRD, CR, PR or MR will be reported with 90% exact binominal confidence 
interval (CI). The exact 90% CI around response ra te will be no wider than 28% with 39 eligible patients  
 
Time to progression  (TTP) is defined as the time from  protocol therapy initiation  until documented progression, 
censored at date last known progression -free for those who have not progressed.  
 
To esti mate the duration of response (time from objective response to disease progression or death, or date last 
known  progression -free and alive  for those  who have  not progressed  or died),  progression -free survival  (time  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
78  
 from protocol therapy initiation to the disease progression or death from any cause, censored at date last known 
progression free for those who have not progressed or died), and overall survival (time from protocol therapy 
initiation to death or date last known alive), the Kaplan -Meier method will be used.  
 
It is expected that approximately 20% of the patients will receive cyclophosphamide (CTX) for mobilization  
and this may influence the PFS. Therefore, in a secondary analysis the 2 year PFS rate will be e valuated among 
those patients who did not receive CTX. Assuming that among the 39 eligible patients between 5 -20% of the 
patients receive CTX for mobilization, the treatment will be considered promising if the observed response rate 
is at least 62%. With t his rule, there is at least 80% probability of concluding the treatment is effective, when  
the true rate is 70% and less than 10% if true rate is 50%.  
 
Safety  analysis  will be conducted  using  the Safety  Population  defined  as any patient  receiving  one dose of study 
treatment. For toxicity reporting, all adverse events and laboratory abnormalities will be graded and analyzed 
using CTCAE version 4 as appropriate.  
 
13.2 Sample  Size,  Accrual  Rate  and Study  Duration  
 
A total of 41 patients will be enrolled. We expect 1.5 years of active accrual (approximately 2 patients per 
month) and 3 years of follow -up of patients.  
 
The final analyses of progression -based  endpoints, such as estimating the 2 -year progression -free rate and 
estimating the TTP distribution, will be conducted at the end of the study, which will occur after either all 
subjects have progressed or died or 2 -years after the initiation of therapy of  the last subject enrolled, whichever 
occurs first.  
 
13.3 Stratification  Factors  
 
There  are no stratification  factors.  
 
13.4 Interim  Monitoring  Plan  
 
The study  will be monitored  by the DFCI  Data Safety  Monitoring  Committee  (DSMC).  The DSMC  will meet  at 
least four times a year and more often if needed (e.g., for safety review). For each meeting, the study will be 
reviewed for safety and progress toward completion. Copies of the toxicity reports prepared by the DSMC 
meetings will be distributed to the P rincipal Investigator. The Principal Investigator will then distribute to sub - 
investigators. Any DSMC recommendations for changes to the study will be distributed to the Principal 
Investigator and then circulated to sub - investigators by the Principal Inv estigator. No interim analysis of the 
outcome data is planned.  
 
13.5 Stopping  Rule  for Safety  
 
All participants will be evaluable for treatment -related toxicity from the time of therapy initiation. The serious 
adverse event (SAE) for this purpose is defined as any grade 4 or higher unexpected, adverse event that is 
assessed as being related to the study intervention.  
 
The following  table  provides  the probabilities  of observing  3 or more  SAEs  after the 20th patient  and before the 
40th patient.  For example, with 2 0 participants, there is 0.60 probability of observing 3 or more SAEs if a true  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
79  
 rate is 15% and the  probability  is 0.021  if a true  rate is 3%. 
 
 
True  SAE  rate 1% 3% 5% 10% 15% 20% 30% 
Probability 
(≥SAEs)  0.001  0.021  0.075  0.32 0.60 0.79 0.96 
 
 
14. PUBLICATION  PLAN  
 
The results  should  be made  public  within  24 months  of reaching  the end of the study.  The end of the study  is the 
time point at which the last data items are to be reported, or after the outcome data are sufficiently mature for 
analysis, as  defined in the section on Sample Size, Accrual Rate and Study Duration. If  a report is planned to be 
published in a peer -reviewed journal, then that initial release may be an abstract that meets the requirements of 
the International  Committee  of Medical  Journal  Editors.  A full report  of the outcomes  should  be made public  no 
later than three (3) years after the end of the study.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
80  
 15. REFERENCES  
 
1. Dispenzieri  A, Stewart  AK, Chanan -Khan  A, et al: Smoldering  multiple  myeloma  requiring  treatment:  time 
for a new definition? Blood 122:4172 -81, 2013  
 
2. Kyle  RA, Greipp  PR: Smoldering  multiple  myeloma.  N Engl  J Med 302:1347 -9, 1980  
 
3. Alexanian  R: Localized and  indolent  myeloma.  Blood  56:521 -5, 1980  
 
4. Durie BG, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma 
cell mass  with presenting  clinical  features,  response  to treatment,  and survival.  Cancer  36:842 -54, 1975  
 
5. Kyle  RA, Durie  BG, Rajkumar  SV, et al: Monoclonal  gammopathy  of undetermined  significance  (MGUS) 
and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for 
progression and guidelines for monitoring and management. Leukemia 24:1121 -7, 2010  
 
6. International Myeloma Working G: Criteria for the classification of mono clonal gammopathies, multiple 
myeloma  and related  disorders:  a report  of the International  Myeloma  Working  Group.  Br J Haematol 
121:749 -57, 2003  
 
7. Rajkumar  SV, Larson  D, Kyle  RA: Diagnosis  of smoldering  multiple  myeloma.  N Engl  J Med 365:474 -5, 
2011  
 
8. Larsen  JT, Kumar  SK, Dispenzieri  A, et al: Serum  free light chain  ratio as a biomarker  for high-risk 
smoldering multiple myeloma. Leukemia 27:941 -6, 2013  
 
9. Hillengass  J, Fechtner  K, Weber  MA, et al: Prognostic  significance  of focal  lesions  in whole -body  magnetic 
resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28:1606 -10, 2010  
 
10. Hillengass  J, Landgren  O: Challenges  and opportunities  of novel  imaging  techniques  in monoclonal  plasma 
cell disorders: imaging "early myeloma". Leuk Lymphoma, 2013  
 
11. Kyle  RA, Remstein  ED, Therneau  TM, et al: Clinical  course  and prognosis  of smoldering  (asymptomatic) 
multiple myeloma. N Engl J Med 356:2582 -90, 2007  
 
12. Dispenzieri  A, Kyle  RA, Katzmann  JA, et al: Immunoglobulin  free light chain  ratio is an independent  risk 
factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111:785 -9, 2008  
 
13. Perez -Persona E, Vidriales MB, Mateo G, et al: New criteria to identify risk of progression in  monoclonal 
gammopathy  of uncertain  significance  and smoldering  multiple  myeloma  based  on multiparameter  flow 
cytometry analysis of bone marrow plasma cells. Blood 110:2586 -92, 2007  
 
14. Ghobrial  IM: Revisiting  treatment  paradigms  in high-risk smoldering  multiple  myeloma:  out with the old, in 
with the new? Leuk Lymphoma 54:2328 -30, 2013  
 
 
15. Mateos  MV, San Miguel  JF: New  approaches  to smoldering  myeloma.  Curr Hematol  Malig  Rep 8:270 -6, 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
81  
 2013  
 
16. Cherry  BM, Korde  N, Kwok  M, et al: Modeling  progression  risk for smoldering  multiple  myeloma:  results 
from a prospective clinical study. Leuk Lymphoma 54:2215 -8, 2013  
 
17. Mateos  MV, Hernandez  MT, Giraldo  P, et al: Lenalidomide  plus dexamethasone  for high-risk smoldering 
multiple myeloma. N Engl J Med 369:438 -47, 2013  
 
18. Anderson  KC, Carrasco  RD: Pathoge nesis  of myeloma.  Annu  Rev Pathol  6:249 -74, 2011  
 
19. Kyle  RA, Durie  BG, Rajkumar  SV, et al: Monoclonal  gammopathy  of undetermined  significance  (MGUS) 
and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for 
progression and guidelines for monitoring and management. Leukemia 24:1121 -7, 2010  
 
20. Kyle  RA, Therneau  TM, Rajkumar  SV, et al: Prevalence  of monoclonal  gammo pathy  of undetermined 
significance. N Engl J Med 354:1362 -9, 2006  
 
21. Dispenzieri  A, Katzmann  JA, Kyle  RA, et al: Prevalence  and risk of progression  of light-chain  monoclonal 
gammopathy of undetermined significance: a retrospective population -based cohort study. Lancet 
375:1721 -8, 2010  
 
22. Landgren  O, Kyle  RA, Pfeiffer  RM, et al: Monoclonal  gammopathy  of undetermined  significance  (MGUS) 
consistently precedes multiple myeloma: a prospective study. Blood 113:5412 -7, 2009  
 
23. Weiss  BM, Abadie  J, Verma  P, et al: A monoclonal  gammopathy  precedes  multiple  myeloma  in most 
patients. Blood 113:5418 -22, 2009  
 
24. Lopez -Corral  L, Sarasquete  ME, Bea S, et al: SNP-based  mapping  arrays  reveal  high genomic  complexity  in 
monoclonal gammopathies, from MGUS to myeloma status. Leukemia, 2012  
 
25. Visone  R, Croce  CM: MiRNAs  and cancer.  Am J Pathol  174:1131 -8, 2009  
 
26. Pichiorri  F, Suh SS, Ladetto  M, et al: MicroRNAs  regulate  critical  genes  associated  with multiple  myeloma 
pathogenesis. Proc Natl Acad Sci U S A 105:12885 -90, 2008  
 
27. O'Donnell  KA, Wentzel  EA, Zeller  KI, et al: c-Myc-regulated  microRNAs  modulate  E2F1  expression. 
Nature 435:839 -43, 2005  
 
28. Chesi M, Robbiani DF, Sebag M, et al: AID -dependent activation of a MYC transgene induces multiple 
myeloma  in a conditional  mouse  model  of post-germinal  center  malignancies.  Cancer  Cell 13:167 -80, 
2008  
 
29. Chiecchio  L, Dagrada  GP, Protheroe  RK, et al: Loss  of 1p and rearrangement  of MYC  are associated  with 
progression  of smouldering  myeloma  to myeloma:  sequential  analysis  of a single  case.  Haematologica 
94:1024 -8, 2009  
 
30. Chapman  MA, Lawrence  MS, Keats  JJ, et al: Initial  genome  sequencing  and analysis  of multiple  myeloma.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
82  
 Nature  471:467 -72, 2011  
 
31. Egan JB, Shi CX, Tembe W, et al: Whole -genome sequencing of multiple myeloma from diagnosis to 
plasma  cell leukemia  reveals  genomic  initiating  events,  evolution,  and clonal  tides.  Blood  120:1060 -6, 
2012  
 
32. Keats  JJ, Chesi  M, Egan  JB, et al: Clonal  competition  with alternating  dominance  in multiple  myeloma. 
Blood 120:1067 -76, 2012  
 
33. Walker  BA, Wardell  CP, Melchor  L, et al: Intraclonal  heterogeneity  and distinct  molecular  mechanisms 
characterize the development of t(4;14) and t(11;14) myeloma. Blood 120:1077 -86, 2012  
 
34. Bahlis  NJ: Darwinian  evolution  and tiding  clones  in multiple  myeloma.  Blood  120:927 -8, 2012  
 
35. Greaves  M, Maley  CC: Clonal  evolution  in cancer.  Nature  481:306 -13, 2012  
 
36. Rasillo A, Tabernero MD, Sanchez ML, et al: Fluorescence in situ hybridization analysis of 
aneuploidization  patterns  in monoclonal  gammopathy  of undetermined  significance  versus  multiple 
myeloma and plas ma cell leukemia. Cancer 97:601 -9, 2003  
 
37. Bergsagel  PL, Kuehl  WM:  Molecular  pathogenesis  and a consequent  classification  of multiple  myeloma.  J 
Clin Oncol 23:6333 -8, 2005  
 
38. Kyle  RA, Larson  DR, Therneau  TM, et al: Clinical  course  of light-chain  smouldering  multiple  myeloma 
(idiopathic  Bence  Jones  proteinuria):  a retrospective  cohort  study.  Lancet  Haematol  1:e28 -e36, 2014  
 
39. Rajkumar  SV, Dimopoulos  MA, Palumbo  A, et al: International  Myeloma  Working  Group  updated  criteria 
for the diagnosis of multip le myeloma. Lancet Oncol 15:e538 -48, 2014  
 
40. Rajkumar  SV, Landgren  O, Mateos  MV:  Smoldering  multiple  myeloma.  Blood,  2015  
 
41. Sehgal  K, Das R, Zhang  L, et al: Clinical  and pharmacodynamic  analysis  of pomalidomide  dosing  strategies  
in myeloma: impact of immune activation and cereblon targets. Blood 125:4042 -51, 2015  
 
42. Anderson  K, Lutz C, van Delft  FW, et al: Genetic  variegation  of clonal  architecture  and propagating  cells in 
leukaemia. Nature 469:356 -61, 2011  
 
43. Barrett  MT, Sanchez  CA, Prevo  LJ, et al: Evolution  of neoplastic  cell lineages  in Barrett  oesophagus.  Nat 
Genet 22:106 -9, 1999  
 
44. Morgan  GJ, Walker  BA, Davies  FE: The genetic  architecture  of multiple  myeloma.  Nat Rev Cancer  12:335 - 
48, 2012  
 
 
45. Walker BA, Wardell CP, Melchor L, et al: Intraclonal heterogeneity is a critical early event in the 
development  of myeloma  and precedes  the development  of clinical  symptoms.  Leukemia,  2013  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
83  
 46. Chng  WJ, Huang  GF, Chung  TH, et al: Clinical  and biological  implications  of MYC  activation:  a common 
difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25:1026 -35, 2011  
 
47. Lopez -Corral  L, Sarasquete  ME, Bea S, et al: SNP-based  mapping  arrays  reveal  high genomic  complexity  in 
monoclonal gammopathies, from MGUS to myeloma status. Leukemia 26:2521 -9, 2012  
 
48. Paiva  B, Gutierrez  NC, Rosinol  L, et al: High -risk cytogenetics  and persistent  minimal  residual  disease  by 
multiparameter flow cytometry predict unsustained complete response after autologous stem cell 
transplantation in multiple myeloma. Blood 119:687 -91, 2012  
 
49. Lohr  JG, Stojanov  P, Lawrence  MS, et al: Discovery  and prioritization  of somatic  mutations  in diffuse  large 
B-cell lymphoma (DLBCL) by whole -exome sequencing. Proceedings of the National Academy of 
Sciences of the United States of America 109:3879 -84, 2012  
 
50. Cibulskis  K, Lawrence  MS, Carter  SL, et al: Sensitive  detection  of somatic  point mutations  in impure  and 
heterogeneous cancer samples. Nat Biotechnol 31:213 -9, 2013  
 
51. Hammerman  PS, Hayes  DN, Wilkerson  MD, et al: Comprehensive  genomic  characterization  of squamous 
cell lung cancers. Nature 489:519 -25, 2012  
 
52. Chen  CL, Rappailles  A, Duquenne  L, et al: Impact  of replication  timing  on non-CpG  and CpG  substitution 
rates in mammalian genomes. Genome research 20:447 -57, 2010  
 
53. Lieberman -Aiden  E, van Berkum  NL, Willi ams L, et al: Comprehensive  mapping  of long-range  interactions 
reveals folding principles of the human genome. Science 326:289 -93, 2009  
 
54. Beroukhim R, Getz G, Nghiemphu L, et al: Assessing the significance of chromosomal aberrations in 
cancer:  methodology  and application  to glioma.  Proceedings  of the National  Academy  of Sciences  of the 
United States of America 104:20007 -12, 2007  
 
55. Eswaran  J, Horvath  A, Godbole  S, et al: RNA  sequencing  of cancer  reveals novel  splicing  alterations.  Sci 
Rep 3:1689, 2013  
 
56. Kothari  V, Wei I, Shankar  S, et al: Outlier  kinase  expression  by RNA  sequencing  as targets  for precision 
therapy. Cancer Discov 3:280 -93, 2013  
 
57. Yu M, Ting  DT, Stott  SL, et al: RNA  sequencing  of pancreatic  circulating  tumour  cells implicates  WNT 
signalling in metastasis. Nature 487:510 -3, 2012  
 
58. Griffith  M, Griffith  OL, Mwenifumbo  J, et al: Alternativ e expression  analysis  by RNA  sequencing.  Nat 
Methods 7:843 -7, 2010  
 
 
59. Rosenblatt J, Glotzbecker B, Mills H, et al: PD -1 blockade by CT -011, anti -PD-1 antibody, enhances ex 
vivo T-cell responses  to autologous  dendritic  cell/myeloma  fusion  vaccine.  J Immunother  34:409 -18, 
2011  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
84  
 60. Azzi  J, Moore  RF, Elyaman  W, et al: The novel  therapeutic  effect  of phosphoinositide  3-kinase -gamma 
inhibitor AS605240 in autoimmune diabetes. Diabetes 61:1509 -18, 2012  
 
61. Martinez -Lopez  J, Lahuerta  JJ, Pepin  F, et al: Prognostic  value  of deep  sequencing  method  for minimal 
residual disease detection in multiple myeloma. Blood 123:3073 -9, 2014  
 
62. Paiva  B, Gutierrez  NC, Rosinol  L, et al: High -risk cytogenetics  and persistent  minimal  residual  disease  by 
multiparameter flow cytometry predict unsustained complete response after autologous stem cell 
transplantation in multiple myeloma. Blood 119:687 -91, 2012  
 
63. Rajkumar SV, Harousseau JL, Durie B, et al: Consensus recommendations for the uniform reporting o f 
clinical  trials:  report  of the International  Myeloma  Workshop  Consensus  Panel  1. Blood  117:4691 -5, 
2011  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
85  
 APPENDIX  A: PERFORMANCE  STATUS  CRITERIA  
 
ECOG  Performance  Status  Scale  Karnofsky  Performance  Scale  
Grade  Descriptions  Percent  Description  
 
0 Normal activity.  Fully  active, able 
to carry on all pre -disease 
performance without restriction.  100 Normal, no complaints, no evidence 
of disease.  
90 Able  to carry  on normal  activity; 
minor signs or symptoms of disease.  
 
 
1 Symptoms, but ambulatory. 
Restricted in physically strenuous 
activity, but ambulatory and able  
to carry out work of a light or 
sedentary nature ( e.g., light 
housework, office work).   
80 Normal  activity  with effort;  some 
signs or symptoms of disease.  
 
70 Cares  for self, unable  to carry  on 
normal  activity  or to do active  work.  
 
 
2 In bed <50% of the time. 
Ambulatory and capable of all  
self-care, but unable to carry  out 
any work activities.  Up and about 
more than 50% of waking hours.   
60 Requires occasional assistance, but  
is able to care for most of his/her 
needs.  
50 Requires  considerable  assistance  and 
frequent medical care.  
 
3 In bed >50% of the time.  Capable 
of only limited  self-care,  confined  
to bed or chair more than 50% of 
waking hours.  40 Disabled,  requires  special  care and 
assistance.  
30 Severely  disabled,  hospitalization 
indicated.  Death not imminent.  
 
4 100% bedridden.  Completely 
disabled.  Cannot carry on any  
self-care.  Totally confined to bed 
or chair.  20 Very  sick, hospitalization  indicated. 
Death not imminent.  
10 Moribund,  fatal processes 
progressing rapidly.  
5 Dead.  0 Dead.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
86  
 APPENDIX  B: SPECIMEN  COLLECTION  SCHEDULE  
 
Sample  Time  Point  Recipient  Sample  Type  Shipping  Method  Container1,2,4 
 
 
 
 
Baseline   
 
 
DFCI  Peripheral  Blood   
 
Fridge  pack  same  day 3x10mL Purple Top 
1x10mL  Streck  Tube  
Bone  Marrow  Aspirate  2x10mL  Purple  Top 
Oragene  Kit or Buccal 
Swab2  
Ambient  same  day 2x Buccal  Swabs  or 1 
Oragene Kit  
 
Adaptive   
Bone  Marrow  Aspirate  Same  day – Use kit 
provided   
1x3ml  Purple  Top 
Cycle  1 Day 1 
(Pre Dose)  DFCI  Peripheral  Blood  Fridge  pack  same  day 2x10mL Purple Top 
1x10mL  Streck  Tube  
Cycle  2-6 Day 1 
(Predose)  DFCI  Peripheral  Blood  Fridge  pack  same  day 2x10mL  Purple  Top 
1x10mL  Streck  Tube  
 
End of Cycle 6 
(Cycle  7 Day 1)  
DFCI   
Peripheral  Blood   
 
Fridge  pack  same  day 2x 10mL  Purple  Top 
1x10mL  Streck  Tube  
Bone  Marrow  Aspirate  2x10mL  Purple  Top 
Cycle  8-12 Day 1 
(Predose)  DFCI  Peripheral  Blood  Fridge  pack  same  day 2x10mL Purple Top 
1x10mL  Streck  Tube  
 
 
Confirm  Complete 
Response 3  
DFCI  Peripheral  Blood   
Fridge  pack  same  day 2x 10mL  Purple  Top 
1x10mL  Streck  Tube  
Bone  Marrow  Aspirate  2x10mL  Purple  Top 
 
Adaptive   
Bone  Marrow  Aspirate  Same  day – Use kit 
provided   
1x3ml  Purple  Top 
 
End of Treatment 
and/or Disease 
Progression   
DFCI  Peripheral  Blood   
 
Fridge  pack  same  day 2x 10mL  Purple  Top 
1x10mL  Streck  Tube  
Bone  Marrow  Aspirate  2x10mL  Purple  Top 
 
Clinically  Indicated   
DFCI   
Bone  Marrow  Aspirate   
Fridge  pack  same  day  
2x10mL  Purple  Top 
 
1 Purple Top= K2EDTA Tube; Streck Tube –Cell Free DNA collection tube -Please ensure you alert the lead site with enough notice if you need 
additional Streck tubes for your site. - All shipping materials are to be purchased and obtained by the external sites  except for the buccal swabs and  
the Streck tubes, which will be provided by the lead site.  
2 Buccal  swabs  and or Oragene  kits will be provided  by the lead site, and can be taken/sent  at any time point  during  the trial 
3 For definition  of Complete  Response,  please  refer  to section  11.2.2  
4 Streck  Tubes  should  be drawn  before  any heparinized  tubes  if applicable  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
87  
 Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
APPENDIX  C: SPECIMEN  REQUISITION  
 
Complete this form  and include with  the specimen shipment.  Label all materials with  DFCI participant study ID, collection time point and collection 
date and time. Email Patrick Henrick ( Patrick_Henrick@dfci.harvard.edu ) and Alexandra Savell ( AlexandraE_Savell@dfci.harvard.ed u) to alert 
study team of shipment and include tracking number.  
 
Ship specimen(s)  to:  Irene  Ghobrial,  MD 
Dana  Farber  Cancer  Institute 
77 Louis Pasteur Avenue 
HIM 240; MA551  
Boston,  MA 02115  
 
Specimen  Information  
DFCI  Participant  Study  ID Number:     
Date specimen(s) shipped:   
 
Correlative  Sample  Time  Points  
(indicate  inclusion  in shipment  by checking  box) Sample  Type  Quantity  of Tubes  
(6ml)  Collection  Date  Collection  Time  
 
Pre-treatment/Baseline  Blood  
Saliva  Aspirate   Streck  Top 
 Purple  Top 
Buccal  Swab    
Cycle  1-12 Day 1  Specify  Cycle   Blood   Streck  Top 
 Purple  Top   
Confirm  Response  Blood  Aspirate   Streck  Top 
 Purple  Top   
Cycle  7 Day 1 (end of Cycle 6) Blood  Aspirate   Streack  Top 
 Purple  Top   
End of Treatment  Disease  Progression  Blood  Aspirate   Streck  Top 
 Purple  Top   
 
Clinically  Indicated/  Standard  of Care  
Aspirate   
Blood   Purple  Top 
 Streck  Top   
 
 
Responsible Contact:   Email:   
 
Site:   Phone number:   
 
Note:  All samples  are to be shipped  with a fridge  pack  Fed-Ex priority  overnight - Please  retain  a copy  of the waybill,  and reference  the tracking  number  in the 
email and paper correspondence. Ship only Monday - Thursday , as shipments cannot be received over the weekend.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
88  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX D: MANAGEMENT ALGORITHMS FOR ENDOCRINOPATHY, 
GASTROINTESTINAL,  HEPATIC,  RENAL,  SKIN,  NEUROLOGICAL,  AND  PULMONARY 
ADVERSE EVENTS DUE TO NIVOLUMAB  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
89  
  
 

Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
90  
  
 
 
 
 

Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
91  
  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
92  
  
 

Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
93  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX  E: DANA -FARBER/HARVARD  CANCER  CENTER  MULTI -CENTER  DATA  AND 
SAFETY MONITORING PLAN  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
94  
  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
95  
  
TABLE  OF CONTENTS  
1. INTRODUCTION  96 
1.1 PURPOSE  96 
1.2 MULTI-CENTER  DATA  AND  SAFETY  MONITORING  PLAN  DEFINITIONS  96 
2. GENERAL  ROLES  AND  RESPONSIBILITIES  97 
2.1 DF/HCC  SPONSOR  97 
2.2 COORDINATING  CENTER  97 
2.3 PARTICIPATING  INSTITUTION  98 
3. DF/HCC  REQUIREMENTS  FOR  MULTI -CENTER  PROTOCOLS  98 
3.1 PROTOCOL  DISTRIBUTION  99 
3.2 PROTOCOL  REVISIONS  AND  CLOSURES  99 
3.3 INFORMED  CONSENT  REQUIREMENTS  99 
3.4 IRB  DOCUMENTATION  100 
3.5 IRB RE-APPROVAL  100 
3.6 PARTICIPANT  CONFIDENTIALITY  AND  AUTHORIZATION  STATEMENT  100 
3.7 DF/HCC  MULTI-CENTER  PROTOCOL  REGISTRATION  POLICY  100 
3.8 DF/HCC  PROTOCOL  CASE  NUMBER  101 
3.9 SAFETY  ASSESSMENTS  AND  TOXICITY  MONITORING  103 
3.10 DATA  MANAGEMENT  103 
4. REQUISITIONING  INVESTIGATIONAL  DRUG  104 
5. MONITORING:  QUALITY  CONTROL  104 
5.1 ONGOING  MONITORING  OF PROTOCOL  COMPLIANCE  104 
5.2 MONITORING  REPORTS  105 
5.3 ACCRUAL  MONITORING  105 
6. AUDITING:  QUALITY  ASSURANCE  105 
6.1 AUDIT  PLAN: 101 
6.2 AUDIT  PLAN: DF/HCC  SPONSORED  TRIALS  106 
6.3 AUDIT  NOTIFICATION  106 
6.4 AUDIT  REPORTS  106 
6.5 PARTICIPATING  INSTITUTION  PERFORMANCE  106 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
96  
 1. INTRODUCTION  
 
The Dana -Farber/Harvard Cancer Center  Multi -Center Data and Safety Monitoring Plan (DF/HCC DSMP) 
outlines the procedures for conducting a DF/HCC Multi -Center research protocol. The DF/HCC DSMP serves 
as a reference for any sites external to DF/HCC that are participating in a DF/HCC clinical t rial. 
 
1.1 Purpose  
 
To establish standards that will ensure that a Dana -Farber/Harvard Cancer Center Multi -Center protocol will 
comply with Federal Regulations, Health Insurance Portability and Accountability Act (HIPAA) requirements 
and applicable DF/HCC Stan dard Operating Procedures.  
 
1.2 Multi -Center  Data  and Safety  Monitoring  Plan  Definitions  
 
DF/HCC Multi -Center Protocol : A research protocol in which one  or more outside institutions are 
collaborating with Dana -Farber/Harvard Cancer Center where  a DF/HCC invest igator is the sponsor. DF/HCC 
includes  Dana -Farber/Partners  Cancer  Care  (DF/PCC)  Network  Clinical  Trial  Affiliates.  
 
Lead Institution:  One of the Dana -Farber/Harvard Cancer Center consortium members (Dana -Farber Cancer 
Institute (DFCI), Massachusetts Gener al Hospital (MGH), Beth Israel Deaconess Medical Center (BIDMC), 
Boston Children’s Hospital (BCH), Brigham and Women’s Hospital (BWH) responsible for the coordination, 
development, submission, and approval of a protocol as well as its subsequent amendments  per the DFCI IRB 
and applicable regulatory guidelines (CTEP, Food and Drug Administration (FDA), Office of Biotechnology 
Activities (OBA) etc.).  The Lead Institution is typically the home of the DF/HCC Sponsor. The Lead  
Institution also typically serves as the Coordinating Center for the DF/HCC Multi -Center Protocol.  
 
DF/HCC Sponsor:  The person sponsoring the submitted Multi -Center protocol who takes responsibility for 
initiation, management and conduct of the protocol at  all research locations. In applicable protocols, the 
DF/HCC Sponsor will serve as the single liaison with any regulatory agencies. The DF/HCC Sponsor has 
ultimate authority over the protocol and is responsible for the conduct of the study at DF/HCC and al l 
Participating Institutions. In most cases the DF/HCC Sponsor is the same person as the DF/HCC Overall 
Principal Investigator; however, both roles can be filled by two different people.  
 
Participating Institution:  An institution that is outside the DF/HCC  and DF/PCC consortium that is 
collaborating with DF/HCC on a protocol where the sponsor is a DF/HCC Investigator.  The Participating 
Institution acknowledges the DF/HCC Sponsor as having the ultimate authority and responsibility for the  
overall conduct of the study.  
 
Coordinating Center: The entity (i.e. Lead Institution, Medical Monitor, Contract Research Organization 
(CRO), etc) that provides administrative support to the DF/HCC Sponsor in order that he/she may fulfill the 
responsibilities outlined in the protocol document and DSMP, and as specified in applicable regulatory 
guidelines (i.e. CTEP Multi -Center Guidelines). In general, the Lead Institution is the Coordinating Center for 
the DF/HCC Multi -Center Protocol.  
 
DF/HCC  Office  of Data  Quality  (ODQ):  A group  within  DF/HCC  responsible  ensuring  high-quality  standards 
are used for data collection and the ongoing management of clinical trials, auditing, and data and safety 
monitoring. ODQ also coordinates quality assurance efforts related to multi -center clinical research.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
97  
  
DF/HCC  Clinical  Trials  Research  Informatics  Office  (CTRIO):  A group  within  DF/HCC  responsible  for 
providing a comprehensive data management platform for managing clinical trial data.  
 
2. GENERAL  ROLES  AND  RESPONSIBILITIES  
 
For DF/HCC  Multi -Center  Protocols,  the DF/HCC  Sponsor,  the Coordinating  Center,  and the Participating 
Institutions are expected to  adhere to the following general responsibilities:  
 
2.1 DF/HCC  Sponsor  
 
The DF/HCC Sponsor, Irene Ghobrial, MD will accept responsibility for all aspects of conducting a DF/HCC  
Multi -Center protocol which includes but is not limited to:  
• Oversee  the coordinatio n, development,  submission,  and approval  of the protocol  as well as 
subsequent amendments.  
• Ensure  that the investigators,  study  team  members,  and Participating  Institutions  are qualified  and 
appropriately resourced to conduct the protocol.  
• Include  the Multi -Center  Data and  Safety  Monitoring  Plan as an appendix  to the  protocol.  
• Ensure  all Participating  Institutions  are using  the correct  version  of the protocol.  
• Ensure that each participating investigator and study team member receives adequate protocol training 
(and/or a Site Initiation Visit prior to enrolling participants) and throughout trial’s conduct as needed.  
• Ensure  the protocol  will be provided  to each participating  site in a language  understandable  to all 
applicable site personnel when English is not the primary language.  
• Monitor  progress  and overall  conduct  of the study  at all Participating  Institutions.  
• Ensure  all DFCI  Institutional  Review  Board  (IRB),  DF/HCC  and other  applicable  reporting 
requirements are met.  
• Review  data and maintain  timely  submission  of data for study  analysis.  
• Act as the single  liaison  with the FDA  
• Ensure  compliance with all  requirements  as set forth  in the Code of Federal  Regulations, applicable 
DF/HCC requirements, HIPAA requirements, and the approved protocol.  
• Commit to the provision that the protocol will not be rewritten or modified by anyone other than the  
DF/HCC Sponsor.  
• Identify and qualify Partic ipating Institutions and obtain accrual commitments prior to extending the  
protocol to that site.  
• Monitor  accrual  and address  Participating  Institutions  that are not meeting  their accrual  requirements.  
 
2.2 Coordinating  Center  
 
The general  responsibilities  of the Coordinating  Center  may include  but are not limited  to: 
• Assist  in protocol  development.  
• Maintain  FDA  correspondence,  as applicable.  
• Review  registration  materials  for eligibility  and register  participants  from  Participating  Instituti ons in 
the DF/HCC clinical trial management system (CTMS).  
• Distribute  protocol  and informed  consent  document  updates  to Participating  Institutions  as needed.  
• Oversee  the data collection  process  from  Participating  Institutions.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
98  
 • Maintain documentation of Serious Adverse Event (SAE) reports and deviations/violation submitted 
by Participating  Institutions  and provide  to the DF/HCC  Sponsor  for timely  review  and submission  to 
the DFCI IRB, as necessary.  
• Distribute  serious  adverse  even ts reported  to the DF/HCC  Sponsor  that fall under  the DFCI  IRB 
Adverse Event Reporting Policy to all Participating Institutions.  
• Provide Participating Institutions with information regarding DF/HCC requirements that they will be 
expected to comply with.  
• Carry  out plan to monitor  Participating  Institutions  either  by on-site or remote  monitoring.  
• Maintain  Regulatory  documents  of all Participating  Institutions  which  includes  but is not limited  to the 
following: local IRB approvals/notifications from all Participating Institutions, confirmation of 
Federalwide Assurances (FWAs) for all sites,  all SAE submissions, Screening Logs for all si tes, IRB 
approved consents for all sites  
• Conduct  regular  communications  with all Participating  Institutions  (conference  calls,  emails,  etc) and 
maintain documentation all relevant communications.  
 
2.3 Participating  Institution  
 
Each  Participating  Institution  is expected  to comply  with all applicable  federal  regulations  and DF/HCC  
requirements, the protocol and HIPAA requirements.  
 
The general  responsibilities  for each Participating  Institution  may include  but are not limited  to: 
 
• Document  the delegation  of research  specific  activities  to study  personnel.  
• Commit to  the accrual of  participants  to the protocol.  
• Submit  protocol  and/or  amendments to  their local  IRB. 
• Maintain  regulatory  files as per sponsor  requirements.  
• Provide  the Coordinating  Cent er with regulatory  documents  or source  documents  as requested.  
• Participate in protocol training prior to enrolling participants and throughout the trial as required (i.e. 
teleconferences).  
• Update  Coordinating  Center  with research  staff changes  on a timely  basis.  
• Register  participants  through  the Coordinating  Center  prior  to beginning  research  related  activities.  
• Submit  Serious  Adverse  Event  (SAE)  reports  to local  IRB per institutional  requirements  and to the 
Coordinating Center, in accordance with DF /HCC requirements.  
• Submit  protocol  deviations  and violations  to local  IRB per institutional  requirements  and to the 
DF/HCC Sponsor in accordance with DF/HCC requirements.  
• Order,  store  and dispense  investigational  agents  and/or  other  protocol  mandated  drugs  per federal 
guidelines and protocol requirements.  
• Have  office  space, office  equipment,  and internet  access  that meet  HIPAA  standards.  
• Participate  in any quality  assurance  activities  and meet  with monitors  or auditors  at the conclusion  of a 
visit to review findings.  
• Promptly  provide  follow -up and/or  corrective  action  plans  for any monitoring  queries  or audit 
findings.  
 
3. DF/HCC  REQUIREMENTS  FOR  MULTI -CENTER  PROTOCOLS  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
99  
 The following section will clarify DF/HCC Requir ements and further detail the expectations for participating in 
a DF/HCC Multi -Center protocol.  
 
3.1 Protocol  Distribution  
 
The Coordinating Center will distribute the final DFCI IRB approved protocol and any subsequent amended 
protocols to all Participating I nstitutions.  
 
3.2 Protocol  Revisions  and Closures  
 
The Participating Institutions will receive notification of protocol revisions and closures from the Coordinating 
Center.  It is the individual Participating Institution’s responsibility to notify its IRB of these revisions.  
 
• Non life -threatening revisions:  Participating Institutions will receive written notification of protocol 
revisions regarding non life -threatening events from the Coordinating Center. Non -life-threatening 
protocol revisions must be IRB approved and implemented within 90 days from receipt  of the 
notification.  
 
• Revisions for life -threatening causes: Participating Institutions will receive immediate notification 
from  the Coordinating  Center  concerning  protocol  revisions  required  to protect  lives  with follow -up by 
fax, mail, e -mail, etc.  Life-threatening protocol revisions will be implemented immediately followed 
by IRB request for approval.  
 
• Protocol closures and temporary holds: Participating Institutions will receive notification of  
protocol closures and temporary holds from the Coordinatin g Center. Closures and holds will be 
effective immediately.  In addition, the Coordinating Center, will update the Participating Institutions 
on an ongoing basis about protocol accrual data so that they will be aware of imminent protocol 
closures.  
 
3.3 Informed  Consent  Requirements  
 
The DF/HCC approved informed consent document will serve as a template for the informed consent for 
Participating  Institutions.  The Participating Institution consent form  must follow the consent  template  as closely 
as possible and sh ould adhere to specifications outlined in the DF/HCC Guidance Document on Model Consent 
Language for PI -Initiated Multi -Center Protocols.  This document will be provided separately to each 
Participating Institution upon request.  
 
Participating Institutions are to send their version of the informed consent document and HIPAA authorization, 
if a separate document, to the Coordinating Center for  review and approval prior to submission to their local 
IRB. The approved consent form must also be submitted to the Coordinating Center after approval by the local 
IRB for all consent versions.  
 
The Principal Investigator (PI) at each Participating Instit ution will identify the physician members of the study 
team who will be obtaining consent and signing the consent form for therapeutic protocols. Participating 
institutions must follow the DF/HCC requirement that only attending physicians obtain informed c onsent and  
re-consent for all interventional drug, biologic, or device research.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
100  
 3.4 IRB Documentation  
 
The following  must  be on file with the Coordinating  Center:  
 
• Initial  approval  letter  of the Participating  Institution's  IRB. 
• Copy  of the Informed  Consent  Form(s)  approved  by the Participating  Institution’s  IRB. 
• Participating  Institution’s  IRB approval  for all amendments.  
• Annual  approval  letters  by the Participating  Institution's  IRB. 
 
3.5 IRB Re-Approval  
 
Verification of IRB  re-approval from the Participating Institutions is required in order to continue research 
activities.  There is no grace period for continuing approvals.  
 
The Coordinating Center will not register participants if a re -approval letter is not received from t he 
Participating Institution on or before the anniversary of the previous approval date.  
 
3.6 Participant  Confidentiality  and Authorization  Statement  
 
In 1996, congress passed the first federal law covering the privacy of health information known as the Health  
Insurance  Portability  and Accountability  Act (HIPPA).  Any information,  related  to the physical  or mental  health 
of an individual  is called Protected Health Information (PHI). HIPAA outlines how and under what 
circumstances PHI can be used or disclosed.  
 
In order for covered entities to use or disclose protected health information during the course of a study, the 
study participant must sign an authorization statement.  This authorization statement may or may not be  
separate  from  the informed  consent  docume nt. The Coordinating  Center,  with the  approval  from  the DFCI  IRB, 
will provide a consent template, with information regarding authorization for the disclosure of protected health 
information.  
 
The DF/HCC Sponsor will use all efforts to limit its use of pro tected health information in its trials. However, 
because  of the nature  of these  trials,  certain  protected  health  information  must  be collected.  DF/HCC  has chosen 
to use authorizations, signed by the participant in the trial, rather than limited data sets with data use  
agreements.  
3.6.1 DF/HCC  Multi -Center  Protocol  Confidentiality  
All documents, investigative reports, or information relating to the participant are strictly confidential. 
Whenever reasonably feasible, any participant specific reports (i.e. Pathology Reports, MRI Reports, Operative 
Reports, etc.) submitted to the Coord inating Center should be de -identified. It is recommended that the assigned 
protocol case number (as described below) be used for all participant specific documents. Participant initials 
may be included or retained for cross verification of identification.  
3.7 DF/HCC  Multi -Center  Protocol  Registration  Policy  
 
See section  4.4 of the protocol document  for specific  registration details  and logistics.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
101  
  
3.7.1 Participant  Registration  
 
To register a participant, the following documents should be completed by the P articipating Institution and 
faxed or e -mailed to  the Research Project Manager at the lead site  
 
• Copy  of required  laboratory  tests including  labs that satisfy  inclusion  criteria  
• Signed  informed  consent  document  
• HIPAA  authorization  form  (if separate  from  the informed  consent  document)  
• Completed  Eligibility  Checklist  complete  with appropriate  signatures  
• Study  specific  cover  sheet  
The Coordinating  Center  will review  the submitted  documents  in order  to verify  eligibility  and consent.  To 
complete the registration process, the Coordinating Center will:  
 
• Register  the participant  on the study  with the DF/HCC  Clinical  Trial  Management  System  (CTMS).  
• Upon  receiving  confirmation  of registration,  the Coordinating  Center  will inform  the Participating 
Institution and provide the study specific participant case number.  
 
Treatment  may not begin  without  confirmation  from  the Coordinating  Center  that the participant 
has been registered.  
 
Enrollment  can only occur  during  normal  business  hours, Monday  through Friday from 8:00  AM to 5:00 PM 
Eastern Standard Time unless given ample notice to the lead site.  
 
3.7.2 Initiation  of Therapy  
 
Participants must be registered with the DF/HCC CTMS before  the initiation of treatment or other protocol - 
specific interventions. Treatment and other protocol -specific interventions may not be initiated until the 
Participating Institution receives confirmation of the participant’s registration from the Coordinati ng Center. 
The DF/HCC Sponsor and DFCI IRB must be notified of any violations to this policy.  
 
3.7.3 Eligibility  Exceptions  
 
No exceptions to the eligibility requirements for a protocol without DFCI IRB approval will be permitted. All 
Participating Institutions are required to fully comply with this requirement. The lead site will provide the 
appropriate paperwork to submit an eligibility exception request at the time of study start up.  
 
 
3.8 DF/HCC  Protocol  Case  Number  
 
At the time of registration, the following identifiers are required for all subjects: initials, date of birth, gender, 
race and ethnicity. Once eligibility has been established and the participant successfully registered, the 
participant is assigned a uniq ue protocol case number.  Participating Institutions should submit all de -identified 
subsequent communication and documents to the Coordinating Center, using this case number to identify the 
subject.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
102  
 3.8.1 Protocol  Deviations,  Exceptions  and Violati ons 
 
Federal Regulations require an IRB to review proposed changes in a research activity to ensure that researchers 
do not initiate changes in approved research without IRB review and approval, except when necessary to 
eliminate apparent immediate hazards  to the participant. DF/HCC requires all departures from the defined 
procedures set forth in the IRB approved protocol to be reported to the DF/HCC Sponsor, who in turn is 
responsible for reporting to the DFCI IRB.  
 
For reporting purposes, DF/HCC uses the terms “violation”, “deviation” and “exception” to describe departures 
from a protocol. All Participating Institutions must adhere to these requirements for reporting to the DF/HCC 
Sponsor and will follow their institutional policy for reporting to their lo cal IRB.  
 
3.8.2 Definitions  
 
Protocol  Deviation : Any departure  from  the defined  procedures  set forth  in the IRB-approved  protocol  which  is 
prospectively  approved  prior  to its implementation.  
 
Protocol  Exception : Any protocol  deviation  that relates  to the eligibility  criteria,  e.g. 
enrollment of a participant who does not meet all inclusion/exclusion criteria.  
 
Protocol  Violation : Any protocol  departure  that was not prospectively  approved by the IRB prior  to its initiation 
or implementation.  
 
3.8.3 Reporting Procedures  
 
DF/HCC Sponsor:  is responsible for ensuring that clear documentation is available in the medical record and/or 
regulatory documents to describe all protocol exceptions, deviations and violations. The DF/HCC Sponsor will 
also be responsible for ensu ring that all protocol violations/deviations are promptly reported per DFCI IRB 
guidelines.  
 
Participating Institutions : Protocol deviations require prospective approval from the DFCI IRB. The 
Participating Institution must submit the deviation request to the Coordinating Center who will then submit the 
deviation request to the DFCI IRB. Upon DFCI IRB approval the deviation is submitted to the Participating 
Institution IRB, per institutional policy. A copy of the Participating Institution’s IRB report and d etermination 
will be forwarded to the Coordinating Center within 10 business days after the original submission.  The 
deviation may not be implemented without all required approvals.  
 
All protocol  violations  must  be sent to the Coordinating  Center  in a timely  manner.  The Coordinating  Center 
will provide training for the requirements for the reporting of violations.  
 
Coordinating Center:  Upon receipt of the violation/deviation report from the Participating Institution, the 
Coordinating Center will submit the report to the DF/HCC Sponsor for review. Subsequently, the Participating 
Institution’s IRB violation/deviation report will be submitt ed to the DFCI IRB for review per DFCI IRB 
reporting guidelines. DF/HCC will forward all violation reports to CTEP via an internal DF/HCC process, as 
applicable.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
103  
 3.9 Safety  Assessments  and Toxicity  Monitoring  
 
The study  teams  at all participating  institutions  are responsible  for protecting  the safety,  rights  and well-being  of 
study  participants.  Recording  and reporting  of adverse  events  that occur during  the course  of a study  help ensure 
the continuing safety of study participants.  
 
All participants receiving investigational agents and/or other protocol mandated therapy will be evaluated for 
safety.  The safety  parameters  include  all laboratory  tests and hematological  abnormalities,  physical  examination 
findings, and spontaneous reports of adverse events reported by participants.  All toxicities encountered during 
the study will be evaluated according to the NCI criteria specified in the protocol. Life -threatening toxicities 
must be re ported immediately to the DF/HCC Sponsor via the Coordinating Center.  
 
Additional  safety  assessments  and toxicity  monitoring  will be outlined  in the protocol.  
 
3.9.1 Guidelines  for Reporting  Serious  Adverse  Events  
 
Guidelines  for reporting  Adverse  Events  (AEs)  and Serious  Adverse  Events  (SAEs)  are detailed  in protocol 
section 7 of the protocol.  
 
Participating Institutions must report the SAEs to the DF/HCC Sponsor and the Coordinating Center following 
the DFCI IRB Adverse Event Reporting Policy . 
 
The Coordinating Center will maintain documentation of all Participating Institution Adverse Event reports and 
be responsible for communicating to all participating investigators, any observations reportable under the DFCI 
IRB Reporting Requirements.  Parti cipating Institutions will review and submit to their IRB according to their 
institutional policies and procedures  
 
3.9.2 Guidelines  for Processing  IND Safety  Reports  
 
The DF/HCC  Sponsor  will review  all IND Safety  Reports  and ensure  that all IND Safety  Reports  are distributed 
to the Participating Institutions. Participating Institutions will review/submit to their IRB according to their 
institutional policies and procedures.  
 
 
 
3.10 Data  Management  
 
DF/HCC  CTRIO  develops  case report  forms  (CRF/eCRFs),  for use with the protocol.  These  forms  are designed 
to collect data for each study. DF/HCC CTRIO provides a web based training for all eCRF users.  
 
3.10.1  Data  Forms  Review  
 
Data submissions are monitored for timeliness and completeness of submission. If study forms are  received  
with missing or questionable data, the submitting institution will receive a written or electronic query from the 
DF/HCC Office of Data Quality, Coordinating Center, or designee.  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
104  
 Responses  to all queries  should  be completed  and submitted  within  14 calendar  days.  
 
Responses may be returned on the written query or on an amended paper case report form, or in the case of 
electronic queries, within the electronic data capture (eDC) system. In the case of a written query for data 
submitted on a paper case report form, th e query must be attached to the specific data being re -submitted in 
response.  
 
If study forms are not submitted on schedule, the Participating Institution will periodically receive a Missing 
Form Report from the Coordinating Center noting the missing forms . 
 
4. REQUISITIONING  INVESTIGATIONAL  DRUG  
 
The ordering  of investigational  agent  is specified  in the protocol section  8 of the protocol. 
Participating Institutions should order their own agent regardless of the supplier . 
If the agent  is commercially  available , check  with the local  Director  of Pharmacy  and/or the  Research  Pharmacy 
to ensure that the agent is in stock. If the agent is not stocked, ensure that the agent can be ordered once the 
protocol is approved by the local IRB.  
 
If the agent is investigational, ensure that the pharmacy will be able to receive and store th e agent according to 
state and federal requirements. The local IRB should be kept informed of  who will supply the agent so that any 
regulatory responsibilities can be met in a timely fashion  
 
5. MONITORING:  QUALITY  CONTROL  
 
The quality control process for a c linical trial requires verification of protocol compliance and data accuracy. 
The Coordinating  Center,  with the aid of the DF/HCC  Office  of Data  Quality, provides  quality  control  oversight 
for the protocol.  
 
5.1 Ongoing  Monitoring  of Protocol  Compliance  
 
The P articipating Institutions may be required to submit participant source documents to the Coordinating 
Center for monitoring. Participating Institution may also be subject to on -site monitoring conducted by the 
Coordinating Center.  
 
The DF/HCC lead site will implement ongoing monitoring activities to ensure that Participating Institutions are 
complying with regulatory and protocol requirements, data quality, and participant safety. Monitoring practices 
may include but are not limited to source data verification, and review and analysis of eligibility requirements, 
informed consent procedures, adverse events and all associated documentation, review of study drug 
administration/treatment, regulatory files, protocol departures reporting, pharmacy records, response 
assessments, and data management.  
 
Monitoring practices may include but are not limited to; source verification, review and analysis of the 
following: eligibility requirements of all participants, informed consent procedures, adv erse events and all 
associated documentation, study drug administration / treatment, regulatory records and site trial master files, 
protocol  deviations,  pharmacy  records,  response  assessments,  and data management.  Additionally,  regular  and 
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
105  
 ongoing communication with Participating Institutions will be accomplished by holding all site teleconferences 
at least monthly. The Lead Institution will keep in close touch with the Participating Institutions via email and 
phone. Source documents from Pa rticipating Institutions, will be collected at specific data points that support  
the primary and or secondary endpoints  
 
Remote/  Virtual  Monitoring  
 
The Coordinating Center will request source documentation from Participating Institutions as needed to 
comp lete monitoring activities. Participating Institutions will be asked to forward de -identified copies of 
participants’  medical  record  and source  documents  to the Coordinating  Center  to aid in source  documentation 
verification.  
 
On-Site Monitoring  
 
On-Site M onitoring: On -site monitoring will occur at least once per year depending on a site’s accrual. 
Participating Institutions will be required to provide access to participants’ complete medical record and source 
documents for source documentation verification  during the on -site visit. In addition, upon request from a 
monitor or auditor, Participating Institutions should provide access to regulatory documents, pharmacy records, 
local policies related to the conduct of research, and any other trial -related docum entation maintained by the 
participating site.  If there are concerns for protocol compliance, issues that  impact subject safety or the integrity 
of the study are found, or trends identified based on areas of need, additional monitoring visits may be 
schedu led. On site monitoring  visits  can be supplemented  with virtual  monitoring  assessments,  provided  that the 
minimum monitoring frequencies are adhered to.  
5.2 Monitoring  Reports  
 
The DF/HCC Sponsor will review all monitoring reports to ensure protocol compliance. The DF/HCC Sponsor 
may increase the monitoring activities at Participating Institutions that are unable to comply with the protocol, 
DF/HCC Sponsor requirements or federal  and local regulations.  
 
5.3 Accrual Monitoring  
 
Prior  to extending  a protocol  to an external  site, the DF/HCC  Sponsor  will establish  accrual  requirements  for 
each participating institution. Accrual will be monitored for each participating institution by the DF/HCC 
Sponsor or designee. Sites that are not meeting their accrual expectations may be subject to a formal letter 
regarding accrual expectations, or t ermination. Due to the small patient population of this trial, the accrual 
minimum requirement is at least one patient every year.  
 
 
6. AUDITING:  QUALITY  ASSURANCE  
 
Auditing is a method of Quality Assurance and involves the systematic and independent examinat ion of all trial 
related activities and documents.  Audits determine if evaluated activities were appropriately conducted and 
whether data was generated, recorded and analyzed, and accurately reported per the protocol, applicable 
Standard Operating Procedur es (SOPs), and the Code of Federal Regulations (CFR).  
Local Protocol #: 16 -242 
Version  Date:  23 January  2018  
CONFIDENTIAL  
This document  is confidential.  Do not disclose  or use except  as authorized.  
106  
 6.1 DF/HCC  Internal  Audits  
 
All Participating Institutions are subject to audit by the DF/HCC Office of Data Quality (ODQ). Typically, 
approximately 3 -4 participants would be audited at the si te over a 2 day period. If violations which impact 
participant safety or the integrity of the study are found, more participant records may be audited.  
 
6.2 Audit  Notifications  
 
It is the Participating Institution’s responsibility to notify the Coordinating Ce nter of all scheduled audit dates 
(internal or NCI) and re -audit dates (if applicable), which involve this protocol. All institutions will forward a 
copy of final audit and/or re -audit reports and corrective action plans (if applicable) to the Coordinating  Center, 
within 12 weeks after the audit date.  
 
6.3 Audit  Reports  
 
The DF/HCC Sponsor will review all final audit reports and corrective action plans, if applicable. The 
Coordinating Center, must forward any reports to the DF/HCC ODQ per DF/HCC policy for review by the 
DF/HCC Audit Committee. For unacceptable audits, the DF/HCC Audit Committee would forward the final 
audit report and corrective action plan to the DFCI IRB as applicable.  
 
6.4 Participating  Institution  Performance  
 
The DF/HCC Sponsor, DFCI IRB, is charged with considering the totality of an institution’s performance in 
considering institutional participation in the protocol.  
 
Participating Institutions that fail to meet the performance goals of accrual, submission of  timely and accurate 
data, adherence to protocol requirements, and compliance with state and federal regulations, may be 
recommended for a six -month probation period. Such institutions must respond with a corrective action plan  
and must demonstrate during the probation period that deficiencies have been corrected, as evidenced by the 
improved performance measures. Participating  Institutions that fail to demonstrate significant improvement will 
be considered by the DF/HCC Sponsor for revocation of participat ion. A DF/HCC Sponsor and/or the DFCI 
IRB may terminate a site’s participation if it is determined that a site is not fulfilling its responsibilities as 
described above.  
CA204185  USA  Richardson  Pregnancy  Information  Sheet  1.0 (Draft  0.2) 30Jun2016   
  
 
 
Pregnancy  Risk  – All Patients:  
 
You must  never  share  lenalidomide  (or other  study  drugs)  with someone  else.  You must 
never  donate  blood  while  you are participating  in this study  and for at least  28 days  after 
you have been discontinued from the study. You must receive counseling and complete 
phone surveys as required by the Revlimid REMS® program. Females of childbearing 
potential that might be caring for you should not touch the lenalidomid e capsules or 
bottles unless they are wearing gloves. Any unused lenalidomide should be returned to 
the study staff.  
 
 
Pregnancy  Risk  – Females:  
 
If you are a female  of childbearing  potential,  you will be required  to have  a negative 
pregnancy test prior to  receiving lenalidomide.  
 
• For the purposes  of this study,  a female  of childbearing  potential  is a sexually 
mature female who:  
o Has not undergone  a hysterectomy  (the surgical  removal  of the uterus)  or 
bilateral oophorectomy (the surgical removal of both ovaries)  
o Has not been  naturally  postmenopausal  for at least  24 consecutive  months 
(i.e., has had menses at any time during the preceding 24 consecutive 
months)  
 
You will be required to use TWO reliabl e forms of birth control, one highly effective 
method and one additional effective method at the same time or practice complete 
abstinence from heterosexual intercourse during the following time periods related to 
this study:  1) throughout  lenalidomide  therapy,  including  interruptions  in therapy;  and 2) 
for at least 28 days after discontinuation of lenalidomide. The use of birth control is 
required for 120 days following the last dose of nivolumab.   
Protocol  Number:  16-242 
Principal  Investigator:  Irene  Ghobrial,  M.D. 
Protocol  Title:  Phase  II Trial of the PD-1 Antibody  Nivolumab  in Combination  with 
Lenalidomide and Low Dose Dexamethasone in Patients with High -Risk 
Smoldering Multiple Myeloma  
 
Instruction  Sheet  for Participants  Regarding  Reproductive  Risks  
CA204185  USA  Richardson  Pregnancy  Information  Sheet  1.0 (Draft  0.2) 30Jun2016   
 Pregnancy  Risk  – Males:  
 
Lenalidomide is present at very low levels in human semen of healthy men for three 
days after stopping the drug according to a study. For some men, such as men with 
kidney problems, lenalidomide may be present in semen for more than three days. For 
these r easons, to be safe, all male patients receiving lenalidomide must use a latex 
condom during any sexual contact with a pregnant female or with a female of 
childbearing potential while you are participating in this study, including during times 
when lenalido mide is temporarily stopped, and for at least 28 days after permanently 
stopping  therapy,  even  if you have  had a successful  vasectomy.  You must  never  donate 
blood, sperm, or semen while you are participating in this study and for at least 28 days 
after you  have stopped therapy. In addition, men are required to continue to use birth 
control for 154 days following the last dose of nivolumab.  
 
 Institutional  Conflict  of Interest  Information  Sheet  
 
Phase  II Trial  of the PD‐1  Antibody  Nivolumab  in Combination  with  Lenalidomide  and Low Dose 
Dexamethasone in Patients with High‐Risk Smoldering Multiple Myeloma  
 
Protocol  #16‐242  
 
You are invited  to take  part in a clinical  trial,  a type  of research.  For purposes  of this research,  you will 
be referred to as a “participant”.  This research study is studying a targeted immunotherapy as a 
possible treatment for this diagnosis.  Bristol‐Myers Squi bb is supporting this research study by 
providing the study drug, Nivolumab.  You are receiving this Information Sheet because Dana‐Farber 
Cancer Institute has a financial interest in Nivolumab, which may be affected by the outcome of this 
research. This is  known as a potential “institutional conflict of interest.”  
 
Nivolumab is an investigational drug, which means that the intervention is being studied and has not 
been approved for your type of cancer by the FDA (U.S. Food and Drug Administration). It is po ssible 
that, as the result of this clinical trial and other clinical trials involving this drug that may follow, this 
investigational drug could be approved by the FDA, and become widely available for sale. Specifically, 
the drug being investigated involve s a technology that was discovered through research conducted at 
DFCI.  As a result,  a concern  exists  that DFCI  could  be biased  because  it stands  to benefit  financially  from 
the outcome of clinical trials involving this drug.  
 
Dana‐Farber Cancer Institute (“DFCI”) is committed to ensuring that all of its research and clinical 
activities are conducted with integrity.  As part of this commitment, DFCI fully discloses the existence of 
all actual  or potential  conflicts  of interest  to research  participants,  sponsors,  and regulatory  bodies.  Also, 
we have  made  sure  that appropriate  steps  have  been  taken  to ensure  the safety  of research participants 
and the reliability of research results.  
 
First,  DFCI  will disclose  the existence  and nature  of its financial  interest  to all research  participants.  
 
Second,  DFCI  will disclose  the existence  and nature  of its financial  interest  to all research  collaborators 
and in all public presentations and publications of data related to this research.  
 
Finally, and most importantly, we want to be certain that all research participants are fully informed 
about  the financial  interest,  and are able  to consider  this information  in deciding  whether  to participate 
in this trial. To that end, if you have additional questions about DFCI’s financial interests and their 
potential impact upon this clinical trial, or any of the steps taken by DFCI to safeguard the integrity of 
this research, please contact:  
 
Roberta Driscoll, JD 
Director,  Office  of Research  Integrity  
Dana‐Farber Cancer Institute 
450 Brookline  Avenue,  BP333 
Boston, MA  02215‐5450 
617‐632‐4557  
Roberta_Dris coll@dfci.harvard.edu  
Version  3.0  
 16-242: PHASE  II TRIAL  OF THE  PD-1 ANTIBODY  NIVOLUMAB  IN COMBINATION  WITH  LENALIDOMIDE  AND 
LOW DOSE DEXAMETHASONE IN PATIENTS WITH HIGH -RISK SMOLDERING MULTIPLE MYELOMA  
 
PARTICIPANT  SELF -ADMINISTERED  DRUG  DIARY  
PATIENT  INSTRUCTIONS:  
Take  your medications  exactly  as prescribed  by your doctor.  See the next page  for specific  doses  for each medication  that you are taking  on this 
study.  
• Keep  capsules in  the bottle(s)  provided and  do not  transfer them  to any other  container. Store  at room  temperature.  
• Lenalidomide  should  be taken  by mouth  once  per day for 21 days.  Capsules  must  be swallowed  whole with  water at  the same time  each day. 
• Dexamethasone  should  be taken  by the mouth.  The days you will take dexamethasone  will vary depending  on your cycle.  Please  refer  to 
the next page for  a list  of the appropriate days. Tablets must be swallowed whole and taken with food at the same time each day.  
• If you vomit after taking lenalidomide or dexamethasone, do NOT take another  dose.  Please  note any vomiting in  the Comments section  
of the diary on the next page.  
• If you miss a dose of lenalidomide  and it has been  less than 12 hours  since  the missed  dose,  take it as soon  as you remember  on the same  day. 
If it has been more than 12 hours since missing a lenalidomide dose, you should not take the dose on that day, but take the n ext dose at the 
normal time on the following day.  
• If you miss a dose of dexamethasone,  take it as soon  as you remember  on the same  day. If you miss taking  dexamethasone  for the entire  day, 
take your regular dose the next scheduled day ( do NOT take double  your regular dose to make up for the missed dose).  
• If you miss a dose please  record  “0” for Number  Taken  on the next page.  
• If you accidentally  take an extra  dose of lenalidomide  in one day skip the next day’s  dose and record  the extra  dose on the next page  and 
contact your study team immediately and seek emergency medical care.  
• Please  bring  any unused  lenalidomide  and all empty containers  and diary  to your next visit.  
 
FOR  CLINIC  USE  ONLY:  
• Give patient all 2 pages of Drug Diary stapled 
together.  Provide  one diary  per cycle  (28 days).  
• Enter  the appropriate  dose for the current  cycle.  
• Complete  patient  identifiers  and medical  team 
contact information on page 2.  
• When  patient  returns  pill bottles  and diary  perform  a 
Lenalidomide pill count and record adherence 
information in the box to the right.  Staff  Initials:  
Date  Returned:  # Lenalidomide  capsules  returned:  
# Lenalidomide  capsules  that should  have  been  taken:  
Discrepancy  Notes:  
Version  3.0  
  
STUDY  PARTICIPANT  SELF -ADMINISTERED  DIARY 
CYCLES 1 -6 
Participant Identifier:   Cycle #:   
 
Your MD    
Phone   
Your RN     
Phone   
STUDY  DRUG  INSTRUCTIONS:  
Take  the following  medications  as indicated  below. 
Record the dose of each medication on the chart to 
the right after taking each day.  
 
Lenalidomide:  
Cycles 1 -6:   mg by mouth  on Days  1-21 
 
 
Dexamethasone:  
Cycles 1 -6:   mg by mouth  on Days  1, 8, 15 
 
 
Patient  Signature:  Date:   
 
 
Delegated  Study  Staff  Signature:  Date:     
Date  Number  Taken   
Comments  Lenalidomide  Dexamethasone  
 
Ex:  
6/1/2009   
1  
1 vomited  hour 
later 
Day 1     
Day 2     
Day 3     
Day 4     
Day 5     
Day 6     
Day 7     
Day 8     
Day 9     
Day 10     
Day 11     
Day 12     
Day 13     
Day 14     
Day 15     
Day 16     
Day 17     
Day 18     
Day 19     
Day 20     
Day 21     
Day 22     
Day 23     
Day 24     
Day 25     
Day 26     
Day 27     
Day 28     
 
STUDY  PARTICIPANT  SELF -ADMINISTERED  DIARY  CYCLES  7-12 
Version  3.0  
  
 
 
 
Participant Identifier:   Cycle #:   
 
Your MD    
Phone   
Your RN     
Phone   
STUDY  DRUG  INSTRUCTIONS:  
Take  the following  medications  as indicated  below. 
Record the dose of each medication on the chart to 
the right after taking each day.  
 
Lenalidomide:  
Cycles 7 -12:   mg by mouth  on Days  1-21 
 
 
Patient  Signature:  Date:   
 
 
Delegated  Study  Staff  Signature:  Date:     
Date  Number  Taken   
Comments  Lenalidomide  
 
Ex:  
6/1/2009   
1 vomited  hour 
later 
Day 1    
Day 2    
Day 3    
Day 4    
Day 5    
Day 6    
Day 7    
Day 8    
Day 9    
Day 10    
Day 11    
Day 12    
Day 13    
Day 14    
Day 15    
Day 16    
Day 17    
Day 18    
Day 19    
Day 20    
Day 21    
Day 22    
Day 23    
Day 24    
Day 25    
Day 26    
Day 27    
Day 28    
 
STUDY  PARTICIPANT  SELF -ADMINISTERED  DIARY  
Version  3.0  
  
 
 
CYCLES  7-12 FOR  USE  ONLY  IF RECEIVING 
DEXAMETHASONE IN MAINTENANCE  
Participant Identifier:   Cycle #:   
 
Your MD    
Phone   
Your RN     
Phone   
STUDY  DRUG  INSTRUCTIONS:  
Take  the following  medications  as indicated  below. 
Record the dose of each medication on the chart to 
the right after taking each day.  
 
Lenalidomide:  
Cycles 7 -12:   mg by mouth  on Days  1-21 
 
 
Dexamethasone:  
Cycles 7 -12:   mg by mouth  on Days  1, 8, 15 
 
 
Patient  Signature:  Date:   
 
 
Delegated  Study  Staff  Signature:  Date:     
Date  Number  Taken   
Comments  Lenalidomide  Dexamethasone  
 
Ex:  
6/1/2009   
1  
1 vomited  hour 
later 
Day 1     
Day 2     
Day 3     
Day 4     
Day 5     
Day 6     
Day 7     
Day 8     
Day 9     
Day 10     
Day 11     
Day 12     
Day 13     
Day 14     
Day 15     
Day 16     
Day 17     
Day 18     
Day 19     
Day 20     
Day 21     
Day 22     
Day 23     
Day 24     
Day 25     
Day 26     
Day 27     
Day 28     
 
Protocol  #16-242: Drafted  (9/7/16)(KAR)/Approved  (12/20/16)(EMR)   
 DANA -FARBER  CANCER  INSTITUTE  
Nursing  Protocol  Education  Sheet  
Protocol  Number:  16-242 
Protocol  Name:  Phase  II Trial  of the PD-1 Antibody  Nivolumab  in Combination  with Lenalidomide  and Low 
Dose Dexamethasone in Patients with High -Risk Smoldering Multiple Myeloma  
DFCI  Site PI: Irene  Ghobrial,  MD 
DFCI  Research  Nurse:  Kaitlen  Reyes,  DNP ; John  Harran,  Eileen  Regan  Laura  Amweg,  Kathleen  Colson,  Kristen  
Cummings,  Heidi  DiPietro,  Meghan  Leahy  Ray 
Page  the DFCI  research  nurse  or DFCI  site PI if there  are any questions/concerns  about  the protocol.  
Please  also refer  to ONC  15: Oncology  Nursing  Protocol  Education  Policy  
*** Remember  to check  the ALERT  PAGE***  
SPECIAL  NURSING  CONSIDERATIONS  UNIQUE  TO THIS  PROTOCOL  Study  Design  Nivolumab  is a fully human  monoclonal  antibody  that targets  the PD-1 cell surface  membrane  receptor.  
Nivolumab inhibits the interaction of PD -1 with its ligands, PD -L1 and PD -L2, resulting in enhanced T -cell 
proliferation  and interferon -gamma  (IFN-γ) release  in vitro.  Lenalidomide  (REVLIMID)  is a thalidomide  analogue,  is 
an immunomodulatory  agent  with antiangiogenic  properties.  Dexamethasone  is a synthetic  adrenocortical  steroid.  
• The Study  Design  is in Section  1.1 
• The Study  Rationale  is in Section  2.9 
• A cycle  is defined  as 28 days  in Section  5.1 Dose 
Calc.  • Nivolumab  is dosed  in fixed  dosing,  240 mg IV 
• Lenalidomide  is dosed  in fixed  dosing,  between  5-25 mg (increments  of 5 mg for dose  reductions)  
• Dexamethasone  is dosed  in fixed  dosing,  40 mg or 20 mg or 10 mg for dose  reductions  Study Drug 
Administration  Agent  Administration  Guidelines  are found  in Section  5.2 
• Nivolumab  is given  IV every  other  week  on Days  1&15; Lenalidomide  is PO Days  1-21; Dexamethasone  is 
PO Days 1, 8, 15 for Cycles 1 -6 ONLY  
• Nivolumab is given IV over 60 minutes (+/ - 10 minutes); No standard premeds required, unless history of 
infusion  reaction.  A 60 min post-infusion  observation  period  is suggested , especially  during  first 2 cycles,  but 
not mandatory per protocol.  
• The drugs  may be administered  in any order.  
• Criteria  to treat DAY 1: ANC >1,000;  PLT>50; Other  drug related,  non-heme  tox <Grade  1 or baseline.  
• Criteria  to treat DAY 15: 
For Lenalidomide:  ANC >1,000;  PLT>30; Hgb>8 Other  drug related  less than Grade  3 or baseline. 
For Nivolumab: AST <90; ALT <156; Bilirubin <1.8; Creatinine <1.95 or <1.5 x baseline  
• Fasting  is not required.  
• Lenalidomide capsules and Dexamethasone tablets should be swallowed whole, and should not be broken, 
chewed  or opened.  Administration  shoul d be at approximately  the same  time each  day. If a dose  is missed  and 
less than 12 hours  has elapsed  since  the missed  dose,  the patient  may take the dose  for that day. If more  than 
12 hours has elapsed since missing a dose at the normal time, the patient should not take the dose, but take 
the next dose at the normal time on the following day. If a dose is missed, it should be taken as soon as 
possible on the same day. If a dose is vomited, the dose should not be made up and the participant should  
continue  with the regular  schedule  of the drug at the next dose.  Dose 
Mods  & 
Toxicity  Dose  Modifications/Dosing  Delay  for Toxicity  are outlined  in Section  
• This protocol  uses  NCI CTCAE  criteria,  version  4.03 
• There  are no dose  modifications  for Nivolumab,  there  are dose  reductions  per protocol  for Lenalidomide  and 
Dexamethasone.  Con 
Meds  Concomitant  Therapy  Guidelines  are in Section  5.3.1  
• Stem  cell mobilization  and collection  may be performed  at time of best response  or after 6 cycles  of therapy.  
• Filgrastim  is allowed,  pegfilgrastim  is NOT.  
• Transfusions  and supportive  care are allowed;  bisphosphonate  therapy  included.  Required 
Data Study  Calendar  and Assessment  Required  data are outlined  in Section  10 
• The study  calendar  is in Section  10 
• Vital  signs:  Before  any infusion.  
• ECGs : One at screening  and one at EOT.  
• NO PK’s  or biomarkers.  
Protocol  #16-242: Drafted  (9/7/16)(KAR)/Approved  (12/20/16)(EMR)   
 
Charting  Tips All study  drugs  require  documentation  of exact  administration  time.  
Please  be sure to DOCUMENT  study  medication  actual  UP/DOWN  times  in medical  record  (e.g. LMR,  eMAR, 
nursing notes). Edit eMAR as needed to match the exact time given . 
• If there is a discrepancy in the infusion time, delay in administration, or the infusion takes longer than is 
permitted  by the guidelines  of the protocol,  please document  the reason  for the discrepancy  in the medical 
record.  
Please  be sure to also DOCUMENT  any required  observation  periods,  any additional  vital signs,  routes  of 
administration, injection sites, etc.  
 
 450 Brookline  Ave. 
Boston,  Massachusetts  02215  
617-632-3000 
617-632-5330  TDD 
 
 
November  XX, 2017  
 
XXXXXXX 
XXXXXXXX 
XXXXXXXXX 
XXXXXXXXX  
 
 
Re: 16 -242 A Phase II Trial of the PD -1 Antibody Nivolumab in Combination with 
Lenalidomide  and Low Dose  Dexamethasone  in Patients  with High -Risk Smoldering 
Multiple Myeloma  
 
ClinicalTrials.gov  Identifier:  [STUDY_ID_REMOVED] 
Dear XXXXXXXX,  
We are reaching  out to you to follow  up on the recent  closure  of the clinical  trial by 
the Food and Drug Administration that you had been enrolled on.  
 
On August 31st, 2017, the FDA requested that the company that makes this drug (Bristol - 
Myers  Squibb)  notify  patients  of safety  concerns  that were  seen on two clinical  trials  using 
the dru gs pembrolizumab (a similar drug to nivolumab), revlimid and dexamethasone.  
 
It was reported  that there  was an increased  risk of death  on those  trials.  This risk may also be 
associated with nivolumab. Although nivolumab is not the same drug, it works in a similar 
way and these findings may be relevant to your safety.  
 
We are formally  requesting  that you contact  us immediately  if you experience  any new side 
effects. If you never received nivolumab, revlimid, or dexamethasone on this clinical trial, 
please retain this letter for reference.  
 
Please  contact  me at (617)  632-4198  or at Irene_Ghobrial@D FCI.HARVARD.EDU  if you 
have any questions regarding the clinical hold, the future of the trial, or your safety as it 
relates to these findings.  
 
 
Sincerely,  
 
 
 
Irene  M. Ghobrial,  MD 
Sponsor -Investigator  
